<SEC-DOCUMENT>0001104659-25-057741.txt : 20250609
<SEC-HEADER>0001104659-25-057741.hdr.sgml : 20250609
<ACCEPTANCE-DATETIME>20250609140634
ACCESSION NUMBER:		0001104659-25-057741
CONFORMED SUBMISSION TYPE:	N-CSRS
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250609
DATE AS OF CHANGE:		20250609
EFFECTIVENESS DATE:		20250609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Healthcare Investors
		CENTRAL INDEX KEY:			0000805267
		ORGANIZATION NAME:           	
		EIN:				046564285
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-CSRS
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-04889
		FILM NUMBER:		251033551

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKLA HEALTHCARE INVESTORS
		DATE OF NAME CHANGE:	20141015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q HEALTHCARE INVESTORS
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSRS
<SEQUENCE>1
<FILENAME>tm2516624d11_ncsrs.htm
<DESCRIPTION>N-CSRS
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Thu Jun 05 10:32:41 UTC 2025 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d11_n-csrcover.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1" -->

<p style="margin: 0pt">&#xa0;</p>


<p style="margin: 0pt"></p>


<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="margin: 0pt">&#xa0;</p>








<p style="margin: 0"></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SECURITIES AND EXCHANGE COMMISSION</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Washington, D.C. 20549</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#xa0;N-CSR</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES</b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Company Act file number:</font></td>
    <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">811-04889</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exact name of registrant as specified in charter:</font></td>
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt">abrdn Healthcare Investors</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of principal executive offices:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street, Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name and address of agent for service:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Inc.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street Suite&#xa0;200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#x2019;s telephone number, including area
    code:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-800-522-5465</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of fiscal year end:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&#xa0;30</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of reporting period:</font></td>
    <td>March 31, 2025</td></tr>
  </table>




<p style="margin: 0">&#xa0;</p>




<p style="margin: 0"></p>




<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->




<p style="margin: 0"></p>




<p style="margin: 0"></p>










<p style="margin: 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0"></p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d11_item1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1. Reports to Stockholders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&#xa0;A copy of the report transmitted
to shareholders pursuant to Rule&#xa0;30e-1 under the Investment Company Act of 1940 (the &#x201c;1940 Act&#x201d;) is filed herewith.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="margin: 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d11_hqhreport.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1" --><div style="width:100%">
<div style="overflow:hidden; width:100%">
<div style="margin-top:0pt; position:relative; text-align:Right; width:100%">
<img src="tm2516624d11hqhreporti001.gif" alt=" ">
<div style="left:43pt; position:absolute; top:44pt"><img src="tm2516624d11hqhreporti002.gif" alt=" ">
</div><div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; left:43pt; line-height:10pt; position:absolute; text-decoration:none; text-transform:none; top:44pt">&#x2009;</div></div>


</div>
<div style="margin-top:29pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:20pt; font-style:Normal; font-weight:bold; line-height:23pt; text-align:left; text-decoration:none; text-transform:none">abrdn Healthcare Investors (HQH)</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:bold; line-height:17pt; margin-top:14pt; text-align:left; text-decoration:none; text-transform:none">Semi-Annual Report</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:Normal; line-height:17pt; margin-top:2pt; text-align:left; text-decoration:none; text-transform:none">March 31, 2025</div>
</div>
<div style="margin-top:67pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:21.5pt; font-style:Normal; font-weight:bold; line-height:24.5pt; margin-top:2pt; text-align:right; text-decoration:none; text-transform:none">aberdeeninvestments.com</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy
 &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board of Trustees (the "Board") of the
abrdn Healthcare Investors (the &#x201c;Fund&#x201d;) has authorized a managed distribution policy (&#x201c;MDP&#x201d;) of paying quarterly distributions at an annual rate, set once a year, that is a percentage of the
rolling average of the Fund&#x2019;s net asset values over the preceding three month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date (the "Distribution
Policy"). The Distribution Policy is subject to regular review by the Board. The Distribution Policy seeks to provide investors with a distribution out of current income, supplemented by realized capital gains and, to
the extent necessary, paid-in capital.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">With each distribution, the Fund will issue
a notice to shareholders and an accompanying press release which will provide detailed information regarding the estimated amount and composition of the distribution and other information required by the Fund&#x2019;s
MDP exemptive order. The Board may amend or terminate the MDP at any time without prior notice to shareholders; however, at this time, there are no reasonably foreseeable circumstances that might cause the termination
of the MDP. You should not draw any conclusions about the Fund&#x2019;s investment performance from the amount of distributions or from the terms of the Fund&#x2019;s MDP.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:34.5pt; width:92.99%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Distribution Disclosure
Classification &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
</div>
<div style="padding-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s policy is to provide
investors with a stable distribution rate. Each quarterly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to U.S.
corporate tax and securities laws. Under U.S. tax rules, the amount applicable to the Fund and character of distributable income for each fiscal period depends on the actual exchange rates during the entire year
between the U.S. Dollar and the currencies in which the Fund's assets are denominated and on the aggregate gains and losses realized by the Fund during the entire year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Therefore, the exact amount
of distributable income for each fiscal year can only be determined as of the end of the Fund&#x2019;s fiscal year, September 30. Under Section 19 of the Investment Company Act of 1940, as amended (the &#x201c;1940
Act&#x201d;), the Fund is required to indicate</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the sources of certain distributions to
shareholders. The estimated distribution composition may vary from quarter to quarter because it may be materially impacted by future income, expenses and realized gains and losses on securities and fluctuations in
the value of the currencies in which the&#xa0; Fund assets are denominated.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Based on generally accepted
accounting principles, the Fund estimates the distributions for the fiscal year commenced October 1, 2024 through the distributions declared on May 9, 2025 consisted of 23% net realized short-term capital gains, 0%
net realized long-term capital gains and 77% tax return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">In January 2026, a Form
1099-DIV will be sent to shareholders, which will state the final amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:209.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">abrdn Healthcare Investors</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Dear Shareholder,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We present the Semi-Annual
Report, which covers the activities of abrdn Healthcare Investors&#xa0;(the &#x201c;Fund&#x201d;), for the six-month period ended March 31, 2025. The Fund&#x2019;s investment objective is to seek long-term capital
appreciation by investing primarily in securities of healthcare&#xa0;companies. In addition, the Fund seeks to provide regular distribution of realized capital gains.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the six-month period
ended March 31, 2025, the total return to shareholders of the Fund based on the net asset value (&#x201c;NAV&#x201d;) and market price of the Fund, respectively, compared to the Fund&#x2019;s benchmark, &#xa0;is as
follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; border-top:0.5pt solid #000000; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:82.64%; background-color: #F0F0F0;">NAV<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.85%; background-color: #F0F0F0;">-6.80%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:82.64%; background-color: #F0F0F0;">Market Price<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4.80pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.85%; background-color: #F0F0F0;">-6.47%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:16pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:82.64%; background-color: #F0F0F0;">80% Nasdaq Biotechnology Index, 20% S&amp;P Composite 1500 Health Care
Index<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4.52pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.85%; background-color: #F0F0F0;">-9.42%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">For more information about
Fund performance, please visit the Fund on the web at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds. Here, you can view quarterly commentary on the Fund's performance,
monthly fact sheets, distribution and performance information, and other Fund literature.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">NAV, Market Price and
Premium(+)/Discount(-)</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The below table represents a
comparison between the current six-month period end and the prior fiscal year end of the&#xa0;Fund's market price to&#xa0;NAV and associated Premium(+) and Discount(-).</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:97.67%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="padding-bottom:1.75pt; padding-right:4pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.79%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:center; vertical-align:bottom; width:14.54%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:12pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:42.79%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.54%; background-color: #D9D9D9;">NAV
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">Closing<br>
Market<br>
Price
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">Premium(+)/<br>
Discount(-)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.79%; background-color: #F0F0F0;">3/31/2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.54%; background-color: #F0F0F0;">$<font style="padding-left:2.17pt"></font>17.66
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:16.02%; background-color: #F0F0F0;">$<font style="padding-left:0.31pt"></font>16.24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:12pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-8.04%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.79%; background-color: #F0F0F0;">9/30/2024
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.54%; background-color: #F0F0F0;">$20.32
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.02%; background-color: #F0F0F0;">$18.62
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:7.15pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-8.37%
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">During the six-month period ended March 31,
2025, the Fund&#x2019;s NAV was within a range of $17.66 to $20.69 and the Fund&#x2019;s market price traded within a range of $16.03 to $18.73. During the six-month period ended March 31, 2025, the Fund&#x2019;s shares
traded within a range of a premium(+)/discount(-) of -12.77% to -5.89%.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Aberdeen Name Change</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">On March 4, 2025, abrdn plc,
the parent company of the Fund's adviser, announced that it would change its name, and from that date, will use `Aberdeen' as the principal trading identity for its Investments business. On March 12, 2025, abrdn plc
completed the steps to legally change its name to Aberdeen Group plc. Aberdeen has retained `abrdn' as an operational abbreviation across its subsidiary legal entities (including the Fund's adviser, fund names and
descriptors).</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy of paying quarterly distributions at an annual rate, set by the Board of Trustees (the "Board") once a year, as a percentage of the rolling average of the Fund&#x2019;s NAV over the preceding three
month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date. On March 11, 2025, the Board determined the rolling distribution rate to be 12% for the 12-month period
commencing with the distribution payable in June 2025. This policy will be subject to regular review by the Board. The distributions will be made from current income, supplemented by realized capital gains and, to the
extent necessary, paid-in capital, which is a nontaxable return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On May 9, 2025, the Fund
announced that it will pay on June 30, 2025, a stock distribution of US $0.54 per share to all shareholders of record as of May 22, 2025. This stock distribution will automatically be paid in newly issued shares of
the Fund unless otherwise instructed by the shareholder. Shares of common stock will be issued at the lower of the NAV per share or the market price per share with a floor for the NAV of not less than 95% of the
market price. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who will have whole and fractional shares added to
their account.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:15.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. NAV return data include investment management fees, custodial charges and administrative fees (such as Trustee and legal fees) and assumes the reinvestment of all
distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:46pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Assuming the reinvestment of dividends and distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Fund&#x2019;s total return is based on the reported NAV for each financial reporting period end and may differ from what is reported on the Financial Highlights due to financial statement rounding or adjustments.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The NASDAQ Biotechnology Index is an unmanaged stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the
Biotechnology or the Pharmaceutical industry. The S&amp;P Composite 1500<sup style="font-size:85%; font-style:Normal; text-transform:none">&#xae;</sup> Health Care Index is an unmanaged index that comprises those companies included in the S&amp;P Composite 1500 that are classified as members of
the GICS<sup style="font-size:85%; font-style:Normal; text-transform:none">&#xae;</sup> Health Care sector. Indexes are unmanaged and have been provided for comparison purposes only. No fees or expenses are reflected. You cannot
invest directly in an index.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:9.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">1
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Shareholders may request to be paid their
quarterly distributions in cash instead of shares of common stock by providing advance notice to the bank, brokerage or nominee who holds their shares if the shares are in &#x201c;street name&#x201d; or by filling out
in advance an election card received from Computershare Investor Services if the shares are in registered form.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is covered under
exemptive relief received by the Fund&#x2019;s investment manager from the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) that allows the Fund to distribute long-term capital gains as frequently as
quarterly in any one taxable year.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Unclaimed Share Accounts</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Please be advised that
abandoned or unclaimed property laws for certain states require financial organizations to transfer (escheat) unclaimed property (including Fund shares) to the state. Each state has its own definition of unclaimed
property, and Fund shares could be considered &#x201c;unclaimed property&#x201d; due to account inactivity (e.g., no owner-generated activity for a certain period), returned mail (e.g., when mail sent to
a&#xa0;shareholder&#xa0; is returned to the Fund's transfer agent as undeliverable), or a combination of both. If your Fund shares are categorized as unclaimed, your financial advisor or the Fund's transfer agent will
follow the applicable state&#x2019;s statutory requirements to contact you, but if unsuccessful, laws may require that the shares be escheated to the appropriate state. If this happens, you will have to contact the
state to recover your property, which may involve time and expense. For more information on unclaimed property and how to maintain an active account, please contact your financial adviser or the Fund's transfer
agent.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Options Writing</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">In order to further support
the increase in distribution rate for the Fund, the Fund employs a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of
the common stocks in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities generally within the healthcare industry.
This option strategy is intended to generate current income from option premiums as a means to enhance distributions payable to the Fund's shareholders. The Fund's investment team does not anticipate any adverse
implications to the Fund's existing total return potential or risk profile as a result of the strategy; however, the investment adviser may choose to decrease or modify its use of the option writing strategy to the
extent that it may negatively impact the Fund's ability to benefit from capital appreciation. The Fund currently expects that it will not write options on more than 10% of its assets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Open Market Repurchase Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board has&#xa0;approved
an open market repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to purchase, in the open market, its outstanding common shares, with</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the amount and timing of any repurchase
determined at the discretion of the Fund's investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based on historical discount
levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the six-month period ended March 31, 2025, the Fund did not repurchase any
shares through the Program.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On a quarterly basis, the
Board will receive information on any transactions made pursuant to this policy during the prior quarter and management will post the number of shares repurchased on the Fund's website on a monthly basis.&#xa0; Under
the terms of the Program, the Fund is permitted to repurchase up to 12% of its outstanding shares of common stock in the open market during any 12-month period.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Holdings Disclosure</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's complete schedule
of portfolio holdings for the second and fourth quarters of each fiscal year are included in the Fund's semi-annual and annual reports to shareholders. The Fund files its complete schedule of portfolio holdings with
the SEC for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. These reports are available on the SEC&#x2019;s website at http://www.sec.gov. The Fund makes the information
available to shareholders upon request and without charge by calling Investor Relations toll-free at 1-800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Proxy Voting</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">A description of the policies
and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities and information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month
period ended June 30 is available by August 31 of the relevant year: (1) upon request without charge by calling Investor Relations toll-free at 1-800-522-5465; and (2) on the SEC&#x2019;s website at
http://www.sec.gov.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations Information</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">As part of Aberdeen's
commitment to shareholders, we invite you to visit the Fund on the web at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds. Here, you can view monthly fact sheets, quarterly
commentary, distribution and performance information, as well as other Fund literature. Enroll in Aberdeen's email services to receive content related to your fund. In addition, you will receive monthly factsheets
based on your preferences. Sign up today at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">2
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Contact Us:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:5pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Visit: https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:1pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Email: Investor.Relations@aberdeenplc.com; or
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:2pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Call: 1-800-522-5465 (toll free in the U.S.).
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Yours sincerely,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">/s/ Alan Goodson<br>
<font style="font-weight:bold">Alan Goodson<br>
</font>President&#xa0;</div>
</div>
<div style="margin-top:501pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:17pt; text-align:center; text-decoration:none; text-transform:none">All amounts are U.S. Dollars
unless otherwise stated.</div>
</div>
<div style="margin-top:21.79pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">3
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:33.5pt; width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the average annual Fund performance compared to the Fund&#x2019;s primary benchmark&#xa0;for the six-month (not annualized), 1-year, 3-year, 5-year and 10-year periods ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:10pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3.5pt; padding-right:12pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:48.58%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.53%; background-color: #D9D9D9;">6 Months
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.82%; background-color: #D9D9D9;">1 Year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.77%; background-color: #D9D9D9;">3 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.72%; background-color: #D9D9D9;">5 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.58%; background-color: #D9D9D9;">10 Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:2.12pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.58%; background-color: #F0F0F0;">Net Asset Value (NAV)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:16.06pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-6.80%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:17.24pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.82%; background-color: #F0F0F0;">1.52%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">3.70%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.80pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">7.15%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:6pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">3.17%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.58%; background-color: #F0F0F0;">Market Price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:16.06pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-6.47%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.82%; background-color: #F0F0F0;">10.24%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.21pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">2.70%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">8.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.21pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.03%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.58%; background-color: #F0F0F0;">80% Nasdaq Biotechnology Index, 20% S&amp;P Composite 1500 Health Care Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:16.12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-9.42%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.97pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.82%; background-color: #F0F0F0;">-2.62%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.10pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">1.98%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.13pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">6.87%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12.21pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.76%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:48.58%; background-color: #F0F0F0;">Nasdaq Biotechnology Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.53%; background-color: #F0F0F0;">-10.62%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.76pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.82%; background-color: #F0F0F0;">-3.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:13.10pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.77%; background-color: #F0F0F0;">1.46%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.40pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">5.39%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.21pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">2.30%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:13pt; text-align:left; text-decoration:none; text-transform:none">Performance of a $10,000
Investment<font style="font-weight:Normal"> (as of March 31, 2025)</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:7pt; text-align:left; text-decoration:none; text-transform:none">This graph shows the change in
value of a hypothetical investment of $10,000 in the Fund for the periods indicated. For comparison, the same investment is shown in the indicated&#xa0;index.</div>
<div style="margin-left:26.48%; margin-top:5pt; text-align:Center; width:47.22%">
<img src="tm2516624d11hqhreporti003.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">Returns represent past
performance. Total investment return at NAV is based on changes in the NAV of Fund shares and assumes reinvestment of dividends and distributions, if any, at market prices pursuant to the dividend reinvestment program
sponsored by the Fund&#x2019;s transfer agent. All return data at NAV includes fees charged to the Fund, which are listed in the Fund&#x2019;s Statement of Operations under &#x201c;Expenses.&#x201d; Total investment
return at market value is based on changes in the market price at which the Fund&#x2019;s shares traded on the NYSE during the period and assumes reinvestment of dividends and distributions, if any, at market prices
pursuant to the dividend reinvestment program sponsored by the Fund&#x2019;s transfer agent. The Fund&#x2019;s total investment return is based on the reported NAV as of the financial reporting period end date of March
31, 2025. Because the Fund&#x2019;s shares trade in the stock market based on investor demand, the Fund may trade at a price higher or lower than its NAV. Therefore, returns are calculated based on both market price
and NAV. <font style="font-weight:bold">Past performance is no guarantee of future results</font>. The performance information provided does not reflect the deduction of taxes that a shareholder would pay on distributions received
from the Fund or the sale of Fund shares. The current performance of the Fund may be lower or higher than the figures shown. The Fund&#x2019;s yield, return, market price and NAV will fluctuate. Performance information
current to the most recent month-end is available at https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds or by calling 800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The annualized gross operating
expense ratio based on the six-month period ended March 31, 2025 was 1.10%.&#xa0;</div>
</div>
<div style="margin-top:107pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">4
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Summary &#xa0;<font style="font-size:11pt; line-height:14pt"> (as a percentage of net assets) (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #D9D9D9;">Asset Allocation
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.40pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">89.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.02pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">7.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.84pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">2.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.38pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.02pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">2.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Call Options Written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:30.14pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.58pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(1.8%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #D9D9D9;">Industries
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.90pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">64.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:10.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">15.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:15.20pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">7.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.76pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">6.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Life Sciences Tools &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.82pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">5.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.02pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">2.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.58pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(1.8%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #D9D9D9;">Top Ten Holdings
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:5.26%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Gilead Sciences, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6.46pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">6.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Amgen, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.12pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">6.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.62pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">5.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">4.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Eli Lilly &amp; Co.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.37pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">3.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.64pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">2.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.45pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">2.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">UnitedHealth Group, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.45pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">2.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">Abbott Laboratories
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6.74pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">2.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.89%; background-color: #F0F0F0;">BioNTech SE, ADR
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.41pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.26%; background-color: #F0F0F0;">2.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;</div>
</div>
<div style="margin-top:292pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">5
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:56.00%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Convertible Preferred Stocks<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;7.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;4.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Abcuro, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.17pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;532,816
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$&#x2002;&#x2007;&#x2007;2,925,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Abcuro, Inc. Series C1
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.26pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;117,926
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;712,120
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;82,076
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;1,359,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;827,250
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,399,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series A, 6.00%<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;2,353,932
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.57pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;1,077,395
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series B, 6.00%<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.71pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;1,044,322
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.83pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;438,824
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Atalanta Therapeutics Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.94pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;1,777,778
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,200,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Aviceda Therapeutics Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;86,599
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;498,793
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc. Series A3
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;243,458
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.73pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;460,742
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Glycomine, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;6,584,840
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,950,904
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series B, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.80pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;2,875,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;5,947,513
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series C, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.08pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;632,394
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;1,842,733
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;1,769,383
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.85pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,399,993
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Priothera Co. Ltd. Series A, 6.00%<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.56pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;346,666
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;37
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Quell Therapeutics Ltd. Series B<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.74pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;1,798,941
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,739,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Recode Therapeutics, Inc. Series B, 5.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;331,413
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.02pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,060,003
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Seismic Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">647,722
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,924,983
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Third Arc Bio, Inc. Series A, 8.00%
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.08pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">926,718
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.21pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,950,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:12.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">40,889,035
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">IO Light Holdinigs, Inc. Series A2
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">421,634
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:44.47pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;3.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Biotheryx, Inc. Series E, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.08pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,295,238
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:28.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">627,154
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series A<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">21,114,774
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.31pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">10,124,534
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series B<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.37pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">3,219,587
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.52pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,543,792
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.71pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">657,322
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.27pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">4,288,763
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.86pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">121,377
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:27.21pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">791,936
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Engrail Therapeutics, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.88pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">4,768,649
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5,049,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HiberCell, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.51pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">2,773,472
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:24.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,145,167
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HiberCell, Inc. Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,529,261
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">708,966
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,644,892
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.51pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,724,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Qlaris Bio, Inc. Series B
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">4,394,904
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,450,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.65pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">29,455,309
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Convertible Preferred Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">70,344,386
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Convertible Notes<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:56.00%; background-color: #F0F0F0;">Biotechnology&#x2014;0.2%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., 6.00%, 04/10/26
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:2.99%; background-color: #F0F0F0;">$&#x2002;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.85pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">720,872
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.99pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">720,872
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., 8.00%, 04/18/25
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.81pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,569,230
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,569,230
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:19.64pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,290,102
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:56.00%; background-color: #F0F0F0;">Pharmaceuticals&#x2014;0.1%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HiberCell, Inc., 10.00%, 12/31/25
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">439,002
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">439,002
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Total Convertible Notes
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:19.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,729,104
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Common Stocks&#x2014;89.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;59.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">AbbVie, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">74,154
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">15,536,746
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Akero Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">242,032
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.04pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">9,797,455
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Alkermes PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">89,235
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,946,540
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">97,674
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.30pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">26,373,934
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Amgen, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">182,323
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">56,802,731
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arcutis Biotherapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">395,004
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.04pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">6,177,863
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Argenx SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.07pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">29,509
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">17,465,344
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Arrowhead Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">517,298
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">6,590,377
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">ARS Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">433,475
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5,453,116
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Ascendis Pharma AS, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:14.51pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">96,830
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:17.80pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">15,091,924
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:56.00%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:4pt; padding-top:1.5pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">
</td><td style="padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">
</td><td style="padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">
</td><td style="padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; text-align:left; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Avidity Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.25pt; padding-right:4pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;141,554
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$<font style="padding-left:0.14pt"></font>&#x2002;&#x2007;&#x2007;4,178,674
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;393,089
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;27,787,461
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">BioNTech SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.07pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;211,403
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;19,250,357
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.91pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;91,800
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;207,468
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Cidara Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;84,117
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.24pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;1,811,880
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Crinetics Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.16pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;116,778
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.35pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,916,734
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Cytokinetics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.16pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;285,648
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;11,480,193
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Denali Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;422,310
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;5,741,304
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Galera Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;296,462
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;8,894
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Geron Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2007;2,332,131
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,708,088
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Gilead Sciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;520,818
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;58,357,657
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">GRAIL, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.96pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;198,327
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;5,065,272
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Halozyme Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4.05pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;67,157
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,285,288
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Ideaya Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.96pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;286,579
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,694,164
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">I-Mab, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.56pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;53,885
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;44,396
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Immunovant, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;556,610
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.50pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;9,512,465
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Insmed, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.00pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">210,996
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">16,096,885
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Ionis Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">264,178
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">7,970,250
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Janux Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.67pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">153,551
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">4,145,877
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Krystal Biotech, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">24,744
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.85pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">4,461,343
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Merus NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.95pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">56,166
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.64pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,364,027
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Mural Oncology PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">17,390
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:30.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">21,911
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Neurocrine Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">114,326
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">12,644,456
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Newamsterdam Pharma Co. NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">119,582
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,447,844
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Novavax, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">37,188
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">238,375
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Nuvalent, Inc., Class A<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.64pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">42,867
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.24pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,040,128
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Praxis Precision Medicines, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">60,418
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,288,030
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Pyxis Oncology, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.79pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">626,637
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">614,042
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Rallybio Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.42pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">755,076
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">494,197
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">88,608
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">56,197,852
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Rhythm Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">71,232
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.90pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,773,159
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Sarepta Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.05pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">284,179
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.94pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">18,136,304
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Scholar Rock Holding Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">58,722
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,887,912
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Sera Prognostics, Inc., Class A<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.10pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">600,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,208,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Sionna Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">520,716
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.76pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5,446,689
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Summit Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.77pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">788,556
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">15,211,245
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Sutro Biopharma, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.14pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">69,389
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:28.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">45,144
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Travere Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.38pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">330,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.85pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5,913,600
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">TScan Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">498,008
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">687,251
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Ultragenyx Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">324,294
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">11,742,686
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">uniQure NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.33pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,149,694
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">12,186,756
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Vaxcyte, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">177,104
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.41pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">6,687,447
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.92pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">77,609
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">37,626,395
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Vir Biotechnology, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">477,038
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,091,206
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Xencor, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">191,603
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,038,656
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Xenon Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">245,906
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.55pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">8,250,146
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:8.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">570,244,138
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;7.9%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Abbott Laboratories<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">146,684
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.22pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">19,457,633
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Becton Dickinson &amp; Co.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.10pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">46,369
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">10,621,283
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Boston Scientific Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.58pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">22,943
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,314,490
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Dexcom, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.17pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">64,933
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">4,434,275
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Inspire Medical Systems, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">45,501
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">7,247,399
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Insulet Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.20pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">4,770
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">1,252,650
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Intuitive Surgical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.01pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">23,786
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">11,780,492
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Medtronic PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">140,729
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">12,645,908
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Stryker Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.68pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">5,969
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,221,960
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Tandem Diabetes Care, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.80pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">170,194
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,260,917
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Willow Laboratories, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">160,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:42.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">16
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:0.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:0.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:0.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:12.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">75,237,023
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:14pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">6
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:56.00%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Common Stocks (continued)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Health Care Providers &amp; Services&#x2014;6.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Elevance Health, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.57pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;23,071
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$<font style="padding-left:0.11pt"></font>&#x2002;&#x2007;10,034,962
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Guardant Health, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;128,783
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.04pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;5,486,156
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HCA Healthcare, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.13pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;14,452
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,993,888
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">McKesson Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.93pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;3,401
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;2,288,839
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Molina Healthcare, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.76pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;14,994
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.99pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,938,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Tenet Healthcare Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;35,984
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,839,848
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">UnitedHealth Group, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;50,353
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.08pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;26,372,384
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">58,954,951
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Life Sciences Tools &amp; Services&#x2014;5.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Adaptive Biotechnologies Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;764,885
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.48pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;5,683,095
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Danaher Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;20,650
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.76pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,233,250
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Illumina, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(f)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;143,240
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;11,364,662
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Medpace Holdings, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;15,401
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.85pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;4,692,531
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Personalis, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;810,579
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.53pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;2,845,132
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Tempus AI, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.68pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;168,958
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;8,150,534
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Thermo Fisher Scientific, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.11pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;26,994
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;13,432,214
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.29pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">50,401,418
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;10.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Amylyx Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.99pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,687,269
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5,972,932
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">AstraZeneca PLC, ADR
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">127,486
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">9,370,221
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Axsome Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.76pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">34,152
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,983,148
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Bristol-Myers Squibb Co.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.74pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">50,638
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,088,412
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Edgewise Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">196,575
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">4,324,650
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Eli Lilly &amp; Co.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:17.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">41,131
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">33,970,504
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">EyePoint Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.07pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">160,464
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.91pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">869,715
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.70pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">7,593
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:30.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">10,478
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Merck &amp; Co., Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">127,564
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">11,450,145
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Oculis Holding AG<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">407,012
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">7,745,438
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.71pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">79,790
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:48.17pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Structure Therapeutics, Inc., ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">169,939
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2,941,644
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Tetraphase Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.39pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">28,747
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:40.75pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">575
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Teva Pharmaceutical Industries Ltd., ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">235,815
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.65pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,624,477
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Zoetis, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.46pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">45,408
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">7,476,427
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">94,828,766
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Common Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:8.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">849,666,296
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Warrants<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:56.00%; background-color: #F0F0F0;">Pharmaceuticals&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/15/28, exercise price $0.46)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.39pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">1,529,261
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:48.56pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">2
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/13/34, exercise price $0.08)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.52pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">5,487,525
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:48.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">5
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:8pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:8pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.5pt; padding-left:48.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">7
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:56.00%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Short-Term Investment&#x2014;2.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">State Street Institutional U.S. Government Money Market Fund, Premier Class, 4.29%<sup style="font-size:85%; font-style:Normal; text-transform:none">(g)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #F0F0F0;">23,346,081
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$<font style="padding-left:0.57pt"></font>&#x2002;&#x2007;23,346,081
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">23,346,081
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Investments Before Milestone Interests&#x2014;99.5%<br>
(Cost $893,643,696)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:9.35pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">946,085,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.05%; background-color: #CCCCCC;">Interests
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.93%; background-color: #F0F0F0;" colspan="4">Milestone Interests<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;2.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;0.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$<font style="padding-left:1.10pt"></font>&#x2002;&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;3,092,652
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:18.37pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">3,092,652
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.93%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;2.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;&#x2007;1,638,962
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:56.00%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.98pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">&#x2007;17,226,142
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:56.00%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:16.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:15.51pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">18,865,104
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Milestone Interests
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:16.73pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">21,957,756
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Total Investments (Cost $900,374,735)<sup style="font-size:85%; font-style:Normal; text-transform:none">(h)</sup>&#x2014;101.8%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:8.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">968,043,630
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Liabilities in Excess of Other Assets (1.8%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.07pt; padding-right:6pt; padding-top:1.5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.88%; background-color: #F0F0F0;">(16,834,239)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.05%; background-color: #F0F0F0;" colspan="3">Net Assets&#x2014;100.0%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.88%; background-color: #F0F0F0;">$<font style="padding-left:2.80pt"></font>951,209,391
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Level 3 security. See Note 2(a) of the accompanying Notes to&#xa0;Financial Statements.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Non-income producing security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Restricted security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Affiliated issuers in which the Fund holds 5% or more of the voting securities (total market value of $13,184,582).
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Foreign security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">A portion of security is pledged as collateral for call options written.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(g)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">Registered investment company advised by State Street Global Advisors. The rate shown is the 7 day yield as of March 31, 2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.01%">(h)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.56%">See accompanying Notes to Financial Statements for tax unrealized appreciation/(depreciation) of securities.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ADR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">American Depositary Receipt
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ARS
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Auction Rate Security
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">CVR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Contingent Value Right
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">PLC
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Public Limited Company
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; width:100%">
</div>
</div>
<div style="padding-top:160pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.30%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">7
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.91%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:34.14%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.73%; background-color: #CCCCCC;">Number of Contracts<br>
(100 shares each)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.61%; background-color: #CCCCCC;">Notional Amount ($)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.62%; background-color: #CCCCCC;">Value ($)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Option Contracts Written&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Call Options Written&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Abbott Laboratories Apr25 135 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">183
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(2,470,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(42,090)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">AbbVie, Inc. Apr25 215 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">46
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(989,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(4,048)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Akero Therapeutics, Inc. Apr25 50 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">198
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(990,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(5,742)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Alnylam Pharmaceuticals, Inc. Apr25 270 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">37
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(999,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(29,230)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Amgen, Inc. Apr25 330 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">75
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(2,475,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(9,000)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Becton Dickinson &amp; Co. Apr25 240 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">41
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(984,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(4,100)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">BioMarin Pharmaceutical, Inc. Apr25 75 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">264
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,980,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(10,560)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">BioNTech SE Apr25 105 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">141
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,480,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(5,640)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Boston Scientific Corp. Apr25 100 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">99
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(990,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(29,700)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Cytokinetics, Inc. Apr25 50 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">198
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(990,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(10,890)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Gilead Sciences, Inc. Apr25 115 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">129
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,483,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(19,350)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Illumina, Inc. Apr25 90 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">165
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,485,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(5,775)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Intuitive Surgical, Inc. Apr25 520 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">19
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(988,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(2,755)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Medtronic PLC Apr25 95 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">208
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,976,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(5,408)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Regeneron Pharmaceuticals, Inc. Apr25 680 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">15
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,020,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(6,000)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Regeneron Pharmaceuticals, Inc. Apr25 680 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">22
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,496,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(2,860)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Sarepta Therapeutics, Inc. Apr25 85 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">465
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(3,952,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(6,975)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Summit Therapeutics, Inc. Apr25 25 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">594
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,485,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(9,504)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Tenet Healthcare Corp. Apr25 135 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">147
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,984,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(71,295)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Thermo Fisher Scientific, Inc. Apr25 540 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">18
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(972,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(1,836)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">uniQure NV Apr25 15 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">659
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(988,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(6,590)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">UnitedHealth Group, Inc. Apr25 530 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">47
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(2,491,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(84,835)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Vertex Pharmaceuticals, Inc. Apr25 530 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">28
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,484,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(3,024)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.14%; background-color: #E6E6E6;">Zoetis, Inc. Apr25 170 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.73%; background-color: #E6E6E6;">87
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.61%; background-color: #E6E6E6;">(1,479,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(11,310)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:14pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:bottom; width:85.49%; background-color: #E6E6E6;" colspan="3">Total Call Options Written<br>
(Premiums received $(700,455))
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:18.62%; background-color: #E6E6E6;">(388,517)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to Financial
Statements.</div>
</div>
<div style="margin-top:305pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">8
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Assets and Liabilities&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.35%">Assets
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.83%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Investments in unaffiliated issuers, at value(cost $848,891,219)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">$<font style="padding-left:2.43pt"></font>&#x2003;909,555,211
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Investments in affiliated issuers, at value (cost $21,406,385)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:19.93pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#x2003;13,184,582
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Short-term investment, at value (cost $23,346,081)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:17.77pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#x2003;23,346,081
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Milestone interests, at value(cost $6,731,050)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:20.91pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#x2003;21,957,756
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Foreign currency, at value (cost $56)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:58.85pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">54
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Receivable for investments sold
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:30.43pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">9,786,320
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Interest and dividends receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:36.81pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">452,458
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Tax reclaim receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:44.06pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">13,787
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:43.01pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">71,409
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Other assets (Note 2j)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:54.95pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">272
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Total assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:18.84pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">978,367,930
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.35%">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Due to custodian
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:27.62pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">16,120,538
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Payable for investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.74pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">9,385,453
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Investment advisory fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.97pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">847,459
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Written options, at value (premiums received$700,455)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:38.41pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">388,517
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Trustee fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:43.57pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">31,523
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Administration fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:43.05pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">13,629
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Investor relations fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:46.22pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">6,806
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Other accrued expenses
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:37.65pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">364,614
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Total liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:25.91pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.83%; background-color: #F0F0F0;">27,158,539
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Commitments and Contingencies (Notes 8 &amp; 10)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">$<font style="padding-left:6.50pt"></font>951,209,391
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Composition of Net Assets
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Common stock (par value $0.010 per share) (Note 5)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">$<font style="padding-left:17.09pt"></font>&#x2003;538,622
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Paid-in capital in excess of par
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:12.68pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#x2003;970,096,265
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Accumulated loss
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.20pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">&#x2003;(19,425,496)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">$<font style="padding-left:6.50pt"></font>951,209,391
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.35%">Net asset value per share based on 53,862,184 shares issued and outstanding
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.83%; background-color: #F0F0F0;">$<font style="padding-left:36.90pt"></font>17.66
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:213pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.30%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">9
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Operations&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Six-Month Period Ended March 31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net Investment Income
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:12.24%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investment Income:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.94%">Dividends
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">$<font style="padding-left:1.91pt"></font>&#x2003;3,951,904
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Interest and other income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.14pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;780,840
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Total investment income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.64pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">4,732,744
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.94%">Expenses:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investment advisory fee (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:13.83pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;4,952,246
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Legal fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:21.65pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;134,907
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Independent auditors&#x2019; fees and tax expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:26.89pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;78,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Reports to shareholders and proxy solicitation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.77pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;78,390
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Trustees' fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.32pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;70,089
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investor relations fees and expenses (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:24.83pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;49,384
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Insurance expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:26.04pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;32,202
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Custodian&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:26.34pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;31,490
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Transfer agent&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:28.16pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;30,119
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Administration fee
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.72pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;25,605
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.94%">Miscellaneous
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.62pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#x2003;74,659
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Total expenses
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.25pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">5,557,965
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net Investment Loss
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.80pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">(825,221)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net Realized/Unrealized Gain/(Loss):
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net realized gain/(loss) from:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investments in unaffiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:17.07pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">10,822,294
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.92pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">991,833
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.94%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.54pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">11,814,127
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net change in unrealized appreciation/depreciation on:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.24%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investments in unaffiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:13.53pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">(88,668,745)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Investments in affiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:23.20pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">2,123,963
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Milestone interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:30.17pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">612,225
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Written options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.80pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">110,934
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Foreign currency translation
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:52.33pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">(2)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.94%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:14.45pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">(85,821,625)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Net realized and unrealized gain from investments, milestone interests, written options and foreign
currencies
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:14.77pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">(74,007,498)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.94%">Change in Net Assets Resulting from Operations
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.24%; background-color: #F0F0F0;">$(74,832,719)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:156pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">10
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statements of Changes in Net Assets<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:67.71%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.85%">For the<br>
Six-Month<br>
Period Ended<br>
March 31, 2025<br>
(unaudited)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%">For the<br>
Year Ended<br>
September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Increase/(Decrease) in Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:67.71%">Operations:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">$<font style="padding-left:21.27pt"></font>(825,221)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">$<font style="padding-left:22.68pt"></font>(349,962)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net realized gain from investments and written options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:28.47pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">11,814,127
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:28.04pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">47,763,436
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:67.71%">Net change in unrealized appreciation/depreciation investments, milestone interests,
written options and foreign currency translations
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.39pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(85,821,625)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.80pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">137,533,157
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net increase/(decrease) in net assets resulting from operations
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.89pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(74,832,719)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.86pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">184,946,631
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Distributions to Shareholders From:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.72pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(62,538,774)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.36pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(72,972,514)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:62.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.82pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(30,002,831)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net decrease in net assets from distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.72pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(62,538,774)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.17pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(102,975,345)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:67.71%">Reinvestment of dividends resulting in the issuance of 1,732,292 and 2,687,876 shares
of common stock, respectively
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.91pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">28,984,932
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.67pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">46,281,675
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Change in net assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.83pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">(108,386,561)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.16pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">128,252,961
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">Beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:12.68pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.85%; background-color: #F0F0F0;">1,059,595,952
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.59pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">931,342,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:67.71%">End of period
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.85%; background-color: #F0F0F0;">$<font style="padding-left:4.66pt"></font>951,209,391
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">$1,059,595,952
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:296pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.30%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">11
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Cash Flows&#xa0;<font style="font-size:11pt; line-height:14pt"> (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Six-Month Period Ended&#xa0;&#xa0;March
31, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Cash flows from operating activities:
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net increase/(decrease) in net assets resulting from operations
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">$<font style="padding-left:7.92pt"></font>&#x2003;(74,832,719)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:84.76%">Adjustments to reconcile net increase in net assets resulting<br>
from operations to net cash provided by operating activities:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.68pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;(335,036,652)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Investments sold and principal repayments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.45pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;340,783,605
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Proceeds from option contracts written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:28.45pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;1,227,639
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net change in short-term investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:22.30pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;11,085,456
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Decrease in interest, dividends and other receivables
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:37.02pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;42,908
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Decrease in prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:38.08pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;22,992
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Decrease in accrued investment advisory fee payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:35.59pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;(14,022)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Increase in other accrued expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.47pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;146,599
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net change in unrealized depreciation of investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.67pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;85,821,623
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net change in unrealized depreciation on foreign currency translation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:59.73pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;2
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net realized gain on investments transactions and options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.0pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#x2003;(11,814,127)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net cash provided by operating activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:27.18pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">17,433,304
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Cash flows from financing activities:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Increase in payable to custodian
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">$<font style="padding-left:10.82pt"></font>&#x2003;16,120,538
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Distributions paid to shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.26pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">(33,553,842)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net cash used in financing activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:23.88pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">(17,433,304)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Effect of exchange rate on cash
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:64.36pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">(2)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Net change in cash
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:64.36pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">(2)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Unrestricted and restricted cash and foreign currency, beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:62.24pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.42%; background-color: #F0F0F0;">56
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:84.76%">Unrestricted and restricted cash and foreign currency, end of period
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.42%; background-color: #F0F0F0;">$<font style="padding-left:48.83pt"></font>54
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:292pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">12
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9.5pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:36.09%; background-color: #D9D9D9;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.23%; background-color: #D9D9D9;">For the<br>
Six-Month<br>
Period Ended<br>
March 31,
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:50.46%; background-color: #D9D9D9;" colspan="5">For the Fiscal Years Ended September 30,
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:36.09%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.23%; background-color: #D9D9D9;">2025<br>
(unaudited)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #D9D9D9;">2024<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #D9D9D9;">2023<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #D9D9D9;">2022<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #D9D9D9;">2021<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #D9D9D9;">2020<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">PER SHARE OPERATING PERFORMANCE:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:10.45%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.13%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:10.22%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:10.12%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:10.53%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net asset value per common share, beginning of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.55pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$20.33
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.90pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">$18.84
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.37pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">$19.36
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.95pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">$25.47
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">$24.04
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.83pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">$20.33
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net investment loss<sup style="font-size:85%; font-style:Normal; text-transform:none">(c)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.29pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.02)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:30.02pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(0.01)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.07pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">(0.02)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.49pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(0.08)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:29.28pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">(0.14)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:29.55pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">(0.05)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net realized and unrealized gains/(losses) on investments, written
options and foreign currency transactions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.40pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.46)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:32.37pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">3.54
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">1.11
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.95pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(4.20)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:30.54pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">3.63
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:32.95pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">5.50
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Total from investment operations applicable to common shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.27pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.48)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:32.57pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">3.53
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.16pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">1.09
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.99pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(4.28)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:30.39pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">3.49
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:33.0pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">5.45
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Distributions to common shareholders from:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.45%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.13%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.22%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.12%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.53%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net investment income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:30.75pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.19)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:29.27pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(0.56)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:38.09pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:31.14pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(0.11)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:28.68pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">(0.61)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:30.46pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">(0.01)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net realized gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:43.31pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:28.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(0.89)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.74pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">(1.61)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:30.16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(1.72)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:28.73pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">(1.45)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:32.05pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">(1.77)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.31pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.33pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(0.59)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.09pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.38pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:45.59pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Total distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:30.75pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(1.19)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.17pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(2.04)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.74pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">(1.61)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.09pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(1.83)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.53pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">(2.06)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:31.53pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">(1.78)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Effect of Fund shares repurchased
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.31pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:45.14pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.09pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.93pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:43.38pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:32.13pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">0.04
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net asset value per common share, end of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.13pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$17.66
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.38pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">$20.33
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.84pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">$18.84
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.21pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">$19.36
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.39pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">$25.47
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.73pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">$24.04
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Market price, end of period
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.93pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$16.24
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.44pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">$18.62
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.03pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">$15.55
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.89pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">$17.28
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.78pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">$25.57
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.96pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">$20.62
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Total Investment Return Based on<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.45%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.13%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.22%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.12%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:10.53%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Market price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.99pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(6.47%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.31pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">34.58%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.91pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">(1.24%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16.33pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(26.01%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:17.28pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">34.64%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.97pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">23.38%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net asset value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.19pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(6.80%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.41pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">21.28%<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">6.80%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16.94pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(16.78%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">15.03%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:21.26pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">29.77%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Ratio to Average Net Assets Applicable to Common Shareholders/Supplementary Data:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:12.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:10.45%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.13%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:10.22%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:10.12%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:10.53%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net assets applicable to common shareholders, end of period (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:11.96pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$951,209
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">$1,059,596
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">$931,343
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:12.52pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">$916,565
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.63pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">$1,156,902
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">$1,054,696
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Average net assets applicable to common shareholders (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">$1,011,602
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.82pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">$989,149
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.96pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">$976,134
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">$1,007,052
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">$1,143,870
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.34pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">$991,235
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Gross operating expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:21.34pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">1.10%<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.92pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">1.12%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.45pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">1.18%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:26.48pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">1.19%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.05pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">1.11%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:27.91pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">1.10%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Net Investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:21.49pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">(0.16%)<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.86pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">(0.04%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16.55pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">(0.12%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.01pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">(0.36%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.53pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">(0.54%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:21.71pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">(0.20%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:36.09%; background-color: #F0F0F0;">Portfolio turnover
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.01pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.23%; background-color: #F0F0F0;">34%<sup style="font-size:85%; font-style:Normal; text-transform:none">(g)</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:31.17pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.45%; background-color: #F0F0F0;">44%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.31pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.13%; background-color: #F0F0F0;">43%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:31.26pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.22%; background-color: #F0F0F0;">41%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.71pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.12%; background-color: #F0F0F0;">69%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:32.41pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.53%; background-color: #F0F0F0;">52%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Effective October 27, 2023, abrdn Inc. became the investment adviser of the Fund. Prior to October 27, 2023, the Fund was managed by Tekla Capital Management, LLC. Members of the portfolio management
team from Tekla joined abrdn Inc., and continue to manage the Fund.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Beginning with the year ended September 30, 2023, the Fund&#x2019;s financial statements were audited by KPMG LLP.<br>
Previous years were audited by a different independent registered public accounting firm.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Based on average shares outstanding.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Total investment return based on market value is calculated assuming that shares of the Fund&#x2019;s common stock were purchased at the closing market price as of the beginning of the period, dividends,
capital gains and other distributions were reinvested as provided for in the Fund&#x2019;s dividend reinvestment plan and then sold at the closing market price per share on the last day of the period. The computation
does not reflect any sales commission investors may incur in purchasing or selling shares of the Fund. The total investment return based on the net asset value is similarly computed except that the Fund&#x2019;s net
asset value is substituted for the closing market value.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">The total return shown above includes the impact of financial statement rounding of the NAV per share and/or financial statement adjustments.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Annualized.<div style="margin-top:19pt"></div><font style="font-size:9.5pt; line-height:12.5pt">See accompanying Notes to Financial Statements.</font>
</td></tr></table>
</div>
</div>
<div style="margin-top:3pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">13
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt; width:100%">
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(g)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Not annualized.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:620pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">14
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">1.&#xa0;&#xa0;Organization</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">abrdn Healthcare Investors
(the "Fund") is a Massachusetts business trust formed on October 31, 1986 and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund commenced
operations on April 22, 1987. The Fund&#x2019;s investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. In addition, the Fund seeks to provide
regular distribution of realized capital gains. The Fund invests primarily in securities of public and private companies that are believed by the Fund&#x2019;s investment adviser, abrdn Inc. (the "Investment Adviser,"
the "Adviser" or "Aberdeen")&#xa0;to have significant potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western
Europe, Canada and Japan, and securities of U.S. issuers that are traded primarily in foreign markets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">2.&#xa0;&#xa0;Summary of Significant
Accounting Policies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is an investment
company and accordingly follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 946 Financial Services-Investment
Companies. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements. The policies conform to generally accepted accounting principles in the
United States of America ("U.S.&#xa0;GAAP"). The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The accounting records of
the Fund are maintained in U.S. Dollars and the U.S. Dollar is used as both the functional and reporting currency.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Security Valuation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund values its
securities at fair value, consistent with regulatory requirements. "Fair value" is defined in the Fund's Valuation and Liquidity Procedures as the price that could be received to sell an asset or paid to transfer a
liability in an orderly transaction between willing market participants without a compulsion to transact at the measurement date, also referred to as market value. Pursuant to Rule 2a-5 under the 1940 Act, the Board
designated Aberdeen as the valuation designee ("Valuation Designee") for the Fund to perform the fair value determinations relating to Fund investments for which market quotations are not readily available or
deemed&#xa0;unreliable and the Fund's investments in securities of early and/or later stage financing of a privately held companies ("Venture Capital Securities").</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In accordance with the
authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Fund discloses</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the fair value of its investments using a
three-level hierarchy that classifies the inputs to valuation techniques used to measure the fair value. The hierarchy assigns Level 1, the highest level, measurements to valuations based upon unadjusted quoted prices
in active markets for identical assets, Level 2 measurements to valuations based upon other significant observable inputs, including adjusted quoted prices in active markets for similar assets, and Level 3, the lowest
level, measurements to valuations based upon unobservable inputs that are significant to the valuation. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability,
including assumptions about risk, for example, the risk inherent in a particular valuation technique used to measure fair value including a pricing model and/or the risk inherent in the inputs to the valuation
technique. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability, which are based on market data obtained
from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or
liability developed based on the best information available in the circumstances. A financial instrument&#x2019;s level within the fair value hierarchy is based upon the lowest level of any input that is significant to
the fair value measurement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Long-term debt and other
fixed-income securities are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service provider. If there are no current day bids, the security is valued at the
previously applied bid. Pricing services generally price debt securities assuming orderly transactions of an institutional &#x201c;round lot&#x201d; size and the strategies employed by the Valuation Designee generally
trade in round lot sizes. In certain circumstances, some trades may occur in smaller &#x201c;odd lot&#x201d; sizes which may be effected at lower, or higher, prices than institutional round lot trades. Short-term debt
securities (such as commercial paper and U.S. treasury bills) having a remaining maturity of 60 days or less are valued at the last quoted or evaluated bid price on the valuation date provided by an independent
pricing service, or on the basis of amortized cost, if it represents the best approximation of fair value. Debt and other fixed-income securities are generally determined to be Level 2 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Equity securities that are
traded on an exchange are valued at the last quoted sale price or the official close price on the principal exchange on which the security is traded at the &#x201c;Valuation Time&#x201d; subject to application, when
appropriate, of the valuation factors described in the paragraph below. Under normal circumstances, the Valuation Time is as of the close of regular trading on the New York Stock Exchange ("NYSE") (usually 4:00 p.m.
Eastern Time). In the absence of a sale price, the security is valued at the mean of the bid/ask price quoted at the close on the principal exchange on which the security is traded.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">15
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Securities traded on NASDAQ are valued at the
NASDAQ official closing price.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Convertible preferred shares,
warrants or convertible note interests in Venture Capital Securities, milestone interests, and other restricted securities are typically valued in good faith, based upon the recommendations made by&#xa0;the Valuation
Designee pursuant to fair valuation policies and procedures approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Derivative instruments are
valued at fair value. Exchange-traded futures are generally Level 1 investments and centrally cleared swaps and forwards are generally Level 2 investments. Forward foreign currency contracts are generally valued based
on the bid price of the forward rates and the current spot rate. Forward exchange rate quotations are available for scheduled settlement dates, such as 1-, 3-, 6-, 9- and 12-month periods. An interpolated valuation is
derived based on the actual settlement dates of the forward contracts held. Futures contracts are valued at the settlement price or at the last bid price if no settlement price is available. Swap agreements are
generally valued by an approved pricing agent based on the terms of the swap agreement (including future cash flows). Exchange-traded options are valued at the last quoted sales price. In the absence of a sales price,
options are valued at the mean of the bid/ask price quoted at the close on the exchange on which the options trade. When market quotations or exchange rates are not readily available, or if the Adviser concludes that
such market quotations do not accurately reflect fair value, the fair value of the Fund&#x2019;s assets are determined in good faith in accordance with the Valuation Procedures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign equity securities
that are traded on foreign exchanges that close prior to the Valuation Time are valued by applying valuation factors to the last sale price or the mean price as noted above. Valuation factors are provided by an
independent pricing service provider. These valuation factors are used when pricing the Fund's portfolio holdings to estimate market movements between the time foreign markets close and the time the Fund values such
foreign securities. These valuation factors are based on inputs such as depositary receipts, indices, futures, sector indices/exchange-traded funds ("ETFs"), exchange rates, and local exchange opening and closing
prices of each security. When prices with the application of valuation factors are utilized, the value assigned to the foreign securities may not be the same as quoted or published prices of the securities on their
primary markets. A security that applies a valuation factor is generally determined to be a Level 2 investment because the exchange-traded price has been adjusted. Valuation factors are not utilized if the independent
pricing service provider is unable to provide a valuation factor or if the valuation factor falls below a predetermined threshold; in such case, the security is determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Short-term investments are
comprised of cash and cash equivalents invested in short-term investment funds which are redeemable daily.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund sweeps available cash into the
State Street Institutional&#xa0;U.S. Government Money Market Fund, which has elected to qualify as a &#x201c;government money market fund&#x201d; pursuant to Rule 2a-7 under the 1940 Act, and has an objective, which is
not guaranteed, to maintain a&#xa0;$1.00 per share NAV. Generally, these investment types are&#xa0;categorized as Level 1 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the event that a
security&#x2019;s, other than a Venture Capital Security, market quotations are not readily available or are deemed unreliable (for reasons other than because the foreign exchange on which it trades closes before the
Valuation Time), the security is valued at fair value as determined by the Valuation Designee, taking into account the relevant factors and surrounding circumstances using valuation policies and procedures approved by
the Board. A security that has been fair valued by the Adviser may be classified as Level 2 or Level 3 depending on the nature of the inputs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture Capital Securities
are valued based on a consideration of relevant factors, including both observable and&#xa0;unobservable inputs. Observable and unobservable inputs considered may include (i) the existence of any contractual
restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the
price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable
companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value.&#xa0;Significant unobservable
inputs are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Additionally, changes in the market environment and
other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these
financial&#xa0;statements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The three-level hierarchy of
inputs is summarized below:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Level 1 - quoted prices
(unadjusted) in active markets for identical investments;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Level 2 - other significant observable
inputs (including valuation factors, quoted prices for similar securities, interest rates, prepayment speeds, and credit risk, etc.); or</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Level 3 - significant unobservable inputs
(including the Fund&#x2019;s own assumptions in determining the fair value of investments).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Level 3 investments are
valued using significant unobservable inputs. The Fund may also use a discounted cash flow based valuation approach in which the anticipated future cash flows of the investment are used to estimate the current fair
value. The derived value of a</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:22.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">16
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Level 3 investment may not represent the value
which is received upon disposition and this could impact the results of&#xa0;operations.</div>
</div>
<div style="margin-top:8.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">A summary of standard inputs is
listed below:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.05%">Security Type
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.11%">Standard Inputs
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:2.88pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:33.05%; background-color: #F0F0F0;">Foreign equities utilizing a fair value factor
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:2.88pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:66.11%; background-color: #F0F0F0;">Depositary receipts, indices, futures, sector indices/ETFs, exchange rates, and local
exchange opening and closing prices of each security.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of
the inputs used as of March 31, 2025 in valuing the Fund's investments and other financial instruments at fair value. The inputs or methodology used for valuing securities are not necessarily an indication of the risk
associated with investing in those securities. Please refer to the Portfolio of Investments for a detailed breakout of the security types:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:34.95%">Investments, at Value
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%">Level 1 &#x2013; Quoted<br>
Prices
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%">Level 2 &#x2013; Other Significant<br>
Observable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%">Level 3 &#x2013; Significant<br>
Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.82%; background-color: #F0F0F0;" colspan="3">Assets
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:48.96%; background-color: #F0F0F0;" colspan="2">Investments in Securities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:4.17pt"></font>849,447,759
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:16.49pt"></font>218,537
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">$<font style="padding-left:3.62pt"></font>849,666,296
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:58.46pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.07pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">70,344,386
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.77pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">70,344,386
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:58.46pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.14pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">21,957,756
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.84pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">21,957,756
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:58.46pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.89pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">2,729,104
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:27.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">2,729,104
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:34.95%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:58.46pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.04pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">7
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:59.74pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">7
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:19.25pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">23,346,081
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:11.18pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.22pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:20.71pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">23,346,081
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Total Investments
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$872,793,840
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:0.22pt"></font>95,249,790
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.14%; background-color: #F0F0F0;">$968,043,630
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:47.49pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:31.62pt"></font><font style="font-weight:bold">272</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">$<font style="padding-left:38.33pt"></font><font style="font-weight:bold">272</font>
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Total Investment Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$872,793,840
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">$95,250,062
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">$<font style="padding-left:0.23pt"></font>968,043,902
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:69.82%; background-color: #F0F0F0;" colspan="3">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:48.96%; background-color: #F0F0F0;" colspan="2">Other Financial Instruments
</td><td style="line-height:9.5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:18.35pt"></font>(388,517)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.25pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">$<font style="padding-left:19.80pt"></font>(388,517)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:34.95%; background-color: #F0F0F0;">Total Investment Liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:15.88pt"></font>(388,517)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.04pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.14%; background-color: #F0F0F0;">$<font style="padding-left:17.34pt"></font>(388,517)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
</div>
<div style="margin-top:290pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">17
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.26%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:100.00%" colspan="7">Rollforward of Level 3 Fair Value Measurements<br>
For the Six Months Ended March 31, 2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%">Investments<br>
in Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2024
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%">Net Realized<br>
Gain (Loss)<br>
and Change<br>
in Unrealized<br>
Appreciation/<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.95%">Net<br>
Purchases<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.30%">Net<br>
Sales<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.10%">Balance<br>
as of<br>
March 31,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%">Net Change in<br>
Unrealized<br>
Appreciation/<br>
Depreciation<br>
from<br>
Investments<br>
Held at<br>
March 31,<br>
2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Common Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.55pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$207,468
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:36.57pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:39.12pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.02pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.55pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">$207,468
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:36.57pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">$0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.52pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:25.73pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,203
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:24.68pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(1,150)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:30.61pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">11,053
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:24.68pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">(1,150)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Convertible Notes
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.39pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">2,290,102
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.39pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">2,290,102
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.96pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">439,002
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:22.96pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">439,002
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.36pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">34,452,920
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.95pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">955,158
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.05pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">7,297,915
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.07pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">(1,816,958)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10.48pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">40,889,035
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.95pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">955,158
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.51pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.03pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">27,169,007
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(205,061)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.27pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">2,491,363
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">29,455,309
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">(205,061)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Milestone Interests
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.70pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">3,119,480
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.85pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">183,832
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.90pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">(210,660)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.68pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">3,092,652
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.85pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">183,832
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:8.12pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">18,436,700
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.90pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">428,404
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.64pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">18,865,104
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.90pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">428,404
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Warrants
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:47.04pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">7
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:51.04pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">7
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.88%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:37.58pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">272
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:44.08pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.95%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:45.98pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.30%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.58pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.10%; background-color: #F0F0F0;">272
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.53pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.58%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:33.88%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$86,127,219
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$1,361,183
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.95%; background-color: #F0F0F0;">$9,789,278
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.30%; background-color: #F0F0F0;">$(2,027,618)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.10%; background-color: #F0F0F0;">$95,250,062
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.58%; background-color: #F0F0F0;">$1,361,183
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.72%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.43%">Fair Value at<br>
03/31/25
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.09%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.12%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.72%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.12%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.72%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$218,521
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">0.00% - 90.00%<br>
0.00 - 4.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.12%; background-color: #F0F0F0;">74.73%<br>
1.70 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.72%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$2,729,104
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.12%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:14.72%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$59,183,788
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.12%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.72%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$9,644,379
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Timing of events<br>
Implied market volatility<br>
Risk free rate<br>
Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">3 years<br>
113.26% - 137.91%<br>
3.48% - 4.31%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.12%; background-color: #F0F0F0;">3 years<br>
118.00%<br>
3.64%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Decrease<br>
Decrease<br>
Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:14.72%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$1,516,219
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">4.23% - 4.47%<br>
1.00% - 90%s<br>
1.50 - 12 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.12%; background-color: #F0F0F0;">4.35%<br>
27.16%s<br>
5.59 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr></table>
</div>
</div>
<div style="margin-top:40.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">18
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:85.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.72%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.43%">Fair Value at<br>
03/31/25
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.09%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.12%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.72%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$21,957,756
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:15.09%; background-color: #F0F0F0;">4.23% - 10.00%<br>
0.00% - 90.00%<br>
0.00 - 9.25 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.12%; background-color: #F0F0F0;">5.10%<br>
48.43%<br>
3.60 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.72%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$7
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:15.09%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.12%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increase
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:14.72%; background-color: #F0F0F0;">Other Assets
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$272
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:18.44%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.09%; background-color: #F0F0F0;">4.41%<br>
5.00%<br>
6.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.12%; background-color: #F0F0F0;">4.41%<br>
5.00%<br>
6.75 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">Decrease<br>
Increase<br>
Decrease
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.72%; background-color: #F0F0F0;">Total
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.43%; background-color: #F0F0F0;">$95,250,062
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:18.44%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:19.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:15.09%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.12%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.47%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.09%">The valuation technique used as a basis to approximate fair value of these investments is based on a transaction price or&#xa0;subsequent financing rounds.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Restricted
Securities:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Restricted securities are privately-placed
securities whose resale is restricted under U.S. securities laws. The Fund may invest in restricted securities, including unregistered securities eligible for resale without registration pursuant to Rule 144A and
privately-placed securities of U.S. and non-U.S. issuers offered outside the U.S. without registration pursuant to Regulation S under the Securities Act of 1933, as amended (the "1933 Act"). Rule 144A securities may
be freely traded among certain qualified institutional investors, such as the Fund, but resale of such securities in the U.S. is permitted only in limited circumstances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Foreign Currency
Translation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign securities,
currencies, and other assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate of said currencies against the U.S. Dollar, as of the Valuation Time, as provided by
an independent pricing service approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Foreign currency amounts are
translated into U.S. Dollars on the following basis:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">(i) fair value of investment
securities, other assets and liabilities &#x2013; at the current daily rates of exchange at the Valuation Time; and</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">(ii) purchases and sales of
investment securities, income and expenses &#x2013; at the relevant rates of exchange prevailing on the respective dates of such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund does not isolate
that portion of gains and losses on investments in equity securities due to changes in the foreign exchange rates from the portion due to changes in market prices of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">equity securities. Accordingly, realized and
unrealized foreign currency gains and losses with respect to such securities are included in the reported net realized and unrealized gains and losses on investment transactions balances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net unrealized currency gains
or losses from valuing foreign currency denominated assets and liabilities at period end exchange rates are reflected as a component of net unrealized appreciation/depreciation in value of investments, and translation
of other assets and liabilities denominated in foreign currencies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net realized foreign exchange
gains or losses represent foreign exchange gains and losses from transactions in foreign currencies and forward foreign currency contracts, exchange gains or losses realized between the trade date and settlement date
on security transactions, and the difference between the amounts of interest and dividends recorded on the Fund&#x2019;s books and the U.S. Dollar equivalent of the amounts actually received.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign security and currency
transactions may involve certain considerations and risks not typically associated with those of domestic origin, including unanticipated movements in the value of the foreign currency relative to the U.S. Dollar.
Generally, when the U.S. Dollar rises in value against foreign currency, the Fund's investments denominated in that foreign currency will lose value because the foreign currency is worth fewer U.S. Dollars; the
opposite effect occurs if the U.S. Dollar falls in relative value.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:24.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">19
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Rights Issues and Warrants:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Rights issues give the
right, normally to existing shareholders, to buy a proportional number of additional securities at a given price (generally at a discount) within a fixed period (generally a short-term period) and are offered at the
company&#x2019;s discretion. Warrants are securities that give the holder the right to buy common stock at a specified price for a specified period of time. Rights issues and warrants are speculative and have no value
if they are not exercised before the expiration date. Rights issues and warrants are valued at the last sale price on the exchange on which they are traded.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Options:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">An option contract is a
contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a
specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s obligation
under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price, or in the absence of a sale, the mean between the closing bid and asked prices. Gain or
loss is recognized when the option contract expires, is exercised or is closed.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the Fund writes a covered
call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from an increase in the market value of the
underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the
risk of the potential inability of counterparties to meet the terms of their contracts. The Fund&#x2019;s maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may
arise upon entering into option contracts including the risk that an illiquid secondary market will limit the Fund&#x2019;s ability to close out an option contract prior to the expiration date and that a change in the
value of the option contract may not correlate exactly with changes in the value of the securities or currencies hedged.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">All options on securities and
securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the
securities subject to the option or may maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the
option. When the Fund writes a put option, this means that the Fund will maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price
of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Summary of Derivative
Instruments:</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The&#xa0;Fund may
use derivatives for various purposes as noted above. The following is a summary of the fair value of derivative instruments, not accounted for as hedging instruments, as of March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:36.30%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:63.71%" colspan="7">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:36.30%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%">Other
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:100.00%; background-color: #F0F0F0;" colspan="8">Liabilities:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">Unrealized depreciation on:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:36.30%; background-color: #F0F0F0;">Written Options, market value
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:2.14pt"></font>388,517
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.55%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:2.14pt"></font>388,517
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:36.30%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$388,517
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$388,517
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
</div>
<div style="padding-top:128.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">20
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The effect of derivative
instruments on the Statement of Operations for the six-month period ended March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.57%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.43%" colspan="6">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:42.57%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.42%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Realized Gain/(Loss) on Derivatives Recognized<br>
as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:42.57%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:2.16pt"></font>991,833
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:2.16pt"></font>991,833
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.57%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.42%; background-color: #F0F0F0;">$991,833
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.42%; background-color: #F0F0F0;">$991,833
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="7">Net Change in Unrealized Appreciation/Depreciation on<br>
Derivatives Recognized as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:42.57%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:3.04pt"></font>110,934
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:3.04pt"></font>110,934
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.57%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:0.80pt"></font>110,934
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.42%; background-color: #F0F0F0;">$<font style="padding-left:0.80pt"></font>110,934
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Information about derivatives reflected as
of the date of this report is generally indicative of the type of activity for the six-month period ended March 31, 2025. The table below summarizes the weighted average values of derivatives holdings for the Fund
during the six-month period ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:71.24%">Derivative
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:26.46%">Average<br>
Notional Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:71.24%; background-color: #F0F0F0;">Written Options Contracts
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:26.46%; background-color: #F0F0F0;">$278,806
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Security Transactions,
Investment Income and Expenses:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Security transactions are
recorded on the trade date. Realized and unrealized gains/(losses) from security and currency transactions are calculated on the identified cost basis. Dividend income and corporate actions are recorded generally on
the ex-date, except for certain dividends and corporate actions which may be recorded after the ex-date, as soon as the Fund acquires information regarding such dividends or corporate actions. Interest income and
expenses are recorded on an accrual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Distributions:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy to pay distributions from net investment income supplemented by net realized capital gains and return of capital distributions, if necessary, on a quarterly basis. The managed distribution policy
is subject to regular review by the Board. The Fund will also declare and pay distributions at least annually from net realized gains on investment transactions and net realized foreign exchange gains, if any.
Dividends and distributions to shareholders are recorded on the ex-dividend date. Dividends and distributions to shareholders are determined in accordance with federal income tax regulations, which may differ from
U.S.&#xa0;GAAP.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Federal Income Taxes:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to
continue to qualify as a &#x201c;regulated investment company&#x201d; ("RIC") by complying with the provisions available to certain investment companies, as defined in Subchapter M of the Internal Revenue Code of 1986,
as amended (the "Code"), and to make distributions of net investment income and net realized capital gains sufficient to relieve the Fund from all federal income taxes. Therefore, no federal income tax provision is
required.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund recognizes the tax
benefits of uncertain tax positions only where the position is &#x201c;more likely than not&#x201d; to be sustained assuming examination by tax authorities. Management of the Fund has concluded that there are no
significant uncertain tax positions that would require recognition in the financial statements. Since tax authorities can examine previously filed tax returns, the Fund's U.S. federal and state tax returns for each of
the most recent four fiscal years up to the most recent fiscal year ended September 30, 2024 are subject to such review.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Milestone Interests</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund holds financial
instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated
risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The
milestone interests were received as part of the proceeds from the sale of six private companies. Any payments&#xa0;received are treated as a reduction of the cost basis of the milestone interests with payments
received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the milestone interests provide for</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:28.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">21
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">payments at various stages of the
development of Afferent, Amolyt, Amphivena, Ethismos Research, Invetx and Neurovance principal product candidate as of the date of the sale.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of
the impact of the milestone interests on the financial statements as of and for the six-month period ended March 31, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:75.04%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Milestone interests, at value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.66%; background-color: #F0F0F0;">$<font style="padding-left:1.83pt"></font>21,957,756
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:75.04%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Total distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:22.66%; background-color: #F0F0F0;">$15,226,706
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:75.04%; background-color: #F0F0F0;">Statement of Operations, Change in unrealized appreciation/depreciation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.66%; background-color: #F0F0F0;">$<font style="padding-left:12.26pt"></font>612,225
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">j.&#xa0;&#xa0;Other Assets</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Other assets in the
Statement of Assets and Liabilities consists of amounts due to the Fund at various times in the future in connection with the sale of investments in one private company.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">3.&#xa0;&#xa0;Agreements and Transactions
with Affiliates</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Investment Adviser and
Other Affiliated Fees</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective as of the close
of business October 27, 2023, abrdn Inc. serves as the Fund&#x2019;s Investment Adviser pursuant to an investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) with the Fund. The Adviser is a wholly-owned
indirect subsidiary of Aberdeen Group plc. In rendering management services, the Adviser may use the resources of investment adviser subsidiaries of Aberdeen Group plc. These affiliates have entered into procedures
pursuant to which investment professionals from affiliates may render portfolio management and research services as associated persons of the Adviser. As compensation for its services to the Fund, the Investment
Adviser receives an annual investment advisory fee at an annual rate of (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all
other net assets, 0.98% of the average net assets up to $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net
assets thereafter. The aggregate fee would not exceed a rate when annualized of 1.36%. For the six-month period ended March 31, 2025, the Fund paid the Adviser $4,952,246.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Effective upon the close of
business on October 27, 2023, the Adviser entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding leverage costs, interest, taxes, brokerage commissions,
acquired fund fees and expenses and any non-routine expenses) from exceeding 1.17% of the average daily net assets of the Fund on an annualized basis for twelve months (the &#x201c;Expense Limitation Agreement&#x201d;).
The Expense Limitation Agreement may not be terminated before October 27, 2025, without the approval of the Fund&#x2019;s trustees who are not</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">&#x201c;interested persons&#x201d; of the Fund
(as defined in the 1940 Act). For the six-month period ended March 31, 2025 the Adviser did not waive any Fund's expenses pursuant to the Expense Limitation Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Investor Relations:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective March 1, 2024,
under the terms of the Investor Relations Services Agreement, abrdn Inc. is compensated to provide and may pay third parties to provide investor relations services to the Fund and certain other funds advised by
Aberdeen or its affiliates as part of an Investor Relations Program.&#xa0; Under the Investor Relations Services Agreement, the Fund owes a portion of the fees related to the Investor Relations Program (the "Fund's
Portion"). However, investor relations services fees are limited by Aberdeen&#xa0;so that the Fund will only pay up to an annual rate of 0.05% of the Fund's average weekly net assets. Any difference between the capped
rate of 0.05% of the Fund's average weekly net assets and the Fund's Portion is paid for by Aberdeen.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pursuant to the terms of the
Investor Relations Services Agreement, abrdn Inc. (or third parties engaged by Aberdeen), among other things, provides objective and timely information to shareholders based on publicly-available information; provides
information efficiently through the use of technology while offering shareholders immediate access to knowledgeable investor relations representatives; develops and maintains effective communications with investment
professionals from a wide variety of firms; creates and maintains investor relations communication materials such as fund manager interviews, films and webcasts, publishes white papers, magazine articles and other
relevant materials discussing the Fund's investment results, portfolio positioning and outlook; develops and maintains effective communications with large institutional shareholders; responds to specific shareholder
questions; and reports activities and results to the Board and management detailing insight into general shareholder sentiment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the six-month period
ended March 31, 2025, the Fund incurred investor relations fees of approximately $49,384. For the six-month period ended March 31, 2025, Aberdeen did not contribute to the investor relations fees for the Fund because
the Fund&#x2019;s contribution was below 0.05% of the Fund&#x2019;s average weekly net assets on an annual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">4.&#xa0;&#xa0;Investment Transactions</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Purchases and sales of
investment securities (excluding short-term securities) for the six-month period&#xa0;ended March 31, 2025, were $344,422,105 and $348,594,529, respectively.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:22.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">22
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">5.&#xa0;&#xa0;Capital</div>
</div>
<div style="margin-top:7pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund is authorized to
issue an unlimited number of common shares of beneficial interest at par value $0.01 per common share. As of March 31, 2025, there were 53,862,184 shares of common stock issued and outstanding.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table shows the
shares issued by the Fund as a part of a quarterly distribution to shareholders during the fiscal year ended March 31, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:88.10%">Payment Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.90%">Shares Issued
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">January 10, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">884,565
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">March 31, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">847,727
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">6.&#xa0;&#xa0;Other Transactions with
Affiliates</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">An affiliate company is a
company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the six-month period ended March 31, 2025 were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.26%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:3pt; padding-right:2pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:15.92%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.05%">Value at<br>
September 30,<br>
2024
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.08%">Cost of<br>
Purchases
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:8.30%">Proceeds<br>
from<br>
Shares Sold
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.79%">Realized<br>
Gain (Loss)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.40%">Change in<br>
Unrealized<br>
Appreciation/<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:8.49%">Value at<br>
March 31,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.69%">Shares held at<br>
March 31,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.54%">Principal<br>
Amount at<br>
March 31,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.36%">Dividend<br>
Income
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.00%">Capital<br>
Gains<br>
Distributions
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:2pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.92%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:7.45pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.05%; background-color: #F0F0F0;">$1,196,819
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:23.60pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.08%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4.46pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:8.30%; background-color: #F0F0F0;">$(1,816,958)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:2.34pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.79%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4.14pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.40%; background-color: #F0F0F0;">$2,136,358
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:9.58pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:8.49%; background-color: #F0F0F0;">$1,516,219
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:7.25pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.69%; background-color: #F0F0F0;">3,398,254
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:2.34pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:7.54%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:2.34pt; padding-right:2pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.36%; background-color: #F0F0F0;">$0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:2.34pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.00%; background-color: #F0F0F0;">$0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:2pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.92%; background-color: #F0F0F0;">Curasen Therapeutics, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4.95pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.05%; background-color: #F0F0F0;">10,922,803
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:5.28pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.08%; background-color: #F0F0F0;">754,809
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:38.05pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.30%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.79%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:18.42pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.40%; background-color: #F0F0F0;">(9,286)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:8.23pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.49%; background-color: #F0F0F0;">11,668,326
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:4.26pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.69%; background-color: #F0F0F0;">24,334,361
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.54%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.36%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.75pt; padding-left:6.52pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.00%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:4pt; padding-right:2pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.92%; background-color: #F0F0F0;">Priothora Co. Ltd.
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:32.95pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.05%; background-color: #F0F0F0;">39
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:15.47pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.08%; background-color: #F0F0F0;">3,107
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:38.05pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.30%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.79%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:19.84pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.40%; background-color: #F0F0F0;">(3,109)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:35.68pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.49%; background-color: #F0F0F0;">37
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:12.79pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.69%; background-color: #F0F0F0;">346,666
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.54%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:6.52pt; padding-right:2pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.36%; background-color: #F0F0F0;">0
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:6.52pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.00%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:4pt; padding-right:2pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.92%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.05%; background-color: #F0F0F0;">$12,119,661
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.08%; background-color: #F0F0F0;">$757,916
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.30%; background-color: #F0F0F0;">$(1,816,958)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.79%; background-color: #F0F0F0;">$0
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.40%; background-color: #F0F0F0;">$2,123,963
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:8.49%; background-color: #F0F0F0;">$13,184,582
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.69%; background-color: #F0F0F0;">28,079,281
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:7.54%; background-color: #F0F0F0;">$0
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:2pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.36%; background-color: #F0F0F0;">$0
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3pt; padding-left:2pt; padding-right:4pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.00%; background-color: #F0F0F0;">$0
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">7.&#xa0;&#xa0;Open Market Repurchase
Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">In March 2024, the Board
approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July 14, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">For the six-month period ended
March 31, 2025, the Fund did not repurchase any shares through this program.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">8.&#xa0;&#xa0;Private Companies and Other
Restricted Securities</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund may invest in private
companies and other restricted securities if these securities currently comprise 40% or less of net assets. The value of these securities represented 10.01% of the Fund&#x2019;s net assets at March 31, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">At March 31, 2025, the Fund had
a commitment of $6,742,873 relating to additional investments in three private companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table details the
acquisition date, cost, carrying value per unit, and value of the Fund&#x2019;s private companies and other restricted securities at March 31, 2025. The Fund on its own does not have the right to demand that such
securities be registered.</div>
</div>
<div style="margin-top:215pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">23
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.88%">Security
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%">Acquisition<br>
Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%">Cost
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.29%">Carrying Value<br>
per Unit
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Abcuro, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">12/19/23, 8/10/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.55pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.51%; background-color: #F0F0F0;">$2,927,272
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.38pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.29%; background-color: #F0F0F0;">$5.49
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.58pt; padding-right:6pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.44%; background-color: #F0F0F0;">$2,925,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Abcuro, Inc., Series C1 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">2/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:33.20pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">712,120
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">6.04
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.43pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">712,120
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/27/16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:35.78pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">57,300
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.28pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,598,208
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:5.82pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">102.55
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.63pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,638,962
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:56.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/29/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.73pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,367,906
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">16.57
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.91pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,359,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/27/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.21pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,408,611
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.36pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">4.11
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.41pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,399,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/24/22, 1/23/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.13pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,398,454
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.13pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.44pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">438,824
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">5/16/19, 04/2/20,<br>
7/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.75pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">4,244,888
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.46
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.85pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,077,395
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Atalanta Therapeutics, Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.77pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,201,518
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.02pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.80
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.68pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,200,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Aviceda Therapeutics, Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">12/17/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.84pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">509,922
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.32pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">5.76
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.85pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">498,793
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Biotheryx, Inc., Series E &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/19/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.15pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">6,814,111
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.30pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">627,154
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/14/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:34.45pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">35,802
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.71pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">2.26
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.80pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">207,468
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">8/20/24, 1/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,545,504
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,543,792
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/20/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.20pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">10,165,381
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.72pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">10,124,534
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">1/21/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,106,638
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">6.53
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.05pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">4,288,763
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/19/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:30.45pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">792,452
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">6.53
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.28pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">791,936
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Engrail Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/14/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.74pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">5,051,699
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.15pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.06
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.36pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">5,049,999
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/31/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:56.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc., Series A3 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/21/20, 10/28/20
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.89pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">5,612,058
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.89
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.5pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">460,742
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/10/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:41.92pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">4,176
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.27pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.38
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.97pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">10,478
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Glycomine, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">7/22/24, 3/26/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.19pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,952,262
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.80pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.60
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.16pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,950,904
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">HiberCell, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/5/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:32.36pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">711,659
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.46
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.96pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">708,965
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">HiberCell, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/5/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,415,841
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.03pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.41
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.99pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,145,167
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant, expiration date 9/15/28
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/20/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:40.76pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">2,749
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.98pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">2
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.01pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">439,002
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.24pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">439,002
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant, expiration date 9/13/34
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:56.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.70pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">6
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">11/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.46pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">2,055,041
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">2.91
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.15pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,842,733
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/22/20, 6/17/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.59pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">6,925,074
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.88pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">2.07
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.68pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">5,947,513
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:30.80pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">720,872
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">720,872
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/12/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.24pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,412,960
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.92
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.62pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,399,993
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,569,230
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.86pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,569,230
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/4/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.95pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">2,908,820
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.23pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">99.14
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.96pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,092,652
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">IO Light Holdinigs, Inc., Series A2 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/30/20, 5/17/21,<br>
9/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.88pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,395,847
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:45.78pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/20/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">2,166,711
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:7.27pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">351.51
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.49pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">17,226,141
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.86pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,731,484
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">1.05
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,724,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Priothera Co. Ltd., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/7/20
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.26pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">4,052,158
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:45.57pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">38
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Qlaris Bio, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.04pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,453,838
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.79
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.70pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,450,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Quell Therapeutics Ltd., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">11/29/21, 03/23/22,<br>
2/18/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.78pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,420,830
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.12pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">2.08
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.98pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,739,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Recode Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/26/24, 10/12/21,<br>
2/16/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.82pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">3,074,644
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.56pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">9.23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.64pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">3,060,003
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Seismic Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/30/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.91pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">2,931,369
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">4.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.97pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">2,924,983
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/2/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:39.22pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">6,383
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Tetraphase Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/1/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:40.74pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">5,749
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.09pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.02
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:41.71pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">575
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Third Arc Bio, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/15/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">1,956,945
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">2.10
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.99pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">1,950,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.88%; background-color: #F0F0F0;">Willow Laboratories, Inc. &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/31/98
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:56.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.29%; background-color: #F0F0F0;">0.00*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:46.80pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">16
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.88%; background-color: #F0F0F0;">Total
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.51%; background-color: #F0F0F0;">$102,863,488
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:11.29%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.44%; background-color: #F0F0F0;">$95,249,790
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.39%">*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:99.17%">Carrying value is less than $0.01.
</td></tr></table>
</div>
</div>
<div style="margin-top:12.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">24
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">9.&#xa0;&#xa0;Portfolio Investment
Risks</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Concentration Risk:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s portfolio may be more
sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare industries than a portfolio of companies representing a larger number of
industries. This risk is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities. As a result of its concentration policy, the
Fund&#x2019;s investments may be subject to greater risk than a fund that has securities representing a broader range of investments and may cause the value of the Fund&#x2019;s shares to fluctuate significantly over
relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Derivatives Risk
(including Options):</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Derivatives are speculative
and may hurt the Fund&#x2019;s performance. The potential benefits to be derived from the Fund&#x2019;s options strategy are dependent upon the portfolio managers&#x2019; ability to discern pricing inefficiencies and
predict trends in these markets, which decisions could prove to be inaccurate.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Equity Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The stock or other security
of a company may not perform as well as expected, and may decrease in value, because of factors related to the company (such as poorer than expected earnings or certain management decisions), to the industry in which
the company is engaged (such as a reduction in the demand for products or services in a particular industry) or to the market as a whole (such as periods of market volatility or instability, or general and prolonged
periods of economic decline). Holders of common stock generally are subject to more risks than holders of preferred stock or debt securities because the right to repayment of common shareholders' claims is
subordinated to that of preferred stock and debt securities upon the bankruptcy of the issuer.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Key Personnel Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">There may be only a limited
number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare companies. If one or more of the team members dies, resigns,
retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Restricted Securities
and Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Some of the Fund&#x2019;s
investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity. The valuation process requires an analysis of various
factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii)</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">information obtained from the issuer which
may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the company&#x2019;s technologies; and (iii) the price of a security sold at arm&#x2019;s length
in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market&#xa0;value for some of the Restricted Securities in the Fund&#x2019;s portfolio, such Restricted
Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund&#x2019;s valuation policy and a consistently applied valuation
process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund&#x2019;s investments determined in good faith by
the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Risks Associated with
the Fund&#x2019;s Option Strategy:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The ability of the Fund to
achieve its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated with transactions in options on securities used in connection with
the Fund's option strategy. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree because of
market behavior or unexpected events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As the writer of a call
option covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the market value of the security covering the call option above the sum of the
premium and the strike price of the call but retains the risk of loss should the price of the underlying security decline. As the Fund writes such covered calls over more of its portfolio, its ability to benefit from
capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities in its portfolio (such as calls on an index or sector), it will lose money if the portion
of the security or securities underlying the option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise price of the option by an amount that exceeds the premium received
on the option plus the exercise price of the option. The amount of this loss theoretically could be unlimited. The writer of an option has no control over the time when it may be required to fulfill its obligations as
a writer of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">25
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">When the Fund writes put options, it bears
the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Fund could incur a loss if it is required to purchase the stock underlying
the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential gain as the writer of a covered
put option is limited to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus the put premium.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Sector Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">To the extent that the Fund
has a significant portion of its assets invested in securities conducting business in a broadly related group of industries within an economic sector, the Fund may be more vulnerable to unfavorable developments in
that economic sector than funds that invest more broadly.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pharmaceutical Sector
Risk<font style="font-style:Normal">. The success of companies in the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs and the related intellectual property
rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the pharmaceutical sector may be adversely
affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products depends in part on the extent to which
reimbursement for the cost of such products and related treatments are available from third-party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Biotechnology Industry
Risk.<font style="font-style:Normal"> The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the
development, protection and exploitation of</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">intellectual property rights and other
proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the expiration of patents or the loss of, or the inability to enforce, intellectual property
rights. The research and other costs associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and
expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug, product or technology.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the
biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals, that transact with companies in the biotechnology industry,
often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a portion of the cost of healthcare related products or services.
Biotechnology companies will continue to be affected by the efforts of governments and third-party payors to contain or reduce health care costs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed Care Sector
Risk.<font style="font-style:Normal"> Companies in the managed care sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future
medical costs over the fixed contract period; however, many factors may cause actual costs to exceed what was estimated and reflected in premiums or bids.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are
regulated at the federal, state, local and international levels. The evolution of the ACA and other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct
business and their results of operations, financial position and cash flows. New laws or regulations could drive substantial change to the way healthcare products and services are currently delivered and paid for in
the United States. A transformative overhaul of the U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life Science and Tools
Industry Risk.&#xa0; <font style="font-style:Normal">Life science industries are characterized by limited product focus, rapidly changing technology,</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:19.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">26
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">extensive government regulation, and intense
competition.&#xa0; In particular, technological advances can render an existing product, which may account for a disproportionate share of a company&#x2019;s revenue, obsolete. Extensive regulation can delay cause
delays in product development, which may disadvantage a company in an intensely competitive environment. These various factors may result in abrupt advances and declines in the securities prices of particular
companies, and, in some cases, may have a broad effect on the prices of securities of companies in particular life science industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk.<font style="font-style:Normal"> Companies in the healthcare technology sector may incur substantial cost related to product-related liabilities, interruptions at their data centers or client support facilities, claims for
infringement or misappropriation of intellectual property rights of others, or infringement or misappropriation of their intellectual property.&#xa0; Each of these may adversely impact the prices of securities of
companies in the healthcare technology sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Additionally, the success of
healthcare technology companies depends upon the recruitment and retention of key personnel. The failure to attract and retain qualified personnel could have a material adverse effect on healthcare technology
companies&#x2019; prospects for long-term growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk.<font style="font-style:Normal"> The operations of healthcare services companies are subject to extensive federal, state and local government regulations. A violation or departure from any of these legal requirements may
result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare services companies fail to adhere to
all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk. <font style="font-style:Normal">If healthcare supplies companies are unable to successfully expand their product lines through internal research and development and acquisitions or are unable to successfully grow their
business through marketing partnerships, their business may be materially and adversely affected.</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely important to healthcare
supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and services. If a healthcare
supplies company fails to meet these standards or fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk.<font style="font-style:Normal"> A healthcare facility&#x2019;s ability to negotiate favorable contracts significantly affects the revenues and operating results of such healthcare facilities. If a healthcare facility is
unable to enter into and maintain managed care contractual arrangements on acceptable terms, if it experiences material reductions in the contracted rates received from managed care payers, or if it has difficulty
collecting from managed care payers, its results of operations could be adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other regulatory changes which could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services to patients and the timing
of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial condition, results of operations or cashflows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Equipment Sector
Risk. <font style="font-style:Normal">The medical device markets are highly competitive and characterized by rapid change, which may affect a company&#x2019;s ability to be competitive. They are also rigorously regulated and it
is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation may increase compliance and legal costs, exposure to&#xa0;&#xa0;&#xa0; litigation, and
other adverse effects to operations.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may negatively impact the ability of healthcare
equipment companies to sell current or future products.&#xa0; Quality problems with the processes, goods and services of a healthcare equipment company could harm the company&#x2019;s reputation for producing
high-quality products and erode its competitive advantage, sales and market share. Quality certifications are critical to the marketing success of goods and services. If a healthcare equipment company fails to meet
these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Distributors
Sector Risk.<font style="font-style:Normal"> Companies in the healthcare distribution sector operate in markets that are highly competitive and in an industry that is highly regulated and often subject to legal proceedings. Due to the
nature of the business of healthcare</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">27
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">distribution companies, each of the above
may have an adverse impact on the securities prices of companies in the healthcare distribution sector.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond
the control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The price that the Fund
could receive upon the sale of any particular portfolio investment may differ from the Fund's valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a
fair valuation methodology or a price provided by an independent pricing service. As a result, the price received upon the sale of an investment may be less than the value ascribed by the Fund, and the Fund could
realize a greater than expected loss or lower than expected gain upon the sale of the investment. The Fund's ability to value its investments may also be impacted by technological issues and/or errors by pricing
services or other third-party service providers.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Venture Capital
Investments Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may occasionally
invest in venture capital opportunities. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of risk that can result in substantial losses. Some of the
venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of development, have little or no operating history, operate at a loss or with
substantial variations in operating results</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from period to period, have limited
products, markets, financial resources or management depth, or have the need for substantial additional &#x201c;follow-on&#x201d; capital to support expansion or to achieve or maintain a competitive position. Such
additional investments may dilute the interests of prior investors, such as the Fund. Some of these companies may be emerging companies at the research and development stage with no marketable or approved products or
technology. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Investment Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low
as &#x201c;C&#x201d; in the rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly
speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">10.&#xa0;&#xa0;Contingencies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the normal course of
business, the Fund may provide general indemnifications pursuant to certain contracts and organizational documents. The Fund's maximum exposure under these arrangements is dependent on future claims that may be made
against the Fund, and therefore, cannot be estimated; however, the Fund expects the risk of loss from such claims to be remote.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">11.&#xa0;&#xa0;Tax
Information</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The U.S. federal
income tax basis of the Fund's investments (including derivatives, if applicable) and the net unrealized appreciation as of March 31, 2025, were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.52%">Tax Cost of<br>
Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.12%">Unrealized<br>
Appreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.30%">Unrealized<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.44%">Net<br>
Unrealized<br>
Appreciation/<br>
(Depreciation)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:0pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.52%; background-color: #F0F0F0;">$936,224,700
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.12%; background-color: #F0F0F0;">$205,386,814
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.30%; background-color: #F0F0F0;">$(173,255,947)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.44%; background-color: #F0F0F0;">$32,130,867
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">12.&#xa0;&#xa0;Segment
Reporting</div>
</div>
</div>
<div style="padding-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">In this reporting period, the Fund adopted
FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). Adoption of the new standard impacted disclosures only and did not
affect the Fund&#x2019;s financial position nor the results of its operations. Operating segments are components of a public entity that engage in business activities</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">from which it may recognize revenues and
incur expenses, have discrete financial information available, and have their operating results regularly reviewed by the public entity&#x2019;s chief operating&#xa0;decision maker (&#x201c;CODM&#x201d;) when assessing
segment performance and making decisions about segment resources. The Chief Financial Officer of the Fund acts as the Fund&#x2019;s CODM. The</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">28
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements&#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">March 31, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">CODM monitors the operating results of the
Fund as a whole, and the Fund&#x2019;s asset allocation is managed in accordance with its Prospectus. The Fund operates as a single operating and reporting segment pursuant to its investment objective and principal
investment strategy. The Fund&#x2019;s portfolio composition, total returns, expense ratios and changes in net assets used by the CODM to assess segment performance and make resource allocations are consistent with the
information presented within the Fund's financial statements. Segment assets are reflected on the Fund&#x2019;s Statement of Assets and Liabilities as &#x201c;Total Assets&#x201d; and significant segment expenses are
listed on the Statement of Operations.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">13.&#xa0;&#xa0;Subsequent Events</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Based on this evaluation,
no disclosures and/or adjustments were required to the financial statements as of March 31, 2025, other than as noted below.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On May 9, 2025, the Fund
announced that it will pay on June 30, 2025, a stock distribution of US $0.54 per share to all shareholders of record as of May 22, 2025.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:516.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.70%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">29
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to distribute to
shareholders substantially all of its net investment income and to distribute any net realized capital gains at least annually. Net investment income for this purpose is income other than net realized long-term and
short-term capital gains net of expenses. Pursuant to the Dividend Reinvestment and Optional Cash Purchase Plan (the &#x201c;Plan&#x201d;), shareholders whose shares of common stock are registered in their own names
will be deemed to have elected to have all distributions automatically reinvested by Computershare Trust Company N.A. (the &#x201c;Plan Agent&#x201d;) in the Fund shares pursuant to the Plan, unless such shareholders
elect to receive distributions in cash. Shareholders who elect to receive distributions in cash will receive such distributions paid by check in U.S. Dollars mailed directly to the shareholder by the Plan Agent, as
dividend paying agent. In the case of shareholders such as banks, brokers or nominees that hold shares for others who are beneficial owners, the Plan Agent will administer the Plan on the basis of the number of shares
certified from time to time by the shareholders as representing the total amount registered in such shareholders&#x2019; names and held for the account of beneficial owners that have not elected to receive
distributions in cash. Investors that own shares registered in the name of a bank, broker or other nominee should consult with such nominee as to participation in the Plan through such nominee and may be required to
have their shares registered in their own names in order to participate in the Plan. Please note that the Fund does not issue certificates so all shares will be registered in book entry form. The Plan Agent serves as
agent for the shareholders in administering the Plan. If the Trustees of the Fund declare an income dividend or a capital gains distribution payable either in the Fund&#x2019;s common stock or in cash, nonparticipants
in the Plan will receive cash and participants in the Plan will receive common stock, to be issued by the Fund or purchased by the Plan Agent in the open market, as provided below. If the market price per share (plus
expected per share fees) on the valuation date equals or exceeds NAV per share on that date, the Fund will issue new shares to participants at NAV; provided, however, that if the NAV is less than 95% of the market
price on the valuation date, then such shares will be issued at 95% of the market price. The valuation date will be the payable date for such distribution or dividend or, if that date is not a trading day on the NYSE,
the immediately preceding trading date. If NAV exceeds the market price of Fund shares at such time, or if the Fund should declare an income dividend or capital gains distribution payable only in cash, the Plan Agent
will, as agent for the participants, buy Fund shares in the open market, on the NYSE or elsewhere, for the participants&#x2019; accounts on, or shortly after, the payment date. If, before the Plan Agent has completed
its purchases, the market price exceeds the NAV of the Fund's share, the average per share purchase price paid by the Plan Agent may exceed the NAV of the Fund&#x2019;s shares, resulting in the acquisition of fewer
shares than if the distribution had been paid in shares issued by the Fund on the dividend payment date. Because of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the foregoing difficulty with respect to
open-market purchases, the Plan provides that if the Plan Agent is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium
during the purchase period, the Plan Agent will cease making open-market purchases and will receive the uninvested portion of the dividend amount in newly issued shares at the close of business on the last purchase
date.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants have the option
of making additional cash payments of a minimum of $50 per investment (by check, one-time online bank debit or recurring automatic monthly ACH debit) to the Plan Agent for investment in the Fund&#x2019;s common stock,
with an annual maximum contribution of $250,000. The Plan Agent will wait up to three business days after receipt of a check or electronic funds transfer to ensure it receives good funds. Following confirmation of
receipt of good funds, the Plan Agent will use all such funds received from participants to purchase Fund shares in the open market on the 25th day of each month or the next trading day if the 25th is not a trading
day.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the participant sets up
recurring automatic monthly ACH debits, funds will be withdrawn from his or her U.S. bank account on the 20th of each month or the next business day if the 20th is not a banking business day and invested on the next
investment date. The Plan Agent maintains all shareholder accounts in the Plan and furnishes written confirmations of all transactions in an account, including information needed by shareholders for personal and tax
records. Shares in the account of each Plan participant will be held by the Plan Agent in the name of the participant, and each shareholder&#x2019;s proxy will include those shares purchased pursuant to the Plan. There
will be no brokerage charges with respect to common shares issued directly by the Fund. However, each participant will pay a per share fee of $0.02 incurred with respect to the Plan Agent&#x2019;s open market purchases
in connection with the reinvestment of dividends, capital gains distributions and voluntary cash payments made by the participant. Per share fees include any applicable brokerage commissions the Plan Agent is required
to pay.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants also have the
option of selling their shares through the Plan. The Plan supports two types of sales orders. Batch order sales are submitted on each market day and will be grouped with other sale requests to be sold. The price will
be the average sale price obtained by Computershare&#x2019;s broker, net of fees, for each batch order and will be sold generally within 2 business days of the request during regular open market hours. Please note that
all written sales requests are always processed by Batch Order. ($10 and $0.12 per share). Market Order sales will sell at the next available trade. The shares are sold real time when they hit the market, however an
available trade must be presented to complete this transaction. Market Order sales may only</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">30
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Healthcare Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">be requested by phone at 1-800-647-0584 or
using Investor Center through www.computershare.com/buyaberdeen. ($25 and $0.12 per share).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The receipt of dividends and
distributions under the Plan will not relieve participants of any income tax that may be payable on such dividends or distributions. The Fund or the Plan Agent may terminate the Plan as applied to any voluntary cash
payments made and any dividend or distribution paid subsequent to notice of the termination sent to members of the Plan at least 30 days prior to the record date for such dividend or distribution. The Plan also may be
amended by</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the Fund or the Plan Agent, but (except when
necessary or appropriate to comply with applicable law or the rules or policies of the Securities and Exchange Commission or any other regulatory authority) only by mailing a written notice at least 30 days prior to
the effective date to the participants in the Plan. All correspondence concerning the Plan should be directed to the Plan Agent by phone at 1-800-647-0584, using Investor Center through <font style="color:#0000FF; text-decoration:underline">www.computershare.com/buyaberdeen</font> or in writing to Computershare Trust Company N.A., P.O. Box 43006, Providence, RI 02940-3078.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:517.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:18.30%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Healthcare Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.80%">31
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Corporate Information<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="margin-top:2pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:26.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Trustees</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Todd Reit, <font style="font-style:italic">Chair<br>
</font>Jeffrey Bailey<br>
Rose DiMartino<br>
Kathleen Goetz<br>
C. William Maher<br>
Christian Pittard</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investment Adviser</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA&#xa0;19103</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Custodian</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">State Street Bank and Trust Company<br>
One Congress Street, Suite 1<br>
Boston, MA 02114-2016</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Transfer Agent</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Computershare Trust Company, N.A.<br>
P.O. Box 43006<br>
Providence, RI 02940-3078</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Independent Registered Public Accounting Firm</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">KPMG LLP<br>
191 West Nationwide Blvd., Suite 500<br>
Columbus, OH 43215</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Legal Counsel</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Dechert LLP<br>
1900 K Street N.W.<br>
Washington, D.C. 20006</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA 19103<br>
1-800-522-5465<br>
Investor.Relations@aberdeenplc.com</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:207pt; width:100%">
<div style="margin-left:38.41%; margin-top:5pt; text-align:Center; width:23.19%">
<img src="tm2516624d11hqhreporti002.gif" alt=" ">
</div>


<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">The Financial Statements
as of March 31, 2025, included in this report, were not audited and accordingly, no opinion is expressed thereon.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Notice is hereby given in
accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may purchase, from time to time, shares of its common stock in the open market.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Shares of abrdn
Healthcare Investors are traded on the NYSE under the symbol &#x201c;HQH.&#x201d; Information about the Fund&#x2019;s net asset value and market price is available at
https://www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">This report, including
the financial information herein, is transmitted to the shareholders of abrdn Healthcare Investors for their general information only. It does not have regard to the specific investment objectives, financial situation
and the particular needs of any specific person. Past performance is no guarantee of future results.</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">HQH-SEMI-ANNUAL</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d11_item2-19.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">(b)&#xa0;Not applicable.</p>




<p style="margin: 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. Code of Ethics.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Audit Committee Financial Expert.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Principal Accountant Fees and Services.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5. Audit Committee of Listed Registrants.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. Schedule of Investments.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&#xa0;Schedule of Investments in securities
of unaffiliated issuers as of close of the reporting period is included as part of the Reports to Shareholders filed under Item 1 of this
Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#xa0;Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7. Financial Statements and Financial
Highlights for Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8. Changes in and Disagreements with Accountants
for Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9. Proxy Disclosures for Open-End Management Investment Companies</b></font>.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 10. Remuneration Paid to Directors, Officers,
and Others of Open-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 11. Statement Regarding Basis for Approval
of Investment Advisory Contract.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Disclosure of Proxy Voting Policies and Procedures for
Closed-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This item is inapplicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. Portfolio Managers of Closed-End Management Investment
Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a)&#xa0; Not applicable to semi-annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#xa0;There has been no change, as of the date of this filing, in
any of the portfolio managers identified in response to paragraph (a)(1)&#xa0;of this Item in the registrant&#x2019;s most recently filed
annual report on Form&#xa0;N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Purchases of Equity Securities by Closed-End Management
Investment Company and Affiliated Purchasers.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Period</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(a)&#xa0;Total&#xa0;No.<br> of&#xa0;Shares<br> Purchased</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(b)&#xa0;Average<br> Price&#xa0;Paid&#xa0;per<br> Share</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(c)&#xa0;Total&#xa0;No.<br> of&#xa0;Shares<br> Purchased&#xa0;as<br> Part&#xa0;of<br> Publicly<br> Announced&#xa0;Plans<br> or&#xa0;Programs(1)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">(d)&#xa0;Maximum&#xa0;No.<br> of&#xa0;Shares&#xa0;that<br> May&#xa0;Yet&#xa0;Be<br> Purchased&#xa0;Under<br> the&#xa0;Plans&#xa0;or<br> Programs(1)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; font: 10pt Times New Roman, Times, Serif">Month #1 (Oct.&#xa0;1, 2024 &#x2014; Oct.&#xa0;31, 2024)</td><td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Month #2 (Nov.&#xa0;1, 2024 &#x2014; Nov.&#xa0;30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Month #3 (Dec.&#xa0;1, 2024 &#x2014; Dec.&#xa0;31, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Month #4 (Jan.&#xa0;1, 2025 &#x2014; Jan.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Month #5 (Feb.&#xa0;1, 2025 &#x2014; Feb.&#xa0;28, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif">Month #6 (Mar.&#xa0;1, 2025 &#x2014; Mar.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,169,130</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#xa0;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;  border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 26px">&#xa0;</td>
    <td style="width: 23px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June&#xa0;30, 2011, the share repurchase program was announced, which has been subsequently reviewed and approved by the Board of Trustees. In March&#xa0;2024, the Board approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July&#xa0;14, 2025. </font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 15. Submission of Matters to a Vote of Security Holders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the period ended March&#xa0;31, 2025, there were no material
changes to the procedures by which shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Controls and Procedures.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(a)</td><td style="text-align: justify">The Registrant&#x2019;s principal executive and principal financial officers, or persons performing similar
functions, have concluded that the Registrant&#x2019;s disclosure controls and procedures (as defined in Rule&#xa0;30a-3(c)&#xa0;under
the Investment Company Act of 1940 (the &#x201c;Act&#x201d;) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing
date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required
by Rule&#xa0;30a-3(b)&#xa0;under the Act (17 CFR 270.30a3(b)) and Rule&#xa0;13a-15(b)&#xa0;or 15d-15(b)&#xa0;under the Securities Exchange
Act of 1934, as amended (17 CFR 240.13a-15(b)&#xa0;or 240.15d15(b)).</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(b)</td><td style="text-align: justify">There were no changes in the Registrant&#x2019;s internal control over financial reporting (as defined
in Rule&#xa0;30a-3(d)&#xa0;under the Act (17 CFR 270.30a-3(d))) that occurred during the period covered by this report that has materially
affected, or is reasonably likely to materially affect, the Registrant&#x2019;s internal control over financial reporting.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. Disclosure of Securities Lending Activities for Closed-End
Management Investment Companies</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. Recovery of Erroneously Awarded Compensation</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not appliable</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. Exhibits.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(1)</td><td style="text-align: justify">Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(2)</td><td style="text-align: justify">Any policy required by the listing standards adopted pursuant to Rule&#xa0;10D-1 under the Exchange Act
(17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant&#x2019;s
securities are listed. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in"><a href="tm2516624d11_ex99-cert.htm" style="-sec-extract: exhibit">(a)(3)</a></td><td style="text-align: justify"><a href="tm2516624d11_ex99-cert.htm" style="-sec-extract: exhibit">The certifications of the registrant as required by Rule&#xa0;30a-2(a)&#xa0;under the Act are exhibits
to this Form&#xa0;N-CSR.</a></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(4)</td><td style="text-align: justify">Any written solicitation to purchase securities under Rule&#xa0;23c-1 under the 1940 Act (17 CFR 270.23c-1)
sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(a)(5)</td><td style="text-align: justify">Change in Registrant&#x2019;s independent public accountant. Not applicable.</td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 31.5pt"><a href="tm2516624d11_ex99-906cert.htm" style="-sec-extract: exhibit">(b)</a></td><td style="text-align: justify"><a href="tm2516624d11_ex99-906cert.htm" style="-sec-extract: exhibit">The certifications of the registrant as required by Rule&#xa0;30a-2(b)&#xa0;under the Act are exhibits
to this Form&#xa0;N-CSR.</a></td></tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.5in">(c)</td><td style="text-align: justify">A copy of the Registrant&#x2019;s notices to stockholders, which accompanied distributions paid, pursuant
to the Registrant&#x2019;s Managed Distribution Policy since the Registrant&#x2019;s last filed N-CSR, are filed herewith as <a href="tm2516624d11_ex99-xcx1.htm">Exhibits (c)(1)</a>&#xa0;and
<a href="tm2516624d11_ex99-xcx2.htm">(c)(2)</a>, as required by the terms of the Registrant&#x2019;s SEC exemptive order.</td></tr></table>


<p style="margin: 0">&#xa0;</p>


<p style="margin: 0"></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="margin: 0">&#xa0;</p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2516624d11_sigpage.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1" -->

<p style="margin: 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><b><font style="text-decoration:underline">SIGNATURES</font></b></font></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Healthcare Investors</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;June 9, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;June 9, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sharon Ferrari</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Healthcare Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;June 9, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>2
<FILENAME>tm2516624d11_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d11_ex99-cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.CERT</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sharon Ferrari, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Healthcare Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date June&nbsp;9, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Alan Goodson, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form&nbsp;N-CSR of abrdn Healthcare Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule&nbsp;30a-3(c)&nbsp;under the Investment Company Act of 1940) and internal control
over financial reporting (as defined in Rule&nbsp;30a-3(d)&nbsp;under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed to the Registrant&rsquo;s
auditors and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June&nbsp;9, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Principal Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906CERT
<SEQUENCE>3
<FILENAME>tm2516624d11_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d11_ex99-906cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.906CERT</B></P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><U>Certification
Pursuant to Rule&nbsp;30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>b<FONT STYLE="text-transform: uppercase">)&nbsp;under
the 1940 Act and Section&nbsp;906 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Goodson, Principal Executive Officer, and
Sharon Ferrari, Principal Financial Officer, of abrdn Healthcare Investors (the &ldquo;Registrant&rdquo;), each certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s periodic report on Form&nbsp;N-CSR for the period ended March&nbsp;31, 2025 (the
 &ldquo;Form&nbsp;N-CSR&rdquo;) fully complies with the requirements of Section&nbsp;13(a)&nbsp;or Section&nbsp;15(d)&nbsp;of the Securities
Exchange Act of 1934, as amended, as applicable; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Form&nbsp;N-CSR fairly presents, in all material respects, the financial
condition and results of operations of the Registrant.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL EXECUTIVE OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Healthcare Investors</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Alan Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June&nbsp;9, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PRINCIPAL FINANCIAL OFFICER</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">abrdn Healthcare Investors</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sharon Ferrari</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date: June&nbsp;9, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is being furnished solely pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of Form&nbsp;N-CSR or as a separate disclosure document.
A signed original of this written statement, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section&nbsp;906, has been provided to the Registrant
and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</P>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(1)
<SEQUENCE>4
<FILENAME>tm2516624d11_ex99-xcx1.htm
<DESCRIPTION>EXHIBIT 99.(C)(1)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d11_ex99-xcx1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 389pt">Exhibit&nbsp;99.(c)(1)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d11_ex99-xcx1img001.jpg" ALT="" STYLE="width: 200px; height: 60px"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d11_ex99-xcx1img002.jpg" ALT="" STYLE="height: 45px; width: 450px">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B></B>abrdn
U.S. Closed-End Funds</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">1-800-522-5465</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Investor.Relations@abrdn.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABRDN U.S. CLOSED-END
FUNDS</B></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Philadelphia, January&nbsp;10, 2025) - The <U>abrdn U.S. Closed-End
Funds</U> (NYSE: ASGI, HQH, HQL,&nbsp;IFN, JEQ, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on January&nbsp;10, 2025, on a per share basis to all
shareholders of record as of December&nbsp;30, 2024 (ex-dividend date December&nbsp;30, 2024). These dates apply to the Funds listed
below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc.
(IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund,&nbsp;Inc. (JEQ) which paid on January&nbsp;10, 2025, to all shareholders
of record as of November&nbsp;21, 2024 (ex-dividend date November&nbsp;21, 2024)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Ticker</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 57%; font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Global Infrastructure Income Fund</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.2000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Australia Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">The India Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Japan Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors with
a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors
(HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund,&nbsp;Inc. (JEQ) the stock
distributions were automatically paid in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in
cash. Shares of common stock were issued at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share
with a floor for the NAV of not less than 95% of the market price on December&nbsp;17, 2024. The reinvestment prices per share for these
distributions were as follows: $16.83 for abrdn Healthcare Investors (HQH); $13.87 for abrdn Life Sciences Investors (HQL); $4.35 for
abrdn Australia Equity Fund,&nbsp;Inc. (IAF); $16.8 for the India Fund,&nbsp;Inc. (IFN) and $5.81 for abrdn Japan Equity Fund,&nbsp;Inc.
(JEQ). Fractional shares were generally settled in cash, except for registered shareholders with book entry accounts at Computershare
Investor Services who had whole and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To have received the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity
Fund,&nbsp;Inc. (JEQ) quarterly distributions payable in January&nbsp;2025 in cash instead of shares of common stock, for
shareholders who hold shares in &ldquo;street name,&rdquo; the bank, brokerage or nominee who holds the shares must have advised the
Depository Trust Company as to the full and fractional shares for which they want the distribution paid in cash by December&nbsp;16,
2024; and for shares that are held in registered form, written notification for the election of cash by registered shareholders must
have been received by Computershare Investor Services prior to December&nbsp;16, 2024.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under applicable U.S. tax rules, the amount and character
of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year.
However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds
may be required to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted thereunder. The tables have
been computed based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current
distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources:
net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated
compositions of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains
and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Current Distribution per Share</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
 Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Investment <BR>
Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Short- <BR>
Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Long- <BR>
Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><B>Return of Capital</B></TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%">ASGI</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0120</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1985</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0117</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1079</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">JEQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0234</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1566</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
 Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Investment <BR>
Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Short- <BR>
Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Long- <BR>
Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><B>Return of Capital</B></TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0372</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.5828</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">94</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1985</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0117</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1079</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.3000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0702</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4698</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end. IAF
and JEQ have a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for
the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to shareholders for the prior calendar year that will tell you
how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables provide the Funds&rsquo; total return performance
based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund Performance and Distribution Rate Information</TD></TR>


<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt">Fund</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average<BR>




    Annual Total<BR>
 Return on NAV<BR>
 for the 5 Year<BR>
 Period Ending<BR>
 11/30/2024<SUP>1</SUP></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Current Fiscal<BR>
 Period&rsquo;s<BR>
 Annualized<BR>
 Distribution<BR>
 Rate on NAV</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Total Return <BR>
on NAV<SUP>1</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Distribution <BR>
Rate on NAV<SUP>2</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<B><SUP>3</SUP></B></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.79</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%<SUP>3</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">11.79</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">-1.73</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.01</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.82</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.05</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-4.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1&nbsp;</SUP>Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of November&nbsp;30, 2024.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>The
Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July&nbsp;29,
2020) through November&nbsp;30, 2024.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund Performance and Distribution Rate Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average
    <BR>
Annual Total<BR>
 Return on NAV<BR>
 for the 5 Year<BR>
 Period Ending<BR>
 10/31/2024<SUP>1</SUP></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><B>Current Fiscal<BR>
 Period&rsquo;s<BR>
 Annualized<BR>
 Distribution<BR>
 Rate on NAV</B></TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Total Return<BR>




    on NAV<SUP>1</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Distribution<BR>




    Rate on NAV<SUP>2</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.97</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">-2.31</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.91</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-1.16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.60</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16.79</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.07</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24.10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.47</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of October&nbsp;31, 2024.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*The Fund&rsquo;s fiscal period to date is October&nbsp;1, 202 to October&nbsp;31,
2024, and there were no distributions in this period.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholders should not draw any conclusions about a
Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution
policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally
taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower
rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution Policy
may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in the Fund&rsquo;s
annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market price correlates closely
to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the Fund&rsquo;s investment activities
to the extent that the Fund is required to hold larger cash positions than it typically would hold or to the extent that the Fund must
liquidate securities that it would not have sold, for the purpose of paying the distribution. Each Fund&rsquo;s Board has the right to
amend, suspend or terminate the Distribution Policy at any time. The amendment, suspension or termination of the Distribution Policy
may affect the Fund&rsquo;s market price per share. Investors should consult their tax advisor regarding federal, state, and local tax
considerations that may be applicable in their particular circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States, abrdn is the marketing name for the following
affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>abrdn.com/en-us/cefinvestorcenter</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(2)
<SEQUENCE>5
<FILENAME>tm2516624d11_ex99-xcx2.htm
<DESCRIPTION>EXHIBIT 99.(C)(2)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2516624d11_ex99-xcx2.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2516624-11/tm2516624-11_ncsrsseq1/users" -->

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 381pt">Exhibit&nbsp;99.(c)(2)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d11_ex99-xcx2img001.jpg" ALT="" STYLE="height: 60px; width: 200px"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2516624d11_ex99-xcx2img002.jpg" ALT="" STYLE="height: 45px; width: 450px"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Aberdeen U.S. Closed-End Funds</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1-800-522-5465</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN U.S. CLOSED-END
FUNDS</B></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE
DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Philadelphia, March&nbsp;31, 2025) - The <U>Aberdeen U.S. Closed-End
Funds</U> (NYSE: ASGI, HQH, HQL,&nbsp;IFN, JEQ, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on March&nbsp;31, 2025, on a per share basis to all shareholders
of record as of March&nbsp;25, 2025 (ex-dividend date March&nbsp;25, 2025). These dates apply to the Funds listed below with the exception
of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF), the India Fund
Inc. (IFN) and abrdn Japan Equity Fund,&nbsp;Inc. (JEQ) which paid on March&nbsp;31, 2025, to all shareholders of record as of February&nbsp;21,
2025 (ex-dividend date February&nbsp;21, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Ticker</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 57%; text-align: left; padding-bottom: 1pt">abrdn Global Infrastructure Income Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.1900</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Australia Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">The India Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Japan Equity Fund,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each Fund has adopted a distribution policy to provide investors with
a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors
(HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity Fund,&nbsp;Inc. (JEQ) the stock
distributions were automatically paid in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in
cash. Shares of common stock were issued at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share
with a floor for the NAV of not less than 95% of the market price on March&nbsp;19, 2025. The reinvestment prices per share for these
distributions were as follows: $16.63 for abrdn Healthcare Investors (HQH); $12.99 for abrdn Life Sciences Investors (HQL); $4.045 for
abrdn Australia Equity Fund,&nbsp;Inc. (IAF); $15.45 for the India Fund,&nbsp;Inc. (IFN) and $6.73 for abrdn Japan Equity Fund,&nbsp;Inc.
(JEQ). Fractional shares were generally settled in cash, except for registered shareholders with book entry accounts at Computershare
Investor Services who had whole and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To have received the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund,&nbsp;Inc. (IAF), the India Fund Inc. (IFN) and abrdn Japan Equity
Fund,&nbsp;Inc. (JEQ) quarterly distributions payable in March&nbsp;2025 in cash instead of shares of common stock, for shareholders
who hold shares in &ldquo;street name,&rdquo; the bank, brokerage or nominee who holds the shares must have advised the Depository
Trust Company as to the full and fractional shares for which they want the distribution paid in cash by March&nbsp;18, 2025; and for
shares that are held in registered form, written notification for the election of cash by registered shareholders must have been
received by Computershare Investor Services prior to March&nbsp;18, 2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As announced on March&nbsp;11, 2025, to avoid potential
disruption to the timing of the proposed tender offer, the Board of Directors of JEQ suspended the Fund&rsquo;s managed distribution policy
after payment of this distribution payable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under applicable U.S. tax rules, the amount and character
of distributable income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year.
However, under Section&nbsp;19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds
may be required to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section&nbsp;19 of the 1940 Act and the rules&nbsp;adopted thereunder. The tables have
been computed based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current
distributions paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources:
net investment income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated
compositions of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains
and losses on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Current Distribution per Share</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
 Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Investment <BR>
Income</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Short- <BR>
Term Gains**</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Net Realized Long- <BR>
Term Gains</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><B>Return of Capital</B></TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1900</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0133</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1140</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0627</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0456</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5244</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1260</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3440</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0180</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0264</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0756</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0242</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0858</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0198</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1602</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Amounts of Fiscal Year* to Date Cumulative Distributions per Share</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Distribution<BR>
 Amount</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Net Investment <BR>
Income</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Net Realized Short-<BR>
Term Gains **</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Net Realized Long-<BR>
Term Gains</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Return of Capital</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.2000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0840</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.7200</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.3960</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.1900</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0952</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0948</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">92</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9700</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">73</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0375</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0550</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1575</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">63</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0506</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1794</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1188</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.9612</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end. IAF and JEQ
have a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for
the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form&nbsp;1099-DIV will be sent to shareholders for the prior calendar year that will tell you
how to report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables provide the Funds&rsquo; total return performance
based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund Performance and Distribution Rate Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average<BR>




    Annual Total<BR>
 Return on NAV<BR>
 for the 5 Year<BR>
 Period Ending<BR>
 02/28/2025<SUP>1</SUP></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Current Fiscal<BR>
 Period&rsquo;s<BR>
 Annualized<BR>
 Distribution<BR>
 Rate on NAV</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Total Return <BR>
on NAV<SUP>1</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Distribution <BR>
Rate on NAV<SUP>2</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<B><SUP>3</SUP></B></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">8.10</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%<SUP>3</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">11.89</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">-2.55</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">5.07</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.04</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.27</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-3.71</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of February&nbsp;28, 2025.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>3</SUP>The
Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July&nbsp;29,
2020) through February&nbsp;28, 2025.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fund Performance and Distribution Rate Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average
    <BR>
Annual Total<BR>
 Return on NAV<BR>
 for the 5 Year<BR>
 Period Ending<BR>
 01/31/2025<SUP>1</SUP></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><B>Current Fiscal<BR>
 Period&rsquo;s<BR>
 Annualized<BR>
 Distribution<BR>
 Rate on NAV</B></TD><TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Total Return<BR>




    on NAV<SUP>1</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold">Cumulative<BR>
 Distribution<BR>




    Rate on NAV<SUP>2</SUP></TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right">7.34</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">12.70</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">-0.35</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.17</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-0.76</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.09</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.67</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-5.95</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JEQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.41</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.87</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.72</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP>Return
data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested at prices obtained under the Fund&rsquo;s
dividend reinvestment plan.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>2</SUP> Based
on the Fund&rsquo;s NAV as of January&nbsp;31, 2025.</FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholders should not draw any conclusions about a Fund&rsquo;s
investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution policy (the &ldquo;Distribution
Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s investment
performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s investment
in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares in the
open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section&nbsp;19(b)&nbsp;under
the 1940 Act and Rule&nbsp;19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term
capital gains, long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally
taxable at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower
rate not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution
Policy may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in
the Fund&rsquo;s annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market
price correlates closely to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the
Fund&rsquo;s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would
hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the
distribution. Each Fund&rsquo;s Board has the right to amend, suspend or terminate the Distribution Policy at any time. The
amendment, suspension or termination of the Distribution Policy may affect the Fund&rsquo;s market price per share. Investors should
consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular
circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i)&nbsp;avoiding penalties under the Internal Revenue Code or
(ii)&nbsp;promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the United States, Aberdeen Investments is the marketing name for
the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Closed-end funds are traded on the secondary market through one of
the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s shares may be worth
more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value
(NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not
guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Closed end funds | Aberdeen</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2516624d11hqhreporti001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11hqhreporti001.gif
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M^/?X^/GZ^@
M
M
M                                                 "'Y!
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MR7X&8G4>)CC](6P[P%V1 W:&PSCG)"XRQFS^1'2M1<0M%[)$.&@NG>AC,HF
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M6-NLO 9L6[NUL9G'/A1VC(6;B95_11J :,NMT!:E!!AMA0QW='N<(8)9Z<J
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M1+U?7+$^4)>B9 L!19$M$4-BS!3+BL+.7*R7%_7UB5Z@DL^;8&EP/V:DT^+
MM XU<D)C6S$C*\_^2W"$+48AED<H&Y(O1II8EO:B%2[KNY @S1(A&S/<?^O[
M,^TC32+1[!C-O*R,@V"DFYG+7.CBS,>QH:XC1E/C:H=WXTJ;MBM[\K0=A5?'
MFK@=HOFE8DR]4CBA<C0$IQII8#"CTJ_ZI;9--<&RV=)6;0MUI\]*PEJ'^M6E
M%I:#FRFXO$FSKO2QM8,DY]=I;61QP,8(L[Y%ZF[]NA[B0F+53PP/I^3$L2::
MR8F:S:Z.O,)UG) V4>]9NWL*Y3:3TB?]MB>QV1Z9*\ C-Y/#7>2%IOO):&1W
M2)7,;L2/U&)\')EMRR1(+N=;\J-U+D?5)#V9'A>F=++NSE+:)^1"A:;^"B\S
MG4-CYHG_"?1^LMF=9]1=N(,6[N9UZO^(,Y09YR@58+2V[9(2HZ8FD+X/9#FI
M+NB<Y)=J;!04IMI0!58*XOR#H/:Y,^UF0K.6-9K0M,^S96VL<5CKK,W"1X.>
M_2P;5M.&S:+0MR(4NKU^J'(TI#\/^=R#$3W1Q<NN2;2,@7*SYW&(XA2W$U#Y
M8G=YICX-AS)H)&[B1FY[YU!(XH"!UVY'5F6T18&PU18=HR7LYA:C!7G4DS$A
MF!<@]5M@AA=X%SZ)-"=R!F:-!'&%X'"?$6>>1S3353ZA46<Z8S\]%F= Z%V)
M8EDS]C^)8E2+ #6)!EJ$YD^MLWN=HD">0DO^73-\LA1S%41I&-1\T_=\SV%!
M<2-@UI<KVX<W=)-@X: >AV-6)U0L#=)-==5"&.%7-90X]* @$L(X-717M":'
M)28YYI1K201VWT0O2FAKC\5_:7>'JV-/0#*$L5%R(P=WX%5[L,%2BX$P1"8\
MXT85G6AN3V:!;&1NR1.*BD>*%#@Q[G9'L_5N=.1;+*@Q7 8R*[B"@R1<C6%&
M8K9OGC2#,A4DP;49"O=(GP&,D%%Z.D@_=-9PK]=C0/%)SC@CG"6 27,U*W=>
ME8A/5@0*.=9[-7(UY+4U5XB%R9&%S#$O6FA5DF8=ER8>T_=5[PA"U6>&TB(>
M%2$?]8A6!V$>E$/^:B!V:@22-]6D+9TC#\=2(->"+1GV?AMV1*P&8X2%=314
M':5C.BXF6?Z'5]B &TX1/^+E/Y/X>W*7*=2F/>Q3/4[VB>-V P_XB0@C@>=F
M@>BF,!6X/&P$@EZ2>/[V@:ZH&/FV>-7C1_0F%GW492,59BBX><_UD38X/\]%
MC#>H>:['& AGC%1Y<<V8/S[%24*(9P28<4@X;?:41?AT&Y_U3_V415;#5%/E
M:"Q72E0E?367?/R%*K?T'%O%A<ZW#6$5:F)H?0?&*^2Q8&MU33<1(7=UD/41
M+N:WACX$+.\P:P/R'@>9$1W65P\B8A,Y6%3G=2"B&\^P?ZDS!%+D35#^PVW5
M&'N 9F-LYSH\9I*3)%P(<P,X< ,M>5I#,I.QI20Q&7@0A8I'<CRD&&6M>$>'
M5$= ^4>&IR:!Y%RTR(M?QC*#M#*$%(,KHWEI!C[;<S/Q\TAM!B?>N4F3T"?/
M&):RIVCE=4K"URF18F.^MQ1-<6B<U47!YU13Z!OD6'SGJ(7(%X;*EQW+]U]L
M\X5]^5\&6GT^MWWZB(9JB%9Q^(;,(BR%(Y#X>$*021_?M%<>EGXAACAWB#GU
MYRV%2)':-@N)6'8O49JI,UD7\BKGR8.QH1,XAIZP60DU<T;3PQ6UV9+C9@,N
M:5JXB62^68$1F"1)1D=J1#RYQ5 >J*0Z^9S^7A8R*RB"*4-<8S8GTXEE-OAP
M\(,^F;B R/AE.I.,U>4^]-.,/78_\].5L1=*L5> P&>-0I4;C58O9^E/^U*
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M?SQX*^] <>+C:]/S,>4%22F#9T]R:!ZGA.DC<E X,Y^$&I^45%1X5*=4)]]
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M&<30GXV!24V8>]WH,NSX:*#DC4Z%E_BECO:ECNUH<YYJH7528!AJ8&5(JJ?
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MFP_>(HA!9![7<,,8 PGA8"X;!6U(XWGDT+XNM/W*(Q4#2<>4LG1?;V3^T8J
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M&UHI5Q^H39Y"0@W1;:9"-\%[J7'S3>?$@J&BH,Z+0]]1JG)93QM7O=]H+(*
ME]M[%BMC=+::M#;YJG*1#3>E+6Q((.](A?,8.E@X$"[0 BS@ A&74<[^T"O
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M@WF$EBGA=6CL]0W;$%/J,B'>!T@WYT=F<S8, FK_4$B5-U2*PCUPXW/\U6D
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MT*=ZJC];C.]R=R[J#!$MT?7R@C$8R-S(EV_U#M0 .WUU,?%#/[\JAZ[9C=N
MCNDH,I,<'RL#&3YUO%"G713E)?N*,ZT'RM;ZME>6A4*Z%#.@CQG1K79"<<&T
MM\9'P6H(?+@)D5,Z0H#+D7,HN&6QI74H%[4U)P*KU5KMG,0,* ?K&,),:&.3
M%T?$KYMK-H<!K2HYDB]74):%7?:8N@,\,YCQS9PA17>]11@[NYRX=+K^>Y2Z
MPJ<E$X!=Y#]L5-CF-3DUZBN[QD?,JQU76<:?.J!(1D!H2:!H>8LJ?;T,RI;:
MF])"6X(<!K[+L[7-^%6>!*OF^\?KH+5/Z]H PQ'?0'P$,03SHVY6JZ)R F9
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MBG0"3&P%;$AY=JOHE'5%GVXW-5<3*+3HG[&(=W%7;25VBUR)3LZH8ITQ*+#
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MV)G5\LJUW&^W7*[X,:[T?3K@:H8&R7!DYN<:16;D6M;[79OL$-8*%W&[EZ4
MOJ7VVM;Y>HCX^EV7]'S7;+"GVWV4]LS/O#N+KG$"/KK5"=@BHR1)IYVDMA0W
M@-IIHS9!LT3K^>&XQIY(0PF3#;S,:\FSJL9&FR1;<B>-%$;)/8'7JQDJH (G
MEMH?&+3V695%^T+)>+X4!)<.FKZV_8QT:6/3>.356*NY_2EYR;6"T^2$Y\_C
M&*+3 9B6D-S+7=/,G=QF;AE,QLEH.W;P+N;/7<KUSI7[6>8@MIBI#*WT!AX)
M-5NSK#G_UL&@><L:S-[EFE+N8$:WN651&J[^J=F%5DH@$:^:\P"1*Y4@"ZEF
M,;Q'L!G.HCY\;7A=H:O#A?:;X:61=GVFD-[H)>75-O_@+UPA(1'AZ(?.$IV3
M5>PT]5>,.Y",9#$F9B*\\9EDBEIU80R8%R:.@I'&W>Y8E\K.[).F 7$+ 266
MGN$"*I "N;CLZ9L6/F[VK2W;%$2":K/&KKB,T+BT(<V">?=@1WY#&^JK=]]9
MY89/Q=&KM((*2,2#Z]CN/"W -2MY[[C _N[N[1[P-"K4;!N$D4/P5X1OM*7!
MW7#P??N/=.YOWIK+(>7!:G1PN"SH>4[?999<E%'5#"G,YA#6B;[H>VU'N,/H
MQYS7M[_[Q"<\:WK^L(4(_'?MAH\>N2C/('F4KH,NK]ICSJ8>]%#,IZCV&N%9
MC!9TC.X)0<:=@.$XHDD#QNMFL@>H=8<,0S8CE+6;$P5MT!WT&2V@ BOP C2@
MVI<Z[3 VE^M;T?=?[=3NT;,-"#X_@X."A(>(B8J+B4"'CHZ#D8230):4/Y>'
M09"#09\_H*"AH4&$GZ9 HZFFG):HD$$U-32S-3:WMKFXMC0VO+^S-KZ^M[B^
MP;S&MK^XQ\F_Q<W&P]76U-3.S=O<W=LXW]XW-N,WX^3FZ+_IZ3CF[^\V[O#F
M\SCV-S@Y^CGU]^[[_LW+]R_@/8,W<O3CY^X>P8#[(D*,J$^@0H4)*T[^9*CP
M(,.*_'1H['B1XD5^)TFF+,D294J.*EG&-.E2)DL=.7#:S*E0)T\=/GL*'2IS
M!TNC.XNJ1-IR9TV/+UUFE%CP9=*<.[+NX,%UJP^N/+Z&Y2I6[-BP7].B1:MC
M!HP;8+-RS<3)E25(=S-E4O4*E5U+0H $!AQD\*M.=Q,S0N2CL6/'9,<V[LHC
M*U:@/$N.FR'#18L6,&SH0/OX<8]!IQO_:)S:1P_7/TZC7IWH->W8AE072F1H
M,:/>DS A"CY<DB3BF!!W*F5<U292JTR5<@[=;]U/CEII#[*-F;#OMXIY'Q8^
M?+3SRG9Y7]9-?#1CR*S%CZ]ME[?[^/.OVT_^#UV\<NS0(V!#_O0CH#D&"D30
M/ 8UY%%! .6SD$8@Z9//@@]FI)&$()74(4T4Y@051!1"=9!5)*&DHDTUH7C5
M2E2]>--%.^B$V44W]I1C4D@%)6-3,_[(HE,M;=A1B1!.9),.6LD%%EB3E14E
ME)&I-59;;UVY%5J4).;EEZY8)]B8B0V&G9><#':<)-(%)TAND*4UY9-<]:15
M5TS6N(\-;KT@@R^C/;;:FZJQ-JACM*EVVJ*R+1K;HXQ%JMMMA/2VFV^+15))
M<<@UHE>GRY%"%W.H>')**].A"DIVID)':E_(V$?,>N#IDMZMRMRJ2R[V.5,+
M--HXPYZM[$T#3:_^^MUWSC;GE".//_* $RTX[OAWX8+7#N2/0_X0=*% #H(K
MKHD6&IB0N16*:]"Z-)$8E4KE]H,B3/Q,!9-,+0X9TU,>)A6B1"_BA)E/1NF)
MXT]!!IS93SCE*R20_>H+[T8/_B-2D@#?2^.63W(\IV0@5QE9#C'$D$-<=Y*U
M)EY?ZN67*F=>=^:7+=>\&*&EA>R#DW%51F=E68%# PPPS&##R:3A3&BBB!9Z
M:&E0)WK;FXM03>DAO65MZ=6,@*K7(IVVRJEQIK;2":J:LKS7)8?E%0JKHKCR
M PVU[$J>L+MFD_<N=,?*Z[#CU1TL->[Q"@RPB">K>++.CB/M.M3^<H_^/)13
MG@\YZQQ(X#\8<NX0Y]^..VZ!$BY$4>DQEGBDO/N<:Q%5(=8+>XH4Q=OOB2>F
MF#O $<<(I.HC/8RCP$7I&13QPHNDN_#,XSO3[O1"=#&$HB?I, ](_TQ6671"
M%AGV,="0@UEXTOD(V^@KAE>8;:N_=G":8 IGSI-]KSWY<8DTC PRS)!0TH4*
M8-2@IK1"9&U03..:TY8V-4PY,%-=^]37OM:I-C5'4\RAA'2:\[[WJ>U3G*"+
M=5*A"KP)8QCBV=MX[$8+P=DJ/=\)EGN208OW=&>%P<"&L;*QN!YB#D#_P%RU
MFB&M(GI+6P/97+?PD2T';<MSZD+0@C"BH83^'-$BU,/BNK#XH-ZI:"0N^5?P
M(M;%VS5%=L^+W19-DA2?^&A@"Q,*\GS4.X@=+'G-.PF_9@*O=$VO>N.R29-X
M=A:=R4EDV"M:]M;2%8XE9R^0Q.!?^'(7NWQ*;6Y[(,Z>5DB?:8\'JP&947!0
M \X8+0=>$533%BC 5;J2:51SF@&G9BFK8>V6N,14V!RXRTE()X2>@J395N:R
M2-+%;751C%]$)3=5&(X7*9S%K^JF0E[-YX1V.UPOC(7"7-U-<,(*)PV;09]C
M^7!QR]H/M2Y$.6J!HQ[6@L?G"(0M<'6NB5#T7$80Q+G6.4A>4Z0>B5X'1HX
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MZ8AVN'A<DSQQK'M/$LL.8O""/ M""" /^2!^!F"@LOH2#-9$_,"[2_..'+X
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M;G5@M)@V"@8SE(1@/]"U$ KG!GS41"W>3"V!>6ZLQ99"&'J,=B.KPKX,WY&
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MDAH:J+D%1XF%-F3S9F7XMD^"Z-0/Y[;=6V".<=6ASCMY$!?@JFT1@#,!"5)
M@^ET@C>)IJ)%H\LK/3OZ<H[;E7EUV]%>A/$0)2U%IL5+-_=L%UKQ.>_^?-C;
MWF:4+LZLL^FUGB$$^=HQ-JY^=3+&VCNR!K+(WLOO.;(GI*[R.JF)5.:Q/:1W
MA1D,1FJ-E']/M$QT@<_#B]?V6E')5FP3-:V4?W&)Q?U*%:^8E2?VMHI/C&+-
ME[O(:XW>_-Z]<"C/VRMD.M+_^*TR*F&9X G%L.=%[\HC&RDQCI5@Q*\\6:(0
M7/48]#&<(B[QMWC6X"-4OFA1R)F-=X;,/YP^9+X"DN<0;@>_8)NF[,C$KSGF
MY2[_X77/./7$^990?\(YSJ>(\QS0@ 4G,$$+I./;*^J?.*= .A:?WG0!N%'F
M-6DRIQV_0G7@]0J^D!TNA0M<!QRAEE[RU0S^V.(+<19'9A<[I",@_+$? X)3
M^4%?T#8^ZZ)NT,8@C.1(#,(O>*=4G70AR7-(S",2*Y)5IN0@Z.!L-PAMDT=K
MXB-MAK=Y<.4^N?>#TG9YWN9*H3<#G2<#H"=Z4 AZ,4"% /=B.'-+]+-PV61E
M^4,FP 1.7')OWB1DMI=B5(B&5?AM1&573E,F>4)[559E4&9 @-5PPH07?I%9
M<RAQ=J%\RO=9DZ$H)11:I65;/M1QHD%Q(*$"*5 IWC4-LX%#QA!^Z41^Y =U
MO3)UOY4W76-F-F<<DD(")2!1N]%0O?5<J5A15;1_K.ATH*()9_1H6^=1Z\$>
M!-5=$9B+N0@Z\.'^4A(H+7"$(*DS@<B ']RR=F=W@:U#7]Y0(.:B87(7#YMG
M>+Z3.WNW5+\#(;\&*3/"2"VQ5>!H;$RU7QT6(84'=_NU.^I82K4V;>(S8M@V
M:_T%2)BWA)@7;D:5CU&H>3$  VE8;E"8>Y5T>DPA;UKA)<846,%T%5'F5\/'
M*"SB;53XCQ3IC^BV0+G$>P.$05@F3/6F/PT9?%'&A=VD;YSUAH,X&>846I^5
M<5MSB!WW-11' RK@ H\81K6 0^7"*H+"<=4'4)-#',9R1#>'6CE''8J0 ZU%
M LMU X- E"6%BCW$?_DG74JW=)$V@+R"@-JU"J&R@'7C7>F!+%]9'E[^!XS6
M<A]BART=Z%ZM(T=W9"#CXH$!8I="\#! 6$BHQ",!MDD!MI<!5CSY@&#*TQ*W
M5A.%:1*$26R5=(U%E6TQP8(\(F'-!F-E)3'ELVZ,)X\DYF%#-8_QB%:99V+F
M!FYKJ(]3^(]/>&( >9&C9XX?XFX&N87;Q#* $27(]WH,%!@\P2+MP)HQ\ (O
M  /_6)QIR(99F' =!$Z_5TU+P7 CZ7#+V9%]N%EX4DY2\Q@^0QKI]!G4UW&>
MHC<SH (P !?K1SN;0HG6IWQ%247> 43Q"5 >-UI%F0,Q@ (A4 +,!8K/A8K_
M67-5N6C8074<-0M3ERS358!1UU'KP6E:A%+^O2@,#]@YP))&Q9A>%OB,&XIJ
MI3-'&YAVY2(;I#.,](4(;#4^.,B.?[E)+=J7.@B8Y-"7V!@OYP@IJQ$OC+0:
M]8(B!.$P]DAW$#(3E@EB)'B9]%B$\-B.E2>/%&.$UR97:WA[5'B&4/AYQHF&
MQ0D#1K6E6ZIYI3<2.D.;# =E*!,R5%%-6!(E;])C-!-B3ZBEPRFG6KJ:J92%
M3+%O';2FVD0G&Q2=#+>FL9>F409[$Q="$/2'BW&4@C =@;(9F*$JC1I]_Y0W
M.0 #*@!;\%<+;&,-X8=SELB)23EIY2>>C(HH>E(9OK64)Q "),"?G+B*BF9T
M1K1HM\(=6)EIX;7^E5Q):5KY1;3PE=\Q1%E7-Q+J=6@Y:G"IH6-'C!Q8+0&B
MK+E E\L #B-J1T+ =M4@&RD:<)@Y2WXY0_;0HGXI8'^9C8@I+[345$$2$5K5
MHP-&8N>6>S<*$.N"0(*$/OT IIPI8IPI=T18CN03=Z.)CYN'8FKXA*+'I:RI
MI3+0I0X+L1&+8FNU/,K9<-'ID+M4%0DGA[U9)X<5*10IIR_@ B3K BTPI^%&
MF3FC)&[X,GUJ98(*6(8UJ-)YFU/637UXJ".DG>ATE#[KG2RDB&+6<3EPLC;0
M?N]74IRZGIZ!3COG?[DB"O.I&W'CM"=T-+MQGR<  B.0-KUU41?EGT3^IXK6
MD5&,4W54J5LTAY59&8N0UCD$Z("<%BQWQG3!>E['BJ'VP;>DYK?$:)?A,BZJ
M%@YI]P-IAZV!"U1QQVW3]IDNNI?C&J/%(V".!&!CA:/X<G<.EE7!!BF8-['I
MPTS+@SWZ2I ^HE:@U'BDU*_;QGCKV+@K2K"7MWDJ:YHJAJ6IR;#%";%TZK /
M&[H[R+)CNDT=@R0E@V]:\I =VTLM<88PX +1>[(M0+THF[+A%A)\A7#%=YM8
M$2='PC'WPV/U5I(MDS1AF+/Z!H@?U'QHLIU &[2:RAF:^G*"(&@O@)-T(0@[
MJ7(ZY[.[P7_A4;6VE2BC836&<I\EX $AT +^S564B1:@[QG $0S!&$6@P"J
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MIE(69,FG9>TK3:3QJ9G10IL,U8]*?3H0 _=W W_B%J@\C WU,SVC',/^/ I
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MPCB0=$XDJU6[;+& AKB<1@^H0PE/@L=<PAG3<83'2N^H9ZZ0B-=Q8O<)&9Q
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M?.*H*#-Y9XO84?!6*+5Y!3H6&W)28:2524#UW\I<^(U(!0$(/L!Z$) [CB4
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M]H]E$JBWYIM#J%'?U1.AXY#R1:>=XIU#&Y&@0I&35YV5*GO-QH4P$$\>Q:C
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MMP,MI7L[8@RO7%S&-]I*+$JO(=TN+6>+/7I, 2LQ0TK'H76 1SJDR=@#][.
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MQJ&;E"#T>MUJQT=FUE:)1>/*NHH5#.@*EB.JBTZB"S"4HH:LVA@< HNRC1E
MX1A X5!1%8Z,*2/6%4MF8DR7*I#8B#.#QP@<%W=<CIW,R2I^4EY384?"9P[;
M-MKKFJV9I//X9_)#0(T1TLJ4'HO[3YO6:H(]6V'2C+6R&KP< \HP.37^9SD=
MT-@-*"F=HT39$#@(=A?:3,HGF#9E]$I'$B5+LL X=LK7K)<BX  :($S7] $D
MT Q?UX(K8 H?$0-C)R!FYSBY7<)::!-M9TBTQ,(;X $TD(1H.]Q*2,.0$%RY
M!M#2V.CF,DZ_L85:J+?Y8G?^<I/=@=W9S>G_0D#;W4_U@H9?2*M9&,7[V=&G
MQ1@A[1X"*KF.2]+1!NM\F-+^45]9O-(KK=+6BJT>5(@0\J# [@D#U@DHA]:S
MB&!;9.+J1N!8R9<VQD55!>;%( -F 9HV>!1^=;\:@ $8< '=C@&.C:]!]3E<
MH4=_XRGK^+/D:L ^W1E]*H)#QTKR3N\J-<W^JP)OW8NQ:QUO-V1A#@DK02PM
MJ^X([!'DJ*J9=;4X1CYE?+97B%USC'*_:BK5CGVO5R'9;>46)C*QMQ-+1Z5C
M!P&^DHD7Q_M%706+ +'O:G27!!@"#N !,, "'C !$H !(0 -2#$"*3!,IXU,
M_YEIZC"Q>6*I9#(1)6Q6A/H!&9 "<2?<,ZS/HUJJ,1B>C+.ESPW=ZXF2%JUI
MU&+=VHWIG7Y Y=V& ,4OT(2&\U*3&JV%@_=KX\5-/+[JZLW%#86'<PBM>@@Q
MJ#>YM+X(:#Q12'D@@WC?$5+3#*+?'D6+69G CSB"YPKYU LS"!XT,;0+J[L/
MPX".3!Y$^"::]PO^[A=@ 1?P[51-%9@T?</;X<J0-Z4T.F!!<JX#2O(^I'/1
M#6Y&[V6-1?(^BR>.6?B0U/S.(BWE;OFW2 5!2U?H'9DW^)*VMOH1+M'UUUYJ
MY+52_0/X#Z[#^;H;X5\VS!5?U942V=? \W\3%CEDM)C-Y6Y-RHUYEZN\RMGK
ML)\-?RW  0\@ BY0 A)P  60 !4 "" F)B,@'B0G*2HP.#T^/SX^/3LX-C,T
M,S(R-#<X.9\ZH9\X-Z6DG:4S)1@@-T*OL$1"1+*RL$% 0)$]/**C.)[ .9Z?
MQ<;'.3K)H3H[H3O0T=+3TCS4UCS8V3O9W=[?WC[?D>'@W]S9S=;<U-+^S=#/
M.\O,],GSHLR]T.#BDCT_CB()'#@0$L&#" T^.O@#4L.&CPQ"E"AQX<2'%S%J
MW(@1R ^/'#F"_$C2X\B2#8.0)*G29$,@,C+%U"0C1DV:-&=DLCF3!DT:/FG$
M$'HIALZ91G7J3*H4DU*=3C$%O405TZ9,2F%H;;%BA8H3)$:(,-1A@P8,&"Y8
MJ%#!@@4,&C9L\/ !!(@1)$J4,($B18JN*UJP:$'8A6 7+EXHAO&"L=;&6B-K
MC1$#1F6M-6'(L$R9,^7/H$.#QDGZJ6FG4*4"50T4JVO33U&OKD&;M@T;G&R4
M,J8C6X_?&G.5%"[<(*]HQ8"=0F6J$S!3RIW^+R]5J@;0S2]4?"U!(@2(#QXZ
M<)"K04.&N!LZ=/  (L2(O2>TMX!LL^FEU4!QWZ:!FW]__?GM9T,- O+G'X&W
M$:C@@ GB9MN#_MTF(6TSD%"!!(EHD,   P"@0 4?D- =>R28D,(+-_#@R&_6
MZ' #5IO!,(-NNR67PPT22G>#"QUDP((/0;Q"RRQ$$FF+$+@8U^(QP@SC)#+,
MV*,,/?"T8^4[T?3&#CKKL+---UQR:4XY/) SYIE?KO/EENTP \T]4RIC#RAP
M.N,-+[_E&9! "B$4B4-_\ODG1((&VJ="$RT44487_=/0/XN&]%"DDJYTT@\J
M/7322)NBQ*E+0*C^-!--//%$FD^DD:J)3Y0)M<E/K\8:$VRTQF9K5$_%5-D+
M@JF0 EAB?5=6!ABL50$%$U#05@89I-=!>R&((&())YS0%V LK)#M8(,15AAB
M\R4VGV+DDBO9N>A&=IEEFK%;DV@W::)93C,=9=JLL]I+KTSU:I(:?O_9IAN-
MSB6SSV^4YI)+$+C@HC!&O+0HYS#457SC#1<WU]QSI)Q2PPW7P>#""K]R-Y8'
MX8U'7GER<:">77BA@()\B_G;%'[Y&2@@@/KQK//.$C(8M-!#"YS@#0@.B. +
M'CB X0D3&     ,(H  K(Q3B@0C4LF"#;^EX@J,,Y+:@&8V<)%?)C,W^S3""
M!2'@ (20L]12Y)%S%R>.-4PV&0PH<C83CS-84O..X(CKXZ8[O6C3.#9>:B,F
M.!'C"38O_91Y)YK@[(-.EO2$7@\^$P<>^N/=Z+EGGWZVSI#K@%(4Z*(1*7H1
MI0!5.BE&N*^DZ>^^I_32\!YEVM'O+F4*!(R:F!IOJJ>>*M10J**ZZJOV*95O
MOO8V=55KLLFT%0LJH #L6!\,BP%;$TP@0?L46'!>>NRU)VU>?,GLEPJ ]:]M
M8($1C+<&V +#C&L^C(',N2"C0 6FJS.5R<R\H#<J58V*7_ZB8 9/ Q3K_$QH
MT $%.R0Q*(8I3 BA8I@*&?:0/&U#3LKI&'/^*M:Q&,908SBR3F9&]BM"A" $
M*!//RN(2%Y?1Q3TQ4\%@:L8]J=P'9SDS4!1Y1J ($2UI0</1;;1(,"Y."$=(
M.T$%%#"!$XC@ 0?@T  04( 'L&(L'?B 7E90 VX<QP8Q<,&\& ,N%\@@:5S4
M(G]0L0)FO< 'L$BDD6QQ)!0^1'/P^$4,>0,X*UG2<,\0G#/L5 U.VDE+G!N3
M"UEDN8B5:6^:VUL_,L>Y?:Q#</H@W)NFM(QB!*Z6M<S'-X!3D$(1JE % =3K
M6.>G2<WN=@ZI%*5ZISO@5:HX'#'><%X"JE )+U7.PTE1-$@:Z@W%)J:ZCC;K
M!1ON4>5F4+&/53;^0QBOF"]K(D 9!\SCEO9)  (1B, $EJ4!ESW+?B(:A/GZ
MLC_M:,<K_>,?"\BW4 $V=("\0HQB$*-'BB(F@>4R5[K:99-V3;";E'D7-I\'
MO>X]<37_&5H7/?$,:S@*4RS,Q2OFEL@5@H1%SC#&<ZBS4^C4T(8<*T6"0L:5
M'G;'$"F32[-8M@$C?L ])>K+$B%CLUNA]&<Y8]!5>R;%G@U-J%L$(XUR-# P
MXF@&'WA  C"0 A PH !PY5 !##"!#7R' Q[0RPEBH(/CZ, &*\C+"<+5S@)N
M(FC7T0]U9! ""Y @!S2-Q9#NILB'_0!,\AC%,(AARWE<\I)4(ASBLK3^CW>\
M4A_I4-/GP'0F%JG(<BK*!BO](5O+L=(<G_-<FQ87.CH) P>^"!TZ5+>GV;D.
MF*T[E$5B9[O:[8Y/A#)F,IM)7=TE+SC2!$EV,5623+$P"!@$Y[NRB1/R7J\F
MUA-*4'#B%'/6BE:HN4\Y8\25\@'K.QX83P;6XCX(^#<"[UM64__9'A$%-'_Z
M\TM!#<H_@Y+/P=MZ:+<(^"V+)B:CY<*H1C?:KLU\QL.C&8T&3W-2E%HGBSRU
MI3H@Q5T3*K*1KV#AHXZ36:!.AZ?.D0Y0*S8@GS"FJ";@3@@^ !XA#K%EZVD/
M7A)!,ZHVD351[& 5<<;5!JG4RF35HED'-M;^+KL@ PI8ZPD\@("I#<  <56
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M+?B"[!&#0U<8D_'^7N"3@TBW54GG=$2315\UA#@2 QS   .@ .\1 2( !$7
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M8LB([   MD_<:$0AB40EDJNUNZMDF,FL*\G^ W78! 7GPDI0!.4KHNP5W"E
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M^9>/(\2M%0X&#^*89_%'>P[4FUG(H.(8$_?#=7D5+Z@O_J>"LJ? %+>2J2*
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MA\\9%:IX^SN9IT_^SP. S?T7( \[C==3@@HNR*""A?2$W8.%3$AAA1:6I^"
M[N%T$U4=VL0A5,[]9(B%)OY@8HDIEHBBBBU.V"**C?0 E" U8@+)C3A6LLF.
M@S3U@R9!"/EC)IFD$L,,IBS)RBJYJ*)*2C'0\N23@(ERRRJ\&!-88,6P! Q)
M%ZV 0C,BA.!!.1E4,T$$VFS3S0,13& !!N5T<(XZ(I# YSMZS?,01/GDLPQ
M!^FS#Z+_^-,/0K0I)!!#A$(DT3W*6(11IGUU)))(H8244DK!&%:#8C3(1-,-
M.=@TGTX(\D!B)$-%5Y1TM0YIG2#G_<=A5EAQ59.O7W4%;%AB*0E#"[/^G4#"
M""* L%9;;LDU5SD<Y+EG"?/PY8)?3I*2Y2V#M82882R=2QABB;U$66.4.78#
M9#6\@)P"###@P684?# !<-EHID ()Y00PP@6_.9!LR"0\!!%*)" Y@:[*6!
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MH (7T( Y<H>7$FAK+X&R!PM6D"D5M$!X^"">].AQ$.-!;U'1^QTYO7D]3+5
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MJ4Q-8A+. :,PK\ I+KXTPI:8V,3]]*G33Q@3$"1@3AR P0Q>8 (S,R!C4EW
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M"T ! G,"'G !%[ !'T!$S#("'V!5TQ1$W;(!3"1W%F, #$ !&^ !"<!$ <
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M)% !33E4PU$  /"&&% "S! "VX4!TH !:S(!$& !(8 ":+@"-% "&L,Q V
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MFPM7_@L@57A1K%V8[G_$FLK_ #@5 A*P%WN*S (:X (=N. $*P""$+SE@X%
MS"XZT,<,6# "%MQ%!:);P2]80((/:& $)V@!#F9P@A*T(@,)  #F$A"!S<B,
M9P7QC_049BF(7"]A&-'(26@  XI9#"<DL,V86/ ,=-!C?"()2<B&8S+B>.0X
MG6(.<Z SG9C1K#K9L4[.G&<SG($F9^.!8WG4LYXZ#JV.[6G/A,(F(.W^#82+
M?]GB1IPV1SUJ34%< Y"!%MFU/0JH0HFTD"/!!B&S7<B29O/0V3+UH0R9R#0_
MP)&.!'<8NCG";C,JY8YP$R-;V.)&K#R,WP!G2B =KD<U01SB8J6DG4PF<D^:
M@ 0^4:U17 E+$Z  Y[CT 1#L2DQ3Y!^RP.*_7"RE!;[ )C:!X;K8O>E-LR,&
M[/2DIV9PPQO>&)[NAB<MX!G*'>]0%$M %K*^."^([>D0IBQ5O=5L,%,901I^
MP$>2\(5/5390E:H2I;MLLF 0-L&)"(3"DUMU0'ZN:"8L1F"4VY2N= ?T'U3T
MAT#3I2Y9O,C* 9,5E98JD)K=3,8,4%"!!AS^0 (VZ L0BO!/(!!H(SC@2 U>
MT*(<^$ '+0C!"%2P&Q>4X ,8\  )9&B#AX*  Q90   2,($".& #*<@!IYXG
M&HQ@2GI%-**'E"@Q&+0 !9((0>BB*":E*,LL\[C'QT#VQ1 ^)SG)\:*C6$:=
M,J;LC)Q"8WCHP]C%[LP[-Y/CS\Y#V2 &+8]Y9)#8P!.0I&W1.'PAY/,.&4FI
ME74OFM)41E*[M:\%B&L4FI#8*HE)K%T2DYH\FVXYQ%L1 2%'J$2*<$N9RKK9
M"$? 16Z.<#034;KRN8D +G%KDLOUZ?(1D7"?8O;5),E50 +#! 4I2I$Y"2CS
M ESR .B*XE&-;87^@*:[Y@'GR])<N.J!;LIOFJ*AICI=(QS>V-TY ERH= Y*
M6L%31UZ/YYO?<+%E<]Q00S:85HAH4)-^!.1)PG</12$OH:M2J$O,X8Q7T<0$
MLJ)$)2QZ4:!H5 0</4I26@!2&C.%*0)4Z9I:-ZP=5Q.E]9VOZ0JXNF_.X%Y,
MJ840BL#D(0QA-=<[T%UJ((,6Q$ '">$!#2:1@AC@@XDF@.H&0M "D.1B!!V8
M@%8+4($"0 "L*2//>Q@RQ I'^4">$:$+5H""Q<EUHT:1)4B? <]Y+N^+S/.+
MHU;&LN:<T2Z/CK0:WX@=\'"'D)%=8\$04MFCX9$_FD7D?$#362YRSSC^HD6/
M:-RSZD-::-4)*E!J&?G( $5M:F3[6JYM6]M>:RA3(,HMAGH[HE86PKC'QEM2
MGLM*Z+8H?]"-MG)C&23A7I<6D)#$)!3#I,A9@ +")&8H&G E5$A 2ZM@A7J_
MA"1!XZ)8\#U@F=(G9-:UB9KYS7>^Y_3?9? .G:T:\#K/41:\FH50QNMP@X.#
M'T=[Y[3[7%AJKH<]3=&'(_Q8E%[MT6'D*4JA(I8'J[:AE?VM#TRSJD1%?X)1
MGC33F1PM 2T( 3>2AC2D5;%*5ORWXV.TCKY"7B"\=1P[&O# 'S*P0 -RP.0F
MJQ5B-XA!"DQH$=?@( 4@.$$,2%4#&(19W2G^R,>9.^  !0P  !5(P)M/(-:Q
MUC$AP7:(G2DNH8.$T 8S@ %M2"#7H81.YHWPU8V'H> 9K,HW@13L%U?&Z)$-
MTHR#5"/-=.;&>SYVLCZ3+#[M:-G,9M;5H[Y.9Y7SX.< +2.D37UK>; 0A!3H
M:K%-)"*C%J$].HB/?/2U)87MMMU^B/<C2C:0CAW=&P%W;ZZ$&YGR]U!HWZ+F
MT'?^BJ1M"")1%]N\S(GC,*$)*$EIW%8ZQ030W;D-;$"]?Y^%4J3)E?GN3]Y!
M5RFQ?KZFG/M<WZ_C-^[,*>#?28MC?M(["-9."9<\?,4\$&80<S9A&F1G%M8:
M&68?7Z82QU.!%KC^*E>4*"\!#BD%-XZ <A.E<BSF8D,!8V#27K?P4/'%/PM4
M;P:D%3DF?_8V7PI44CS'%2]  P=! VU& C_0=$7P9!NT%SI  UJ1 C/  U6W
M R[P 20  R%A#S!P BX$ AT0 C.0 RVP E;8  90  !P 0T@ >HB5CE#%P)R
M5M-C*0!5%W<W R^P=WT'.DH5)K:0%<?@;_&D$H&D-,;1#X%5:OH11I &>9 V
M>9*''6E$:8PE'@2S6)CW/)NG/7A4'I]&-0U2B9XAB*8&0DY#2 <1BEIS:Z+F
M(/F46JU7(*4E6ZVE( \C293$:_)!6[X&?+^6(6JS(7CS2M+6BW%#)LO^%WWY
MPWQ;J#\R,8S(B(R]&#AV<SC8I6TK]CB9,#E10DSD=DRG<&ZJ@%X:T JOH%1(
M4E<U5H.X4&,D52:YD#_QMV,KY7-XN#HQM2;@Y%]UPB?I]#L!QPT"1@[9,"@%
M.#XH 2K^X&CWI$<;4F$347$!Q1<2^&4BIX$+YG$96($)!@SI U$HYCX4Y3@]
M(3\]H5[-9(+WTVSO-V0A)5\F54T&9%(MY5+Q]U)XJ"Q200,_D ,><  C( ,V
M\(--YBTZ(#'!00,K4 .D@1$V0 (>L (WT#VJ,H4@D %(F0$LH(4JX H.4!EA
M& ';8@*')1YE11H15V$> AH9%P.SP3Y]1PG^=5@"@G9-NY G@#(#\T1/B;9X
MS3%ZC?9#D2=ID\9&EO8=GX%IE?8=D6B)_/%YAJ0U=?1XI'=8TB%:G&8PJJ=Z
MC[1(J&6957-[C>1(FEE[L=8ULT@VNJ=[:X,V= 9*H11=OIA\P AM-?=\R+@_
M,B&;M%F;QO@KLZD_PR@3OD)]C/ (O$0KDP$Y3P)NU?@ R)F<IX *Z+9,&R _
M=,A>@2=XU71 ,K&%3($+Z!A?V,F=+(E251%3/Q>/R!!._&=.Z 1P? (.Z:2/
MNT,.A*(.B8)%WS.0CW)Z$K9!:R@$U=. E,(A&99Q'-<QL0%/L4&@Q[-0$RD/
M)+8-3R$3A]$^(0C^/Q;%$_0S5Z+3*[Y"FUOAECWF.MW4.CTG?S<G9%[A4@/D
M%$FX @_@ 9S& Q'1$$>W'"$D RIP Q?! S'  5C8%UPWA1Z  280 A5  CD0
MAQK@ 1)0 %I% 15P 1Q0 G&V':TF87)71-AC'B%T S5@EBI@,7_V9QR5H79E
M+-$"3_.P<(G'#W[5>",S,LO1$8<X>1>71IU1:7[)%]W11H5)I08QB9C%>8DY
MJ)Z66)RHEWY*%PG1:J.(B0S">@=!(;26F9M9J9=T>[0HBZ.92;TG(KA8FB4"
MC,_EFLE8JBFHF\Q7FR@9=-594O&UG;0YC*YD7=FF)"N&"4Y2 10 7A'^T*O$
M! ' "E[GIDR<4WY=\@JQ$"8TYWY+43J[>9WG6(PWYIWUAE+KV'/R^$UG<B;J
M! [:  SL^2=^4BCPF5< R5>,!HGL8:4(21&?%% JTQ('VC'R^9 6:'CSD*_O
MP"<$)!..P#[N,U$4BBL\H98F6 (H*)O6Q!32Y);=M)+V!F3*4H,I59W%LE(/
MZP(VD DJH(2+5'':LZ6S(2X6L0,KD $FL)2 P:5,= (=8 'LHP$@< -ZEZ1=
MQ0 %( $90 $;8*1G"'$39D03UU,"PI 2$P,TAI9A>K#BZ);1T T(9CQ[]3UL
M:C)WZ::&Q1&1EE@U QXS0VFB)9B:UJ?C81[^E;5Y=$0T@<I8<-HR<*2HBHIZ
MDYEZ282*=<=:M9>WM;:WK_A(#R*:FPJXN.6I^C2X0?":SE>JS(<+LGF;UWEC
MOX)C**HZE M3+<FPJ IMOXDD2B*<W+<)QADEG@"LRWENXU<!V]@YW?@Y@-9>
M2Z&=^B-XJ9J,F-N=TZJP),I212:#_^,F=/)?]'@-OZ./ R>NA1(/-'"N@&B?
MCSA'11.6_,F&%6=Q R&@]# \[& .UVNOB))7Z1 ;SL 4&+DX(5A1MC(_C>-,
M)@@)TTDFN%M TY12%<MS:D)_NJN2[><5R( LM& !+> TJ$5G%J$16SH#CH #
M_Y$#)X !)Q <Y$/^#R]@ AU0 9Q; EUW DEJ 0EPE0V@+1U  C@PF <A6PR8
M5A51=06QI4S4 A\8"W(5"S'7M&;"7W\BG_90 W)I:(F',HT&0G.JEVBDB'=:
M,X\%F3@S,U^;>9((-.?1'X8DJ(6:1F7DPV\+MW$[MX<$:U:390$\J: 'FKJF
MM[!X(;FGJ;5EB\ 7(IVZN+NICK [K7 \N:H3#7:B?]M*)\= %6E20*^:"-A%
MOI30$[@*NN/7J^;6J^ U?DZ*NA=P 1B@NMZH43%F OA3C,JXH;";C-=Y3==T
MFR;YH;K+CFIB?^!T)O[F;^'*.[E3PWAE* IV11^C-&TJ,Y9HI0TX=YS^5!<1
MXY#J- \=$Y'>*W+("P^MDE*"4!,H)Q0@\)&N8*%>\G(B.0L:BKN]2Q7WUD /
M9'\3F\?9RF/39"P#]+ ?8 $EL -#L!=*^ -#N! JPZ53B (WL$@W4 (8@ *J
M,@[]Z%0;0 $QI[$R4 (9X %O<94)L $6(%4AS,0'(\!$="G_5'=\(4(O\% H
MIBLP%G,RAPCS1L>^H,KNP&"H0D]>Y*:%6-*2MJ=V>FFB1VIC!4>7QXB;AA!I
MRWE"DQZ66*>$Y3/F(9E9DS5SFY@,DA&+--18_%JYQHJWE2&8&KB=I%M-[5MT
M=HS$^+C,TA7XA5_5D S0@COLN9Y>77!>G9[^=?Q XKL^&>FYGSLYXS=^YV:Z
MIXNZJJ )G9,!W?B<Z#<K(P!X@O-LT):=^Q.,;7R,M1G')NF.\:=2R%+*+X -
MU[ GYN2MJAS9NM,[]8I0) &(R7&?.<.N^UD]"4-Q',(>'2$2UXN]VEL\^8J@
MWJNO&VB16V@8*'83ROR1SEPK%[J^H\-*#[6J,VP55%$5VMQ?5Y%OB:U?UK !
M$T"33Y8#/>"? QQ:[EP"*1#"FC+/&% "R8NT\F5#$R!7)'!D,A "&A "'O
M"W  !_#(( #"<#1G;%,1:96E=B=",<!G3P3#NY+1N%$F='S*O(-P\9"O"K4H
M??A@Z4I8?\27=]K^6'K*TF[4TI#8B _>IW=T-(5:IX_7X);E-6'#F5C\>3-M
MTZ,1BHHJTT(]XB?^6E(#6[*5U+)8QKA8N$[=J222-AS"L-;$0 RTV+L0V=BP
MV-V G@-'<-WJRAM8Y.U98EMX".SC9U9X"9F@";JZUE0.UZI@ <7ZR'.M 77]
M.2488QE3?+!)8Z:JFY'KU^^'CCA87Q,]GBUX?_T5+><)M04WKD0N/(?B,2+A
MAP@N'GY+9PAY&G1'O1V!#ZE]#@<:&XAB@<(<X*S=*MDT$[0@H;/MS.NV;I2P
MOM*\?M>44O=V4K:S7\*-?W%2GMH:O&-FSDZF ^H<HZU'+GE7 BR P'O^<0,J
M@ $A$ ,T@+2&@1LEH '=711>%@,[(0(88 "8<0 6,&8@[!T <E;^%-^A[8;T
M[40W,::1H-?/IRS6$-D<$Y<!+@\<MW$-UH?U!$9[J>"*V-(-7I!L)$>0.;9_
M>M.":IA*+!UNMQU,W9E9-A\V_6F!ZN]F&RFA"*F6N"DC/L)?[+<=/C9F ^.;
M:HMF(RQ.898^KLI ?O'_W4Y%[LH(!^"%UP[%0ZZNDIU'$E?+/)R1(^6Z2@&+
MS,@6X,A:G@$T_\@TSPKF=ZSU@Q/A*(ZVH'Q K[C#N(6#O9WK6&\\]NEQKG])
MKLJ0+=F#XCOSN1(":;4%>8H"+''6DS#3SBG^#LDJBJ[H]$H\!*K:(\;:&\@F
MZH/,@$Q1RVSIRUP_N#V=)1F354&/Y70GM!.\P:O5?<\-(0 #/^!D0Z"$%I8I
M;B@2+D "+\#J>Y$#3;@9BTUCN40"P&X_*B /,*8!"N O"Y  %N!,)Y#0SEN4
M_RF6(1)0_G #<&@830XF49319-*[Q.O5 P</!9@\5*\T_;"4ID8RCHE8PO]&
MCD68,/V7QH]Y%QZ)4OS#^E[C)B+Q>2OB:$NVDT6),:T]V.\:"H^)M0;QLV7&
M3-VIO)4V%:_Q >CT0_[?MM_+P"/R(5\.]XS[[C!@'7AB8"*<',#EP#08NGKE
M@' A>(&!D7&(F+C^H:&QL<'1X>$!$A(R4H)Y<H*"DI*R AJJ$DH*RK)RRI*:
MVM+J^@K;^N+JTC)KZ_*B^P+#"_/[&R,<#",<4RQC;"S#W,P\ TU#4U-C8WV#
MDY.=DZ.S\\T3'N[C\_,#!"2DODZT[AZ$#O3CT^.=8RU-(P/M+*-/,V/?/GW^
M .:3%@U:0!F]:JU0@>($"1(B1(0  6*2) \?)'W(B-$2"1.;5)A4T2K7KEW
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MAJ!X\M GI9BB2I%%MG"D++?($HLKM^BBTDK^+/'4TS#+&!/0E?U\)HT-U=B
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M R90 !VP Q)6  =P !!0 0G0 "UG TD4<_/ 6S0'&-/6'6]R R?& GS^Q4S
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MD G'< =9'X7!$#P0!$.P%(;A?0 Q#! WD1U0)R$7 CP  QQ0 0H@%Q[  !"
M 2G0C"@I5ANS+6<GC4]A2S%)0.6R:L#S"Q"B2BF5&BI5C16$/)4S04?^N&-)
MR'0FE8UA B;]6)TNVI0JI0U+.954^75C:401<RW0P3]IMR9Z9C)8=Z34\D%C
M&3!'UF8\Q&Q-I5-N"5-TMV3,1H<2DT1QAE!@97CTD7A2I&?UH7A^":?%L!*]
M("4*U&MWFGR+J*?)MS@M 3B2QB&?YP@8< %D@YF762(6$(IR\RCCHV(;4@G'
M1",@8IJ8AIJ/0'^VQYJ,P7LG88NNN0J]R(M(8CBY^8Z&,V^O<WQSRCCK^1.2
M0S7II8\G17UEV6QFUY5'(32BXR_>YW0GA0U,"94[>2_F=T%WLAD&1F[?&4=R
MY$>AM@%T)(HWLH/ ,V_PV#AIQ5;^$%(0DHS^TD>?_3BDVR $_!F0 TF0XM0_
M;9(8/3 ]A4&-1,>=#-H 'S #-C "!4 "// "%Z   W  '6 !"R !&_ "(^2A
MS]$Q+-DM'R,S.F ]BK$"*/ 8)% 2+*! Z=6BV> O'E2->](N$V)-EE,O,#92
M!3AT^8*4"!AU/UJ=3/F42SFDJ]$OF=-*!H6'K)(_*LE07*EV:R=@7B9<'F0Q
MK0%"/?545:6%<J<<U9)U239V @-#7!IW9693R%$<Q&&7]\%G>BF(<"H,_?$2
MA!DEJUJVO):JA+FGE=&G_H6V"N1=IA4[$C$"AT)'=E29GGB9)L)I'_$HY\()
MFG "@S)=K0<BFFC^ 9[(B:SX"*C6.ZSI2([4-YYZ-Z&@BY>4)*-:?+B)"[\(
MC'W:ISLQ2E=R;]'0;<JH;,BI6V;'4-0Q1=\B=]!)7$1)?31+C5 ))K,K)^5'
M)S.1@>76>>A&:6"S6(?51]2Z8D)RJH:I$_?FG@]"8WK"7C*FH_A)?4' GP*)
MKEP9.H41)JK2#C^ H-K&G3;! AO0 ",@#2%0 "AP QU 807@ !N@ "HW BWH
M@DF1EP*F,9\3'3K$#34@0"LPN)]9 CWR%3^GC$;VHCQ*=*$!(?>:1B)K.C>:
MA 5X2Z11C?O2HSIJ/1_LLK?5E.-*9$<:95OJ'4S1'2^HDOP3AERF+=;^ 9:J
MP1H^Y5,O)1M8*D.SP:56*W916[5,!AM6>U4%8WTAY#"^$7,)=6=7M+^ .(AA
M*\7\$;;]80MTFEI9;%I;3%I<C N\ECAM^VNFY5]<?*VP\Q"<5[=S!#:427H3
M4 %P7#88X B,6@*KU@F>(#MOU*R*Q0@BTHD3L+<7T B;*1(6>U%Z[".42[EZ
M@[FC:DFT4"FJ>JW^1:=W"B7Q^*H#@@R6\1G%N4&XU1M=Q;-C*&WCI$,X9VW<
M9ENK!'9'AKL#=WY]LAFWP!C1U:SO%UG%&ZT= 0*/&RF3D<5M"UY9Q#1W-2?W
M>%Q!1YU M@T_8*[HZI\-M10IU - L' T ['^VD8#ST5N!'0!#U "U@ "!0 "
M*?  )>@ $Q 7#X !*& 7)^EA] &B+IQ#)68] VQN.&("G9 NER*?^8E;+QJ$
MLXN/T:M-OR12NL30/=9T&6R<_A@5B/'!SNS,+UND5GC"4 5X![6DG3.&+_RS
M7&8=0/"P'<M24IIU4\NT+H-DKE&6:6C$.1RF.>5"8S<Q:EC3)R0.2PQ%>+FF
MQM ?M< ?5BP,N@DEI?6.2TU:G8NJ[S@+O?9,^5>GIH6;6XR;MRQ=F$BI>6NH
M9*-I=5P)E]#/CS0*LA,1M>-^@+0!8F.9@BP!$\"XADPW%BN+M,A(C,2I>YTN
MM-8*\E:JKY!K3\W^:[9PI]?::W0*;%I"6\6)E&."=TQ4RMO2,5]9@\.J+\CF
M)=29ND"T5$R)G;/<NQ@X;N7&?KF,7:&V6-JEJ8N$"BEA6JQ*C(68:+$:P?SF
MK:GT)=9;NSQP!.::< RHKFRG,^H@7$&6&!.5<26P 1.@ E[2 0/P !S'  NP
M !"@  E0L"X0'&>JL/#0OVHR8AI3S=5S P+TG9Y9UNDB*L@6K,Q(LS":A.;U
M2]A$+TMW?O;2C5_BT$UWG5'7HRA5&J7!0<M8I%=H&-3R)DC,T\*QAQ\-2PP[
M@X'Q+0D>A5UWM"T$9DHEM2WT0D!<,#5MQ'S7AD/\9',XTSD557GXX&G^.A]Z
M:0X8:]1=K-2GRM3"9SC.%-BG=5JXB<F@Z\7!YTPIH0H3BP+255V'VXEZZXDF
M0L<U @*.<L<(M%EI/+C@<Q& I(IC,P%Q'=>?B)I0_LOB@WNSB"&>^B.^%PJS
M:9.4TM2T8#B%S49S'M6[P)N)76^P!7U2PV](N5*:XQS<P;/I<$/2\96Z<1JL
M[-ZAW&1!]$.P4JS<>-\*>@Q_JH/3]7YLG8Z'A6KL&,SNJ)M1PJ?.MRGO^7__
M!ZXYBH!!1L,'!]S!O7!JYRU;-X4)&A O< (=T )>H@$"4(('4  %(#\)L  3
M\ 'XFT22'539UY77 5$X(, N0,!PA",[TF+^,!" &TO#JK&3V'A+[@7NWX;?
MW2C+Q9J$19F[',RC(5S@0GK@-/MD,[553,2'8C5S$AX8?.9VVSZES/C23M94
M:$E"276TAB'B-]4;8EK$:@AW,NU24N7=3,PS@HC5J%745LW4@2W8MLF+.TY:
M8/SC25T+NWA)@.-J@.I^7]/52TYZI*=I&0#E(2 ^OP,*KA *>PR><]36&&"9
M$B !$?#EA1"MD_ HFJ#(1W_69\Y9#U'D?Z,*3PWGFY34AOWC9@N,V1J)>)7;
M/A;*U4=V'SW>,4QBQP&5BEY;G'TQ*;-4#KQCJ.-1D';+^WP[GT=':_,AFSF*
MFGI94:]:V2J/M4W^3?:XS _-V;5K*N;:GP09Z[)>'_I"'&Y2ZQE\ RP0%')2
M 0(    P  "0<@P@/Q5P K:J['EY0_[+%T*3% @JP <&FJJV2"CA<^E5^*WA
ML3QZ/0@X?A64#S=:LMC98P#7WP;X=)=C@,U\T2X+L21<LU1J,0N>\'(F>.60
MIC%(V<P..E3D=BA-9&+VM$SU\!ZN=QJ.,DYU\&66TP@STRM4, U?\%?:_"Q>
MEQ#^Q)UC#DM]X_<O6B9O:T5^FTXOR;H)""TN+RTOAH>"ABXN@BTM+)"1DBLK
M*2@G)",B(!T<&Q@7%144%!.DI!48&1L='R$C)28H*BN.MHXK*BHG)B7^)"$@
M'AL:&!43$A')$A.I&JP>KR0D)Y<IUM<JUMG9E2J/DH*+XHWAC(.+A8.'Z^PO
MB^[M,"\P]# Q]S(R^#$S,S0U_VK8L''#!@X<.7+H6+AC!X^'#WWX^/$#B$4@
M03(&H?A#XL,=.0X.K &0QK\;*!'J< BQAP^("Q/B&#C0I$V3_OSIBT&(1;83
MF$:$ -:A:-$-2).R*NI*! D30%/H8B&(A3AUA^C%L!=#GPP8^<*&G2&CG]D:
M.4FJ%4@3)<&4!Q$F](&D+I(B=XL0V4MDB)"_?RGJL*'C88^&,@O>F.FHQHT9
M$09(EIS@@8(%$C;4:.BPAV$>$B=B_*$1L&G^P!E)_^AQ.&2-&"Y2!'5:XH34
M0C#ZD429L+?OD#.#HQSNEB9-@29ITK"1?#GSX\J-2Y_>=B .MV[C&HS+/:[,
MWG)]ZTBX8^'*ACPX0X3X$O3$T.\YRJ^(46,0(1E/W[_(L7UY\^,%J%" _W%F
M8&$+I0?31^BAQQ!##B6HGH(-.F1A>A9>R*"!&*+7H8$'0MC02CR8MYYA$E&4
MXGP4;<311K=0=0LY,SH"3@LK0&)+CKC<PH@MC!""%2'MT/A-CI%00HDU*)A
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MYB!?_&)W@!.2G?D&:B+BT(EH)32BL4A%$RF:?$!8$1 Z[([TZHA'8'(O\^3
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M%/GA=6;0U34]ZREBJL4+"MSCQ9#PB2*I(%R'8S+BH/5F?]8.6N^:'2_R^3J
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M<RCE\%\G=6-AP6,]]A;B$2K;LR(;@69.4R(Y4! #1@BZ(!4O<'=V!C1THU!
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MUB9=VC:.6H)^_1<"M.%^!E@F]M4"NG YYB8,Q7!_ T->7(8!&N _\085ES"
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M3U</G/ R?O,B=;(VW1-0L>+19IK7'8T0TOIY;YHZ$A5BD<0A+C)R/@$M^(E
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M@;IX(U7E8'5.HI3T2(D[[SS*R5?UA#47/ZK%1M%)$26TD$.:4F21:*!Y]-9
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MP2+!8X !8GI3@S$",5H*TDA:<UL8(FN6I'QSN"&Q,'QU%7F$!@)X=6B%1FB
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M9X". JOCZ4P*1*O(B1/*>9-X^9S*T0%[5#O^KW4V<I,?=C-.E)@LQMFA%C6
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ML*FYFJN^*%D5RF5^1F>D9<$)3T<CU+ UPR=['F(W^O8_)E6OYDO,@9-P0D;
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M*C!D%3.G,LK8N4X00"S*)S7 _VDG7.>XC:XQX1QZ9SMY+LH[/>*H-4P^N,@
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M< RE))HBB_CS @LH- .")1V ($()VXP#"EC[S! ##.DTM8HR)(3W00?^"V*
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ME#(BY1CM::!!#NH;A"P!#< UJAMDRQ\\]M<=$3(B):3QP>-4H@,<T$#^12,
M08(T\"+F?? %(YL-=APQ@Z3@271O:^7<4@=.KO7G//MQW=>B(D8<\I ?N$/+
MEF35K[G(48V \0EV8,*?$B0/,I?X(B<\\:X>FJ),U1O2,EQA-P1EH'L0:(!#
M'9"+"F  FI4RW_OHYHR. 6,:EG)%IC*CGV^(E!Q/$ELI[S>[4IF*2EMI%5A@
M910 'B2>>OP21)9UR 5>1",.=. 0.'(1"%[0)!-4CK*6DTP;R. %T6*&!U4
M0Q$"#R5"Z19>,HBCB1%T*8-CBN%"(18?LE,4'0H%JG"H3MNMZG^PRI);#5*4
MHOSKB&V,RQT+QJR&+%$E3SRC% %)F)C2B:#^TJI;+#3F 1A=PP34BE)G*%E&
MYQQR-!<$I!U==E>8P<PX)A3:78#W)8,=QUN#R2NW?G):09IQD*&QH%\;YSC8
MAN00>F6+=I:*#GM8K9+MJ\:E/.JH3;4'*K$K+E30IC9UB,H]IXR/.E#9%*[Z
MQQ@]$E#J7&&-QDPF;PO2VX/4! WP"(Z7GBA<//!A%80PA''&!(+#DEF#R9$
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MBL,:P.=RE158?K=FVO4@'] FC%43U-0J4B,N2O$H\'90+28ILL!0#5!C#-
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M.^]=2WDM6^I8FV/M#ATS9T[L4=%'OHD[YJF[FA7MO!LV9)@R,0)$A\,@1)0
MU0)&NI8S>^33Y\_B#\F2\;Z-Y]7KV;)I_=9DN[:TZ;>H[>G ^S(NQ==S>6"6
M+#'B;'WW+EK<O:\W[W__ OX XF]BCAN26* 21L)0BQ@T;."8*:RZ=1'^(D80
M,M$)!0H50*5-VT8>!GENYM$W[K8MO?GWI; Y4T9?63),WC6=*$%BA(@0NG"P
M04@#:J !!QV,=%@N@@QCC$\K!,4--]\\18Y5TLVSFFRRQ3-#"R: D($$#3@
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M".R.L-K0#FR+&0X1[ZZ,O6+B2J-BR>JY%Q=3#%85.B78RFJWO,%+ML R0+#
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MZX).*$4_EJ&06*H5"OJ0=..@W85X&H(QF9-D,.@J?G)>1%DRQ00#'QH!#)
M!G  (UJB)UN2&H@-+EIB0M8AYK9U;'.C7)$ZW:1U5YF3.?N"*==<27A6*V9E
M\B1/KW@P!G2'4(3^3Q\&A($W8OXD-2?6%5+9<@W1"RZ %4^(6*@@'L0*(88'
M-0'% F&4 PJS"9X &Q_K5-VFCUO#%:#42Z4RI_^P46O(A@#)LZ8TD&AG98S
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M_=$>K=$EJP"3$TT6< &,B"T:D@[)D S\>+E@Q4+]]=*@<L.B_& JY[,D,E,
M-(TT%1A%NVSK^HRP=\0^(=0;0+'\%94,@0LWH!.0(<59U)"9LEOX!B$F-*8M
MT%@701V$*1(<(<8M &3T*(;C@EST0]9B=Q\A L<B(A"H.1"L:XH\WIJ$$QM[
M3$9^+*AVS8>&>9C)J(SDV'W'XIYR@EL1M7B&?0*S()4;4U:= P/D@QG]%U%W
MPIEW4TGTV&?\>5P(Z$L01G^,]A9(S<H7-K3^_-(OMBH8>XQZFVXR.3U#"5$9
M67%=\AAYU.0"2.A8PQPLNIT2+ $3V??;BNFK;%0K1$JDQ2U THR=JIT;UCP:
MSCVNX+G-YMO-/C-(RSQ;D[4)<.Z^C)0BXM=1Q;!5&@4#]7I)Z'&/Z2&?BH5T
MGE1R2);9;,U#!?E<T!5=2#;?3M*PFBO;#"H4#PJA&?YOB7+/%CJ#U+C'T(B(
MR)0!$U C$?[@)KH )?K1(SS2#["2%KX-W""Z+LN/-;M"8?4+^1?3[^,JG).$
MZ!)7Y_7#?'M\ *-E/-T)CCG1^[0@V=644J/C3DP(/IX(2LW85?SN^!:\M U&
M-#"VFK"'0^#S0T#^$AR! S/ (KVECUHE7O6QQJM"&>CN9'6+I_"BSWJ[M];)
M1 H3XX&I0(,I9@^DU\FHI OCUQT&V':N<%]J%$]W8BL0$&'!BD4R&8%./A13
MQ< +L95X>(YX=>% 7!UN):%R#QAK"Q7</QB:BE3DP[ 9\ID.B\@-&/PRC51$
M%KP0,96,6'S/(0M]3H1PVYOP4ZYN$F#OO-(!O8)8ZY_.E\9'&[)9:;?:@-DI
M&*)US>'ZG<->[-?7S97E'&>$CL W6]D=B$L*&S/ '5KD]\SP#]CNU;KU;>K'
M;=^]GPGF-Z$4.U5YNCM4P&6M9.TSWPBBH,'Y?W5ST 0(7N_!#DGVY5+^QA 7
MW"\%<X@\40(?D $2X  BNM$C>J+/5",V<J(%7Z(I"@@-#0\/$A,5%A@9&QT>
M'R @(B,D)B8G)RJ9FBLLG"PM+2RBHBNAGRXO,3(R,ZTS-*\T-34T-#:WN+<W
M-CB[-S<XMSC#PSG&.3H[/#P]/LX^/<LZ.L$T,"PH)B,A'QR,'R$C)2@J+"XP
M,K6VM[ Q+BLH)R8D(R+<'QWYCR$B)"<K,&;@T,'CQP\A0H@0*:*0",(?/'+(
M4$$O1+AP)#*:0)$B!:<6+E"]$/FB)(P7,$Z>+(G29,J7,M#%7#5C%2N:KV*I
MDS4K%R\;.7CA.)9LAS(?/)X97+H4R(\@4!'^.D28D*I5(%A]_.@1C5G!I%J9
M0N2A(\<-&C%:G!C130.&#1S"_4LUHX;08;=HT5AU$E0+%?&T;>/F(1^'PX<+
M*W;T"(3%<),T7NJHZ1-(E#-9M:JEE[-/7+ML^/I%^M?0H<:($<NA.MBO7)WW
MKAH)*E,*>21*9-PM.86*<S+LXC#*3&L0J0V33Q7RP]FRI&"=+7WF?)G1U+U$
MXPHV#)AJUM]1'QM/M/RTLN>1&9VV@R /9<FL/Y]/_SG2^\ON.Z<NW>!7L0 ^
M%81!SAF%0PTSM "//)><X!%*,V0T0CWUV//8A1A:.&%D)5CB8$<??8)22C7-
M$(,KL,#2B@PQO,3^4DDN@.37)Z+85@D)(H@  C[Y=, ((_DLQEB.'9)CV3DP
MQ* **[5L5PPRY_5"PPL4?9#!! XLD, !!R20  ,./!#!F&02,D@###"PP)II
M,C#( Q <8L$%BAS6B&,3:F2""IBLX"<H(8IB2BB7*7F3*WK-,LLZZX3F&C"0
M<O>=,?$QTXPS74TCY0LMI*!-"!UXPP$X(VRDP@HNG-BD#;7, (."V90PH84?
MU H./[FEX,(,0.F@%1 )*:>0$ /R@ .5%6W(X48>^7E*C"29-.)*+KUDK;5+
MVG2H*SGI)(L-/7TF'I3N+7,I-/TU!014QU&UG%17.=4<==!%)]9SK-7^D-9:
M^&B0@0:CEJI""^C8=5=>ZMB44DFAJ.#I/-N X,'$B%5L9Y 3V_I89'I^F,DI
MEZ%DZ&8[J6/P9Z*5IO)HWL&62ZLU\46;@@[?=D()NO'6CT:^B<B*,#DH ]8/
MZ[8K[+ //9-?=%KQ5]U[.Z0&#&C<"66:::QAE_6XY)'']7GK$400<4+79W:]
M]>V7'U),YP>1?P5-9Y"\T[&]0S SO+!@)9>@  HKNLV:(S\8%KXQ9!Q.1ME'
M+;"4Y(G<INC**BTN/%)((<UHBFV75+1C(SYN\&./&#^2(R5&@H1DDBS&XB1J
MYU%C0]XJE/"!!A,\H "77'Y9R 2'5"#\(1+^E/D FFVJ*0@A$!A"005T+O)-
M)+MU>*JSEH$B**$AL1ZSMSV=G,LNW)76RZ19JR<T-,W,AY>K+61C3^@;D#I.
M.:FBJ H,,0(6N(4[JI5%^G$_&-!@*$DA6K 64H0&(NT'=WL!"NBQC0UEI$C-
M,H<+S/&B:4UK8=>R5DQ4D2V<K(A;.9$%3\27"_#<@"B5BD;3>B W=47%756Q
M"D*"@)7IK"V!";S7>\QB#;6PA0/^6H0'2I4"%J!C'55;U$XV$Y.^V AB%J+8
M843'1;B(KD<3\P D(#' TW6H;Y09A5]8HB0E1<Y;G&F2.E@E1T6I$&9\L1RG
M0K$"V]SF1A*:1([^3N>/)C:.%08;ROK",K<<.D0Y#YF7?9C6G'G1"VI2"\W4
M@F&UU8#G-./A6M?&4Q9DF+(L[7D/U(BC2JB=C6U@69K:H(,?IR&EDF\#$%3J
M)@V\<2HPBBO%B7(FN,$9KG 5Y-@9/]2L-:;$4)#SUN2JF!)4G"1S,=(>"S(1
MC\"%8$<3HQ^02)<QQ^3&5*7H7HM449,YW@6&K)D=E6QW)=WQ[@ *8$ A*$ G
M#?AS V[!P 6&)P$(.$ 0R&O3\N#D/$34B0,3,R<E3D".4W4B>T<2F4U0I$)%
MA>LSY"/&:[SS)/59JCBP+,LN7(4-68'*&XW@1PD<E,Y4P(AFMY&5A;[^N0_(
M%)(%,NB5=( 5+ <N9%A!Z($.;- "B"$N,A[RB!JCY;AK24MDV$I)'K6U413&
M GP?%890@$*I2ED*&@02BU/6I4-XM96'6 &"=+SBE0"-)6HWJ,&K3D "$'0@
MB1OP0 C\P8(7,,DGG9$F*_K2L#]BT2(?""=BNDC9B]W)$8^QQ\XH40E+4.9C
MY?"+2%8'$Q:5D*OHL!:,,C>*FG6D08 ,Y" I=$'?'/(50 O:(I=RPP5"$B%.
MH9?3ZJ8TZT2--:\!#2_,UQK4H*]KSDT?I4P9M62P1QEDP^[9T+8T6M9K/TJS
MY=OB%J !#:BXQK"!#/06&+X]*#@XH^#@C)G^H0L-1A)YRDV#TIC1E[0115]=
MD6JI=;EL-LQAN+$'.//11=(U(F.#1%UH0?+,;-7%8, @I:9N, ,7U,Y*N5/
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M99**"_BSZ(N>9K(-4;K[/+;=J[=<0,,JK'?W5+_YRU=*>5%5#BCZ$,/8<_)
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M3@>,6]@!!QLROL@'[$'"ISUCFKEPBJ41K<,--<S@X@DB=)#!! TH8., -QJ
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M+Q9EC!\D%I');&1S=@'A"FPT7?R75M$($;9'2)GFFN-E,C1D/SZP S@P RK
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M J@RU;@9IE1<A\1VRO5(.NLS)/E^C[%)MZ$;F^0;@C<_:/5Z+?EN!3>"QX6
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MIN2Y"&(T4M@&8  ZD4]K2 W60$ZS4I9,(2A9^@B/P-J96]F4(TY[V!^:W4R
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M$T8@T$694DLUE5^45*'92R24< 6#"B6,()8$#21P%EIJL25!!1EDL(%1(IB
MI+OWP>#7<(&A,-A#*)G8T4\7:?019)+A5%G#R2GG%V?\>?;E:%)6Q7)JFZ3F
M6H/*^#)/0"VDD%-$/'6 T0>[J=#/;\$)!VQ@!B&7UUY^255))JQE"@X/-Z"
M 0-!:@>!!!1L0)<*XH5&0PU8-2+)#%ZQX%2-#CT$WV/$HK#/KQ$'&%7^@% -
M#9R+ Q;(59<),HCG)*RY":>$$ZIC"BRL$.JAA[)R6&'D((KXP@DBZ%;7"N)Y
M]A=@@?$38VTE@(#! P<,((  /@+I0'=%'IEDDI?M)9YS\VQ"929<:BG:> 0V
M=TG8*I>FH"64Q'Q5F<IG*NDCQ3PSR"?@+&+.G(+C::?*>>JI*N2GJ-)*H*_
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MIP!G-C JR,@PF!FE04E>SW%0(121@Q=\  *L@T#6NM.!$-A%:)X)V]@.08E
M LTI7BF625[YF!?"#6U.@AB ^#.T -%M;Z4,V^_\IK*_W6YY#^)&#Z8GBPK!
M*G&,6V"B&B>YR>G !I4;%T9^YIO/=*X@1M.,($G@ 0LX8$>J*T "%," !U
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M [H:!6H5SQBHCJD5DH</WF9L_)>EF[&Q(XF073RP#=:"#/)N\= "&V!AJJ,
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M^*J_P-RLIC?,G^5IQDQL5]41Z%AHP_E"UF*].72MQOV<W)N2M ,CS!A\>+3
MJ>9 -O0!&U !U6C./6>>+JL!<:'.NS:_6NB![RP9\?P>)+0QZ<(S1N$S;B-L
M ?N-ST9**+.T1/HR! T, UWF?E0: I'0EJ9;Q]A[3^)4P_&QYW<<]T'6+'9J
MB+#@)<PCB761(*T!(% "_F?AIX1*D>= 0</2-+H2(1@9LY1^UNE>!VC3H3'$
M14R/V@,FR/5C^@C^M3(.34=6X^\P(36(.- DI3T09R\ Y#T$'C)KMQ)+MO=N
MOZO=NRF@T3VB%D!R;_DVTK$S.\LAI\8#QWW-?B"\UAB7<0NBQW$]?WOW/,<
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M2C1> >59:@:,%B=(@-A0 <*" P4&#+AW0,&#"1>.<_@0@H2)@@=7J),^G?I
M%":84$()A!#BVFS^'OSVFP>VT=>:(8N<@,*$B>G'0@O243:))J%PHAU''WGD
M40X<<6425[-LY1 -,KR V2#:^/8;:B+8E\(*+D@BF6'4/;+.C^HD-$EVY)"#
MRDBUR(0#"QLP4(  4!;@7@3^;# "=)%0<@,M</&@@T,Q+ :#BYH=4D@BB"S2
M"(:13((=D9!!QHDGHWAHBBBOB-)1G1BALDI0*)5%TU0__$(,,<90Y0PN11%:
M:*'31.I##]70 %Z,W7RCP@OC0&98.C]",AEU,(0"T0TPA!"! ?CHLT _$V
MP@F(&11D"Y)T^E-&$K5B9 T4811L1AT%%51((9&(HDHIT<)22U[JX&7^6S3U
ML.A5BS)C2TH@LC+11;'4(FU1/?Q@[5'2 ./44L$,DR@R1RF*;5PZ5;/L5BO9
MNRU::(G+KUIFJ06P3&^]M6B7=\%UE4UWS:M7O'[]<&@TQ^3B4 V&U<J"?M8Y
M1HX,DLG@3B0O@+I"8BAP-F )GX$VFFFHF99::S2[U@T(MVU3&VT\RS;S"+JM
M=EJ"R0EG= 9&#Z<<<]W4>()B_>5H'7;:C2)B*2VR<,(('Y#W@ *LKL>> @[
MA\%P'CAWHWX'7<B?=/\)"&$AKL7((-%WQ]Q:C8:4L-D)!26V#H8YYGH=)IR<
MTA%/(QTKRTDC/6XB1S7(X (+@I"@S=W,-3?^ N XZCC9F(^ "NK@0HX#+#EZ
MQE)6#B]T8$^4!>S33P4:S,J"=3,(I<P/7CHDPV+4G4R@(:M]1H*$CK2S(R9%
MQAE]D8GCV><I(/+ZY^,NN>7HH4\5\ZBB1)$+;U] ]%54-36TD W.W2RO0@MO
MFH..C_NUF64E$-D0@P@20,\!])& !U )(+1"C(4@D2LC6<U/$.S311)WO0EJ
MQULB^@BR(J>L9:%D)2ER5I*DA0L2$J5\UL(63>S%G3HE[ECY8M1-T 4IIQ!!
M*3<4!A#^ B^^[.4H<C'+5NP5%I*DA"RS^->TV!*PM,2D+;<@85OH-:BY(&PN
M!\NBP[8X%;[T16+^@($&^:I1F)*=;'"1,-5C-!$RQK@#$B9+3 I2=H+C$>(S
M>VN-S&2&FM'L#6BB.<W0:G.;!G5#-2/((\Y^HYRD&>TXR%E:<PP1.,)1ITV'
MRPX%@=(33;AH:Q_00 4><)Y[1*D]#I! ?(9#'S49)#\7LF0+3G:"SA@"D*$Y
MS<X\H)P$X48U$/*;"383..BX;4P[.IR=-))!GG1061S\8$E800/#O$AHNZ1-
M:&P4'86,[I+I.-V%;B6J-U$/(D*Y10Y2-8$#"    JC=JZAD@0Z0(!R,H<$-
M5E(5F>3 !L.+SAN-!Z$[KL9&CBA<J:!7#H9&SX6;U%X$M0<2(W+)A'7^ >.A
M-BH^(#*#7(Y*GQ@G52GW8:H03VO!0LI!.G'B2C+OH%,.;B #$E#@ /D8X (:
M\  *9" $":Q0D##)/XF2HGK <D7B?J41Q8F((QN4'(KT-<26D.6B;_DH2+.5
M%6AZJQ2J %0,%3:52/TB&#=,:_A$VI=FG&]>-=$*OE#4+'V)Y5]/)(M9 D8P
M:B5))P:32UT4=HN;8)%AAF68HM[J*#!*[%#2H HN2E)-RT '.K@JE6/8Z!V1
MC:Q'<9SCWX[7,M<(C31[/.3>DK>:NNU,9PRZ36UDY@V:Q>@#C"3.(S< 2>$H
MJ#DB(&:0^D,JQJPT.\PLXPK"XP%1?@T]\1S^VWLN<#8.I&T1!=F8K1Z1H<NI
M $!WQ&,N"\D@Z_JRCZJIT8#^5DS]6%(2C,FD)B\H(I*(M23/1(F*5I2QS(D
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M+L!M_N@3D]$" ND!&S !SZ4> Q!/^S==2/-O U9V^9%W]W,R $(@W9A+X,B
M 9:1V[0(*[,9$^*0Y-0.">=@>L))'42)D_,E-*J2\0=>K$&"#B("?I,"W;0C
M-7F3H=*"O#,]5G,2DS4#*1 "#<H .:B#!;  $("4%' V)> "-( #TM)/7U>'
MQ*.$MH0FA7!M.,)Q.YETBWB%9#D1Q**9UJ.6*<*6OV.*9!A9R,"&=V84N,F&
M,^6&)8!:2U:@G>(=)8,Z4Q-?V1$4-* "&O  #/"'D)I*&]!E"2$X[C4U6%AC
MFGH*$:4X6JB%;(;^+!'7FZ%9B[,@1-%",(F'AK-W,"7$+:P)>34 :$/Q,*:X
M0SB$:(F2/I6W:*_X>5YA4<WB$J87$W^U:<.)>JS7:8."%73!,*U*>_$R0]3J
M17X1&#PD4JYXG66D:VHW<N@T.H3I61HR*OGX"/+V771T@/CFC7X$CJI5;/&Y
M;!G',^N86HL$'(ZTG_@9C^3'-*WA-P9W<#8Y'6XR#AGH"FB' II3;O8'-NNA
M'OK'#_TGC^_67MMU<''C?-@$,[$18#TC&@>UD>Q53+&T8-[48&=J-<WT9APX
MK%\"(B$X;EFY.834&B/0HS\*4[B&8"QXL@QVI@X$*&JAI"/@ 1CP  G^\*0#
M@)#]0 $7L $AD (RH*4VX24T53):^QW?-71BBE(^BB$Z8D[?\BUWHJ9J^HA&
MA4Y2QR6ZT!=D^!>\FG6YT"CFLG5U*6(RH )_.G:!BH$BLX)Z]YU%A0,2-DH+
MP)B!^ #U!&^E<UFQ5*27Z51K>T%\U[*3V(%#)'K/\A)2)*>FV2@.DQ5;<340
M-2*C&)M6 2FTF4.IV&,\U$-Y\8IZ1@LA='C[$IRY6"]9@7K#N8O,&HRO)UA6
M-&K.6:V]>CX1\UB(XF/*6!@P(!W.^(S<:0/K] X\2QG?.9[XLWR:L1D#4E!H
MXFRDD3/OVGT[DWT9YS-\M#/Z.FWC!X_B9QS^RE%M] &VB&@ZL12%_;B36),Q
M6"D"#DM*8;,>!N"T"FFQ]7$?Q92Q^$,0=30WB52.R3:?[/M')EH"PR0A*( ?
M",$F'+<0_=@)%&224D5$TL1G6-,"XT8(N<0-LX4(.CN3HS,=/N)>Y,0F&'A.
M1P)A,X@"(<!+%=  +A<  2 E#0 !\*$!'C "+& #XV(M/9"7EF-)V%A'+ ,T
M+IRS,MD._;APJX-<2X66JG G?@=!50-CV\$5F0@7?2$$O*"*QL!6P!B&V)(7
M(@8#?!O$I<&C3\,I"-LB+C6X\?4**K !$>  CZH "L  #1 K :$8A_A*0$<U
MUY.9FRI1&+1F)OS^3"X;>D>T$L&I5\19MQ_5:'NFPA#E&+(8AL58*."S%)G7
M+HZEO*L+1(-5+Y7H%<0Z0K5XB\ *6,89O*^76*+6,%ADO'CABL#SRMO:S,H+
MR].)K>2C)%CS9,.5*WJ2 X0I9>4Z":,2O9:A79D!ON%;6K@$HH($/_$Z7NO(
M,SUCK^O,(-_W2/![S\,Q' "+O\8D3M_:HM%#J"N E2#0 ?6GM 4LH0G)E/*8
M-M]0=@T\I -12Z2%;YL36_ ,SX*$2(0P( '"P1W\2N[5'Z+3OQVR"@\'FEVA
M(JY@&"T,&N\,@3E['XYP:Y^5=NEP.>$T'989)Z'HMCGPD\T5'!/  $7^3  8
M)@$5@ $:P!PD  ,Y0!3FP@/_5,79=I4>RHV*0& D_<5G"WEP4B=W@A%HN;8N
M=-;;(8J'1U82 \>J6)UQ^193-+IYS+?"QL47LE L$I@M>+#8,0JI8G\-L,B!
M" $4L $E,! KX [J8$PY<EQ)I8&87&-[LF8E*8G6Z[*4&,JDY[EIH:S5@D+S
M@L=F41(1(:OH-(K/Z46X6INN_12X22BVMS#U GJ>?19<,C":5C"[B)S$7,R>
M%GMPY3# LRC%#<W&> QL-3%0\1=%N"(M@LUB.R1 (64L*@GA5FLJV(P$D3(K
M(\'Y5C>O 3.I 8$W V#+9HZSM8"FP8#Z^8[^]^RO]NL-UX:((+<8(>/5>WT8
MX;$-&2 !!)P>!HS _[ !M($('2E'#TE. Z$9OV;1%YTW_38;V]<TG[$R&\S!
M%4* ES2V(+,),08+W -GM@NK[W>(X9%(W?" %D[3-%P9V,R"!#L=(_>")STB
M(T0#*- ![<9;-^ARZ[$ $<#4]EL",J #Y$+5 '4__'$0M71+NI$(/5JFF%H1
M#X6%%N%M?-*I6W[)70@H2#(4;2D$AW9HD+)YJU9G74(4*I3'0A?$:>,TF]*_
M@8L_.GP=F?0))H !B?RHBYF0LB(0/FH. [B_^;1P$;0GD[VIFXRYHOJR;)Q$
ML>A$8EXPC4)Y;:[^RZH,>6RKVM4:#<.0JYDW,5W'BB%&1=M2"RNM5R2$B:H'
MO+S]V\,K6,=,Z\Q):KS S)V7W,I=G;E7RUCQ==?L(_BM*S3@S>\ ,OUK8->(
M8 11SEA<T1^JCO7Y,C(36Q=YKS#,.8VD ?LY;>(7[N,G20YB(V"F7?U\=$A'
M#@G:PB'  1@@ 0Z0  6\'@1>H?=+3 IN*[?R'Q&,;Q.,*;'QDA1N&LDC@0$2
M("GCD&W#7=?ME2 >5B*ATD6DDOR=G@NH?>OY#3="PZ.2=CA<.ONX4"1<POOD
MN360 AY@ ?"Q 1D0 0KP)$C] *NT("!@ C" Y,Q0U>=:@,ME1X=P1_+^TTWQ
MM0G(-99HIK"<*F-FO<I'OX&R&!//69UR;*>Y#+J=R!(.\0(I('8:MRD+90[Y
MV.^%\YWPL*@<(.\,L,C\8-@<0"O?!0.5,Q#KD"-?K&80M,F:W!.<W+)\=I*6
M>$2CK%>PSJI 5FJ)-8LMY"&J( MB_D.@3INO#16XZ:O3RGBI7GJL#H;"O$(#
MLWJ^O8FP9^NW7OH+TU:NN O/;/EBE'L;)1C6O-_<-=TTR<*4P:+@S"%LQ+/T
MUMCJ:LZ+P(V\,=Z] 8'OVM[[EKYWDVRPQ4L< .[>/K\:P-3YZ5O+4>X)_B.0
M&[D<)U^DLUSB@;03T #T+N#VOM#'T0'Q,TS^#9Q=0 +!#Q[P'GN.Z4M;R3.F
M O+1*!K2;=--TM%Q@! S,SA38VAC@Z.(D]/HZ*BCDR/9>&-3$].B<D(R$@("
MXB$*"B(R8H*BT@(3TPH#\_+2PL*R0NO"TH*K^R(C,TA3>)@XN;.C,Y/R@5%Q
MH<&1 9%@0&"P()&QP='1X0$RTG+#PY-C(^/BHIO>LG)20M(Y(C]"4G*BVO+"
M^CM#4T.#R)"_&C8 7CI$\-)!1 P;*BQ( Z"AA#9N6%0T*9*.<3Y^>/P!!(B0
M'T)& @'Y<9S*'2HY\N@!TT>/<3EPT'B1@@2I$"/LJ7@A:)",%[1RY=('P]>O
MB"P\4'C0@($"!0S^&#R8H(%$KE0 912]]0J8/X<5RR:R9(DA6K2(++J]Z!8C
M#AN/ZC;:T4B2L;U\6[)D.6[F3!^$"_\H3!@F#V.-<%@,./8&HQS&5!H^[#%D
MD)(EB1#A7#+(1\R'.V+NB/CE.+Z4]?9EN9''QK^56ZZV;1LP[MT^+!/F\;LW
M<,3$BQOF\6-<\M&HEX_._".(].G2F8_3,9?&4%FYT.%2H<)$IU?Z8K4BA'Y&
M#%;D9<UB 3Y%BA,G3)1X%T^$B!#[0_C_](%_H/PG("@?>./!!P>*PJ"!("S8
M 0<;;*"!!AE86&&&%VHPH3;=!$C/"2BDH$(M)8*'8B[YL!?#4C+$(,O^)CIQ
M@($$#RQ00 $"##"  0=8-8$%''IC"BHCRB??B5^I,)]]^,GSWX,**IC@!P^2
M<F4I/-%#SWTF?&F"B$FN8$L+NKSR2HOH#2,91G91EA<ECA4TE HHE##"?J$P
MZ U/)9"X2BOKP8).+;;08J:*+O2R5"%C573#)(LAHP((&EB 0:8;8!"! @84
M\.,$&#S#38(AI#!#3>:\D ZK9F[RY#STA%GBBDD!0]!$N@J4T# &/4160[\J
M9%!<DT52&V&9G23224(TZQ%P*FVD@V[2SK02=C>A0(((HO#G$U"$#)6HHDDI
MY4M3%4 E%55627 !""NXP*0,-<&0(@NQ^-+^SS]DS9560P&G]5C!;\&UR&1V
M19)7:]6VQE=E>^VF&$>&H?;;:L<H$G! B!P+6&\?F0;2=* )\5EHTS%WFD?*
MIK:2,7I5&W%EL]V&\VXZ2VM;;\(--UQA%@<=G'%&D\8R:21_=%)T'E5'G<N]
M;4QG+&;.PN0)GH3P00=HQI(F,/V@]^*@K*9#"W@HB.@D///H1^ G(,3]2=U8
M+KA@@J(L**4H$4Y880:C9J@AAQY^.#<)8J+(..,LH(-4BS($ PM\6H- XP0.
M3%, CSTF *20&Y@Z@HBIH$BB"K8<FG5]^'42Y8-\*AB*E%GZ-P\\]93P)7UB
MIK""ZBN8B4Z:_ [^,A&DDKT)";*-T4GOG7G*[D$W1/9$H@NLN!++.F3>@LLZ
MB[Y 2$1L1EI,#C.H$((&%U1@XP2"1[# IPDT,,$%&7# OZE:%2(#&*0#'5AS
MA^YDU9-[/ XI_(B(1,SG#X ,Y"$$B<A"@I6\"@[D?&[2B&68)A+0D.0Y+8G$
M8@"#+9@H!B\WH$$+N,6U (F !*G0Q[BX4Y1TG$LI*OC 4QP0E:HPH $1L( '
M4$"4$\ @!SRX ;Y*= M&]6.":E%>60#FD(Z592V2:9-<&E,72;@&61/KBU\H
MU@/BE(8X)XS$(AJ2$(S41CD8 ^%F3H8RE8F&.<V16FI^5K.(+>8VU/K^RTIR
M1K&>\48XC/09&XT&R34B!VDN>XXE41(=T8BF:2,3CB3H!(L"FN 3HN#?!KX6
MMBDZ,!B#<,77UF$B%*S-'J_KUG[@1K?_]*= 4IH2GT:AMSW]+7""R\"&"F>X
M;70 1/48$7B"QZ3XU$H=8),<N5@PGQEA0'.<\QRH0C>D#\R0/JE#DO"^!Y\4
MK,T^!\Q3@2#TRP-9R4K\V1(\[N.EWLD21=]31_%N18A#7,1-&6D8PQQAB1K4
M*04FF%[>1E$D% P/369#&RT.!4M>-# 8%+E(;-3'O@U<X"E3<0"F*-" !!Q
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M7Y266:AKP7!7XE&R63F79'@4Z_&3KE(44)1CZI!6BE<LF[48.,"H'K!-$]
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M]&N_KC87@/R62R=,Y151N9 F@(HU/$><O !08S,#:H$#9"2Y#.D!%D !%.
M!^ C3I;5RU0]@B,!T\#%5 $!G"H!D0V(G)P-RV23J# \7P84#30VJ.G:%BD1
MIED02:5!*HO8NWR6S=,2T&&0=T:*\KM8=9J;,G![,^AY(L [P],*OJ"*H[0!
M%0 !TMR8W3O-F[K)(P #XI!))9,<Y&!NZ(M?X[R)6W3. V7.AT6>D7(1U%C,
MR?=8\<S0V^@21>.-,C$U>"$)AY54)=;/CP=L$ZJ?)S/0G(31](<8%DPMXX=(
M#:U5JO'0MS71$ZW^;>]W;,$VD)9$X+J*H1AZCBCA SH@ R;0;DPY0[12"S(H
M:#!0".=Q@.5L>*DI%-6EHEJ:-6#R.G1G3VIJDK8C3W@CIL+$DA;R@82#7A7"
M/X@37_>1U/;0<DR;AOAE5DQ2 AZJ <U*U4@9I1!  <[P(<@=)IBY"4!H*"BR
M3[YCA">Y@6<=4[/#E2/YHANVB+Q3'[_CIE"NOD%'C<DG,]@Q)P&TUR':(&-8
MADB:R&BS<U<S0(LB.5N7V(=@?8&I-1XP4I@LJ0A08%Q.=PT9"E4.8 J0 &B7
M9*,[NA-  :5;NBZY 0'RF^,CKJJDLJL$>*89:K1KVZQ4A00Q4&]F,<O^TMOW
M3,P G)8-HRIM>7O)_ DS)%:NP )3+M43  '3&D2XB(O:*P$;D +B6Y!0$P3"
M,8SX<CKA*CDMWGOE'1?2R(SJS C+0Z?'TC!<Y<?RNN#Q/M__VL& A)O1:!:T
MVIK^#,(!/5IY)!(C-!+?IRS*L1NP@3,2K!((W> (C2W\J(\2#GW0EVP5O\"8
M)&S"IL#5X0,[( ,EP %:+6A?Q@[@03[+ \,RW!95E%2VGI'TYBKL$+;UH66Z
M0W<S9-/P,$, U]-[(W- +3@NF2%%GKI''B"X@T],'K=-;L=O2G5>R.R70K56
M*V Y**54>K0E3A^;D-3YTC@Z7)6P R!ZPV[^68G6M%,W-0>C7-8);_UA95)Z
MJ.KH5PB\R*(1I(9<2M>0![+F#D>7@,T*Y4% .Y?:A?UE?8DK#'$7D0L#CCU2
M3T'9/J( #U !&M !J[S*#Y(Y#R!$">#Y[R(!GQW:D5VZF%+:(4!3/OEI&*D=
MJN3JH4E%A_</8E/#Z$%%:-G/OPQN! Z?X-BNS .LQ:T3 ](3J4 +W")E$K)-
MTLPN#,"<## !'I "-#!)*L-)4W,#,X 3]M69J!K#P&(PY5[NYY[N""-T[OIF
M1*?GS/9LT<:@%#V^SV'O^1W B&J?_"XUO+U]W,<9&_U;( P(/CX\A(0Z/(>(
MA8N,A#V-/H^2/#W^E964A((\@H.<GI^"/SZBG#^BIJ.CIJ2KJZJJ/T"MLC]!
M0::VN;6YNCLS)1P8&QXA(B0G*R\T-#$O+S$U.#G3.3$S-#;9V#<V-][9W]GB
M-3/9,S,R,C#K+RXM[RKQ*"<F)B0E)/?Y^_SY(?\@ @;T\,&#P8(&#7;HL&&#
M!@P/-4C4T' #!X<2.7#H0/!#L7PE3)0X4:*DR9(G3J!($8]%"Q<PVK%@@:*$
M" \;+$!HD,#   $#!AA(P" "!8@<01A3B4)%RGGQ5,QDH6)%4Y8H4-3+-P(@
M"(0=-G+DZ('LA[-?__T3$6*$6[<E1MP[:2+EB10L5ZQPZ2R&C&LUQ.'^D#9-
M1V$=B!'CX#8#!E5[([XF)/C1!(H5+=;%6 ?#70L6*ZK.]/SRV5\:-<BA!D=X
MQPX<,$R,\'"! H4'!PP80*#@004,'=JJY1H"!,X+$R#L7)"@N8(%#1H\4"ZA
M^@0*%2Q<P)#!0PD5+_Z>NT:#_#(9R]*C7J;-1NKWJ=.?*U]^_/S4K <;UK$C
M$ZQ80 08H"N/&);#8-[<<" UU QF PTOM*""3<45,\)()Y 00ED-96"!! \\
MT  #"RB@0 (+/)"!""S8<$@L00@A(RVR#*(##C.\D!5+?)F6WH/B@)/@D$1Z
M@Z"1-RQ&V& ,'H98#HGQ)Z5KKO%092-89N+^7RJGD.()(3L8.!@.W;AG Y/\
M]=<)*ZH$ 80M,L9)1)PRFD)+*WBNLHDFC1QRR)59.O)((980.N@FC R"Z)Z=
M>.+EHZ6<4DHJL$2*2IYVSK(++KOPPBD/-)RP 40$R76""C#4\ UJ"E)YHS4_
MBL--@HN%DPU^]9V3#@R;N>#.3*&I,$\])?6CS['YL%7<0%^=A98'DBF$$080
M34110Q)5)!9:QLQU4K'XH+125"TXTXZ$-6V8TTX]!35  4,51<$%&B0EPD@I
MI.044\)*I5=46<U##SXCL!406 LI-%9":(&@%EL%OP47"1>:5(]=>%6U@J\O
MP/ 7?F<N=B!AB87^J1@WZE"585?&,6RA"2DDT_%FSGBFUTSOO!-AN=9<8U]@
M(>?0GPXWP'#""!U<4,%MN>V6@ ,49, !"%V)<.]=>,EF7# 42 #! PR<V%-S
M##3@@ ,/. !!=0ZD* $%&H" @@L]7X,>.O2IAUH-R_#M'GRHS6>???2]E]^"
M588"H"R,MZ*)@3G02MB"TY!9GF,IV%-,M\MZH%%#&%0 @0,-E/A !+U5X,&I
MX;G( XPQ"C$@*E;B^(*P+*F@LS7HL8<-.&72.N21(BLXYLC2)-\DE$\BYBJ5
MT%O9GY6%3%^(HHZ^7NF75B96.9FRDFP]EUVNDHN,<PJ1ONQ" (CI^S_^O%[(
MG]0GHH@CA"XRR:&19'*HH(OB!*- X:A7**Y+Y,/4?^ 7"TYM2A>\L(4/;(""
M#B#%8<=H@0S.Q"#K[2 'W9C/[X+'C6X,J4Q!*H?/T!&#%G;&,U')5TI$4JQC
MG2195E/+P3[0LH[T,"P8L19%*'(1C#1D(1WPR#_< I)OZ0,E*FD)"US0,1>
M)@4:\H &*A !GA3 7?!20 ,@<)1Z0<L8=0F8P'(G%=!$15@"LP?%<A@M)(X%
MB0SC(4"*T181,/$MX*)+73)6%9WQ"C!E&A/)G!>EQ=B@,1*RA\'R^+(4N(17
M[*#B.Z@BE9QYTC3C*5Q@F.0:'=C :"+H@ 7^; .!!!0@-P=@@ 0RL &JM64$
M,'/!Q]2Q MEXSD-=@P")$M TYSPG;"9B0(@>4!T,<" $*&@![\YS&O.D)SY]
MX]LR!C>>OXCG'/#IAGZ8-SU8"*B!CC/$-+Z1)$4RR4$V4$<+\L45$4BFB*#C
MH@/"UIP$5& #$B!!"J 2@QLLHA8R<E,ZB9:C@%&E7+SJ'7MN!3SA?<.=(F-2
M.Y/W3FKLAWE1@E[T/$B]+#5J2ZYP!9^LU*!:R2I)0AO??V!Q/CJI;T;G9*#C
M+K6(H?7'>EB2Q/\.)=1 :0E1)R4@I;A$/@/JE(%WRE0M.@5!7O@ !RT(P4.2
M6(Q3P< &TP!4F-;^V0U8!<F$)V3G61]4CES)H(4=.U<+0H,7@=WP6R;!X1Z;
M]966&2=:%[%6M2I2D8EH9"%G66+%P&6L>ZB$1U-TQF>$E44-=(T![0+*  Y
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M/6 "4XHG5= (G6_BE"VH*L$=P& $'*"(1^X%GFB$=4\?=/)BR".DBB[YA.+
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M0SD>!7AA$HI6AF4_E64FA52?D%+<PU(C@T*L00TR52FX "<VM3X)Y3YY(HM
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MG4J%)P,$)F-5K)%G=*5;J9574^ICBYL'ASHU*7%&4D&U>HGG/^W:G9" 5)2
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M%W81%RP3$# @7BL Q9IS$4+- ;2D$4JS7Z:Z3,R$ &,ZD:><V[J=  WP3QP
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MXP*OE  F,*O:LJX&R@!MI5TCJ656M):N,I4+(?F0TMK:!H(-Y,@[(!H QA@
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M&PN!E@O/25:^*)U:=9V3<)V<R7K&V&?3^IWB&9Z[4'O@&0YL]59MA7MK-8W
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M@A$RODM>'('C ^]51WT1]U]X[(? YMC'Y7:KN34)@A .Q@.>+.PG6!/'IQP
MV [4 P8::P^>IE(5)R$.2E+BY%C4VY23E>6]*0OE)2SE)2])(BYS.4]=5)F\
MON3F18'YU6'HYHO%X TRL]1;99"Q2\TDQY>&:](*BE.:V6F-:\B$#00FX+ML
M@. 89RMG.F,5G+:54QH]FUN%*O0+Z  O,Y;)Y3C)"3CNN.T[A;->5B/%H+5L
M;"P3C-SD@.5$)^XS!?WL7.@"A$,"^=0NF!SB7,TRE0BAH#2TDZAJ<#< !#"
MPQC(Z.6>B0(8T*#^+&+!027R)QSC8.:DWC@6C88FG<P18FTZEFF3RG<7F\HL
M<> C4F)YZA_.G4=Q(,Q8E18"KT%M:9Y*92HDP*?8-('3&'$"8#.V@]4GS<"
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M,3$P!3.$+J%PRV5'!B,$/\ #-O "*K ()F4A%1 !*/0 %; !(]!13N$Z';-
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M)U.F)8$R?A)9?N"3*0@$09#@0'+%D;I65R!9CUBR023I#'4A R? ;'\(%B7
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M9A9E.O3Q9#7  B?0 0\0*W&V,!Y7$280 [VI9\N3B<ZT.;)SC]B3CS;^]3U
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M?:-I=,&H):!.A/,KY L/A60(KH49#?M^?M*+'JLU3YRROLEXQ4@T\$F[DL?
M68=[;"PD^6DDC '^2_31C8EWLOVQLEL](\W#&"8\CJSG"]?F !+@,!]  C%0
M>W2=.1:+KLX4-#],M,!7?#15/9IWB=M#HHKF4[ #(4#0?,ZG:=<9 M7G%>SH
MG2P0 P5!6W2AA>4AMU>- UWYJY?JOJ^ D:Z)K<1E'C;@:B I.K%U-/S&;TB8
M&32SMU):&J7LJ*>,RA)Q%-(R2*: T"ND.)*B8,=2RZ\2N1!XIKF\RWN7N:;+
M*^&'"59*;MV@CL5,@NIT@E;);EE9F55A19/JEFQ4;_?66@RGB[5=NV*B@+>E
M*;N[#&\IA-:"NJ<2+HR3-,;+:NH<&<$Q'(U; <Y;C@ICSPZ3#)?4U/O^K%V(
M= -1\9JJ<L 59\Q()+Z]I(A2M-"QP$EQ$5]^ Z4Z5^(:87!JE!&:%IXCUTI\
M-F#\>S%(V%:^G2XZV-U%P1U31RU.@]!@&3,MO3N]N5($9HDB>B/,DP/P^@"M
M-PP- Q;XG _.T78%\7;-%XZ;03,:@0*QN$2[:CCCG!I_@=28\;:U?=4X?&2'
M@9Y+IIX*$E,"!ADP@8Q35C&F\XZ,P9Y%DI] W,3R82!I-B-L+68$BN?T 3U=
M0P,GH $S.RMSQM=#$0(FX *EMU*H<QM,MB"[EZ$^DCV"1NK[^(\+ CZJ_B1.
M*Y #*4O",2[3MRS(L@PQ+-H7LS0;T([Z5C'^M8V]]U!OC0PNQ[HRYY=5=#+;
MEEQ/#*3)M;8G!B1'(3TS,,,7BBG<?VL4Q2V5ZO1THX .H9*!*^06BXL")@ *
MT>TJMVRF.)2F%1@*S2!:HG$:F$7 7;(-QR RR$!)YJ5$S4*5G^(TI"5%/C;-
M]-#>TNPM9 L2C%/5T+X0\5459L1+$U%=!,>K4U0/WI$/PDN#5%U 2FA<["PB
ML1BJ&#<!#<!'5!@4$>XIA'.]%/,?B@2=SD8UM= -(M@->5J]?=I.RGJ1I/;0
M[0L7?<$18>XM^\"PEO$X'GL@"D6MU<J:%81KG-&H@-D=2SDMX9$X6VM,'L(C
MOSD9\'&)0+(\&?;^ ABPQ060  Y0# 6ML]ZI53BP&BS% ],1VC?C#R.23H-#
M*@9,SOL 3PR+S6W^)X5791/KQ)ASL2]EC,<%><K8$AYKZ$XOCV?=.JPSZ G2
MULCTUI>SZ(C'/)?' S 0 N3H"P,@# W@ !60LSO+/$.SGXOW3\5XCZ/.H=AS
M/9FG4Y/=:'@,.S?R>)E6'BB0D-5G"N^$Z]UU$C0C$(5A-,.U" \Q#1'&R.ZE
M7QS/%A'M#UJ%SK,M>*]VBG_R[(O":GB+?W-H[>[P8'6U8.(P;GEU]9] <,:F
MTEO_7G-WB!Z@ 8X+E$)) (!0<+#0$$%QD<'1\1$2,O(H$BDY0O+X"(+^">+A
MT<'!D<BAX:E!JKC1T>'QH?H!TL@8(DE2.4M28E)R>WMB8G+"^PL<[!L,G**2
MDJS"PN+R A,S0T-34T,S(Q/SPJ*"4D+2&/(QOCCN^EARLGM+HM[>GK*RPNSB
M @,S$Q,]PS]38X,CAXX<-F"D(.%A X8*%20X2%! D(('%3!LX- *DP@2*%SX
MNW$#QXT:^5BD0('K40A-G%!YXK")5:98(BS-NH4"Q3$5/'O.8]$": L708$R
M0W82Q;!?OG2V>+%OFHT; G?PZ.$C:X^M/+KNV)&#H V2V*#)N ?#!;<3)$2(
M&P>KYBP3;2-1.J%3Q0H8-&[HT&&51U8?/,#^@LS!XT>0($!^='V<0P6% Q$3
M.*"00<.I$+Z:J7A1$$</QS8^QY#78JC2$R)6>3A' I>MN;Z."7T*-8:,:33&
M^K8!$(?PL'__\M#A%7G7'LN[:OT!_<?@QV!SX  ._%_PJH$%9_4>_0>0\4"$
MC(^N5?#C]>JONF?NM;#\^-3!AX_,@4&! 0,*,&#@@ 08>!!""2W@T!YSA/FP
MU5:#29<5A.%-*%Z%%39V'H;DD2?>AD L!F(00@@1(HDCG@B$#V!=MTTV)G1P
M"@8=4&);#+V1)$-99O4ED@W8U%-+D+44@Q>1P>PDSVVI.7./#$[V(Q5V4@+7
M&S6\]8,E-DY"<X_^,T4E0U<ED:R$"9F;H.*2(IN4&<X(;DD20B6Y^,*3/#RI
M,T((,%Y @0,+'&! 1 8,TH $%%B0R")MUB2)6Y18(D(F,7GPDB@:@+*!!AUH
MBDI,YL1%DRRUY*(++KWPTLNIOJ1:S*F_Y%7G"O68Q<^59ZG5#5UN@0#7!ZBT
M$@NIZN"22VPW_6+;4"] !4T,,#SISU0XZ'"=02(DA($%#36@0$0' #A!!J=D
M!,)&'<TPU0W9E92,.B6X]=:DJ7B:43@T/6)+4SDIPQ,+2=Y&5%%'K9 3D:;B
ME<)3NM4Z50Y?[> @@_!Y5=UU_6SI+ POM$#P"7GR"NR;E,P"B5SP+//^0E_*
M/38=M50EMAATZ^U@PPD24";(919Q ,((G7&SFPPZC,;##)^YH%=J+:!D0@B;
M,&+33731A; *2R[[;([^]/:;M "%)9!Q\W5W%5:#/>@#A(1U%99PZE()W'!?
MK6?V@N%IN"%Z6,T\MW-E<S5SX.RMEW9T/-A P@001:3  @%>L,$'(YPPPWO.
M+7B5Q&>?36'G%W;8888>CAYBZ2.*:"**/ZQH0VIGD;#!10/Z'$\+,6B'I3Y:
MIVO#-435LI&0QA)#;"[%\.O3"DLRV:36TV@WY3_46'.E-/WHYF0V]RR+:PJ_
M?*,2F9F,<V8GGG2J2B-Y.N+F^J/^4F=/>&K^H@&?#_P9* $%($"((1DD&A=(
MN&E,-2D9)B;5DI=DIA2DT SZTB<.5\0B%L*[B2UND2I799 8PL@@7F 5CWDX
M(RK4*PNNO-&65\ E%>.(Q0A(1:I4?:,=)T@&:F:ECX5A(QK_H JU;/""%%Q+
M(=J2 +<"=0 %0* B&U!%)LSED:GXAB0P:$$WAN6FE9#/-:I@!;E6(K):X.)5
MQ]B)OWZB)&;X2R\G84HO2E4"G31#'PRCBL,:-!V^M6TL6G*6]EZ@%J6  Q,M
M;$0!;5&RN]10>7P)2]_.QCJ'A<XQ:R/("!Z LP-<!E&1BXT)>D*#W>C@.S X
M6M)2XXVF/<V%<_G^A@?S,A0F88\W-YJ2<(9#G.-0;'""B1AZSI8<Z_3(&MB1
M&]DP]Z#HX.V7WW$/+WO9G(D]DV7L@4Z*CN."#>BG/PE@0*$LT$01& @QR%P0
M'C<GG71"IW#6M% [K2FZT9'N0XLYW>E0ASH4^8!:.*@!4&;0@A!H)E,]JZ'5
M9*"=:URC5M< CKI"212W@.--<:J@\'9QO!/X1&E#04OVI%&-D$KI'R&M7I:R
MMR6-;<R*[9HAO%Q!2->@(G87Z12;)CC .%4T-CGQR9U*, (0[&D"#F   B)"
M@$'U[U")(A#[:A(JNUA"?)LX7R(248I-B<(4\^J5O1IE%PL2:X,<7-7^4IB"
MUGV=Q(;T@(K6<@>#-:)P?;UB(2-J M1T% N&W_B%/.:AK'OH)H?\Z*% 6(0"
MA&P@ Q?85@(. %D&+#%1F2A7'*.(';)4$1E,H40C0-8KN%367H:42U^KMA.]
MJ%$HK/UK&U%5/&&A@ 7/V(=A 5.V9NIQF/QPDA^U$904Z"JTAL07R0HX.8.V
MH)& "4S:"&.8D"3F/&OKB@YH$(((="LBA:H .#W@,XT>@P:@:0_2XEHG5/KB
M+;"@!%U<.;5762TUM742+:T!O5L&A#C%$9LSZ8;.=#:S8M?!3F]NZ;"'+:>9
M[)1G8Q)S-FFN+#U< =PTGYDVZAXN<0?@3P+^'"<!"VB 0"1(00T6S#*M1"S
M[/1<8R[T8@[A;9[T!!&)\)DZU &A!_R< 0OPP0*!<B!3CC#H"Q!:/87R1HK
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MFT?J5$==9/&M/C3&#)2L[S6<-AE0!ZC(VL&@!F&;VW1V<)V7@:ZZ/,B!#$)
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M7+2!9;=AD%G3:^T&TA7L6][Y:NX L.,C4^:S578ELGU+$S?14STA@*VQ*19
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M$B?W&"(Q&4JW=": #UUS$<;U<U$W88"Q*[AT=<&C=:XQ 1 @,*E'75FC&_*
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M$E!$''.JR*! %.'R2#Q(HHBN/:XN+A ; T,W'_VQQC6P85LV>< >'%CL!"(
MP0;JUK<'J+,![#36 A3PM\ %IP*:G,6M%N'^F7U$\XV/\XQGBD<Y&XU/2 (J
M$.?2@P,$73,^38K0Z.ICNOP0TT+F(>CKAD2^Y=FI-+NSW>GL,SH>3.@P[#F/
MU$")JHM(CCLKS(MHRH:8&\Q !=$;3J&LT2T2I !Y>BE-@_)W TWTJ$=0^='X
M_$,3A)Z/-.]Q&OO>Q[;X52FJ\Z-?E[SD)2OQ@*(WL01-91$+L[1)!2B+TP&+
M&I&]M(<T>2KFG_BDM[A"( )XFR %[[HH10WG48YZ$?6HY\%K8"I3 >-4-W;%
M*U$ACX4<:D$>V0BS<8FD(YIB1<;6H<,=]O!6)GF<Y(;8KW(*JVX/:,"QGA&-
M!LSSB5DS1+2H: K^CT02K-=*AQ9QB(IN<22,XHI6N?!QKC2JZXTI*0A6WJ46
M%3K$$D8UU0ND\PE1$(,CLKW9P,Q8QI/,TA''>XEW":@VFUS, ZWH"26!<LD'
M4  #(K/N4E;PR1:R[(4HV$=6N$(9F='L,F&Y62O#E2M^S&66_'A++N(2%ZXE
MI#O(@\'E7AK,P="'0E&KP43PE4S)$",>65/*+O2I8,_8I9JS@P_IG'<#QJRM
M;=\D&VXN!@(.5" "QU%G:?^F@ 3H6,?P?$"BJ(<->R[%'[6$#KP:X<_(V04T
MI1JHYL9CT(.NYW.'J7+S4).?CZ+N;1>J:)#$PY@@/?@&!V)>A)Z4Y?G^ $:D
M)(4:AB82@TVHU"IKZ<6'D&<O'.G)!C X@0<RT*@)8- :')@16<7&T:CR@,\.
MF\1WB&K'B(!9;0=-*)(^E[XFN0]*5)7?E>@7A*S:3TM 4 UK8- "2Z2 O"-T
MSM=8X.#Q/(6.F! 2>G9 -B6MC@9O?2M=^00<NUK0@GE=U%X;Q4%) =8:&<!
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M#KB)G(46H/((BF6!8O=SS&0KE%5#:8)9S^9,MC*"9S%MH5*%/S<*[$8WQ-(
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M#\ZUVIPRP;QRS0FK*JT?]T?3V\[5:V1?*,_^TC'/D%!-%UX#,="]O7I.?>T
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M2YH+MC(\+W.2]Y5L1_0P=^L-0C2Y]&*2NW(,SH)9/+8?8J& ]=  Y\HM#Z@
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MMYFM<:S3,RA*+6K12;[%QA]$46$X$H@(C6#^=7,=$;FMBF@="(YI$NU$W*"
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M<HC;B2K982$?YO+@E+:VDR8*;:J8Z 6+/M HC0DLH,"-$5Q^P04:-OACG*:
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M4"*+W!C)0COT0)$T/.R@PXTVM, "+R%L@($&&%!P60(%) !5!AU@L($'(J2
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M( \H,&LA$#&S4SC<P3WC:JYNQ4>\A4$9! DOA:1H5+J+P%1,"H66 'IGITW
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M&N[A;Y,D./0WBA)QZX1W-KUA;@-_YE&=G#AX)<'1UTFEZT+2D('CUGS!DF<
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M(.:8_S56PYEGVE##8QSJ<-L./.APPPPN@/1B1B1\,,LL'8"@E446N54"1LS
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M)QZX;$K)+CFI<X45$*M4(?\6$AN!:<XR(>_D,U))1R-W$3FC1SG#<!>!524
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M(A?_8I58"7DT=X5227?KN3L0!W$7,1/]PQK^6^$1,, 809@";%D+;QD!#8
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MZ(D^UW7]HW<]I'J]#YB]25H$"Y8>V-/6MS5X(NT9MVW^,1/@;7Y\MY M#H*
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M*G+DDI1IJ#*9=(:-DS5JV$A:&.5)PRA1WF#J4H<-&"Y8J-B%0NH($!XXV.X
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M[$WPGGOP6>Y>DCQ6V=^+ -966P?"')B?@@O^\C?)F)Y,U%6C#M463P43<*A
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M&HGQ8$WW=+WD-**)859S&1N6O3&DO2AQ-<>*&E&4-Z'4*0IQ(4=E=J*&5<M
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M/>PCR^K)Q!KY2--&<I)+>6U(?'8/D:&V'IH\F=D$ LH)B90QM9'9S$SYB=S
MI0:': %]>O8S"?C^0@$&X(\M&2 !I!GFA(EA6C#1XB'1J&PRT1&7RBZ#$/$M
M<YE;J]EHF!--*XJ-FLC-YE961F''6'A+6PKG..,V'-VD@*^<(N%SOO7)*8W%
M;W,CCN" =T\>)$FQ_&2/XLCCN!ODB%,%Q< &,D !7R2 /P]XXN8JX140F$"B
MJ3J>1:E#GPB!M&9KV<1H-"&JM=QXI+5[BRIP-ZG=)6D0+OW=C&8$'A>9YT8T
M30$GH)33ZFQF1();D3YC<+WL3=C+M*'9]S2SMJ7VIJDV2-_ZHDJ$J>:@JC_
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MUUX::."::J&YM-%$]AZ6[T6+-0:92Q10UA)-,IUUV66;<6938)Q=H*3^U1:
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M[JF[>4>AY#-0=$@./NT#$T#+<[UR[$=C!17^'>\^)+K3):BA'NX2<3)IG$3
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M@=?01#:Y(MS@#=6R9:FE'X>*2!L;;\0Q-_KC"UW*@L? #2X( PB4.;TA+B^
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M/?D!!Q*C.8L"M=J"90)=?DGHHX\F6L&>)ZK90)MN!L6 F_$S6.>=N_.)_Y^
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M$R*UG"@Z\QG17#$A@6F("-@E+5!!@EM9Z<3^12I"QAC,+ <CV1<L<\-&U^Q
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M7W0F1)V) D6]T$+CU[ZF+HA-"7VJA!X@"Q/=[T6<_M.@^@>H__EBJ^<#8(P
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MR))ZTJ,5+<,)3^%O9U02)*$#OU4#=-%;,8%P]Z%P)E )'7 !$E,!LY   S
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M=K#8IVG;-Z(CRF@GVL3^DZ*H5FJK-B92_*))*Y%).RD1I%;N1T$?2[P>@X>
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M"6FBL]"C,\7!Y#I:1XNT+I0G3+NT)#G2Q))J<C4.:E(.:OQ#-[!<*7FG 0B
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M:Q:F>D:J7K$06F@D&8!2Q3/25(J(K"\9RV#$6ZQ7)E!4+QNM@D%1MH(L0MS
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M(IA:TP>R(0L_=-+^ F/**.]B;_'BE&'$ QA*E6+T SI0 BH0IS=@0SF@#H9
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M;KI!.72Q,, DAOW%2=VS5<KA'&]QCTX1%.NH 7PX+EE63> 8$LW )]+^.(V
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M8"?E/6DV(RS2GD/B1@"6 J/')NO30@AY4SJ5GZSG4["V*)NIC;-'0^)7H-,
M@<IVJ2<C:1%A;@8W@@G!CJ8Y?,6W2:6"?,LQ)IVAH1SJ?+!R;;) "R0*/P*Y
M>BI$#"RJ:L/PHJR'/\N"837JD.@7D84%/12)D1W9#K>G+4-D+<)&;/D $) 5
M,NGB<E]FDHN&=8;)<BTYH,\7HK/BLP_(#UIJ"!ZUC!;X&V@3@.F81^F67D()
M;VSZMW":E%4Q*9YB,71Z7SI1$W;ZC@P#I@X#J%01MHCP%U[)-H*!7)O^E*@'
M>Y:>-!F6@0,7%PH7L4$F<*DJ@8 .\$H#(  )$ %/MY=;4VX+!!5;8W.)5#ZM
MFA:D JNGV*C(0:N;)4<&D:N[ZG&WAIF L@QT8@P)6:+.4&BW!RG'2A\>A1^I
M61- .)7%83E<%QW;E7DJQF*=XP./V /9.@,X5H,RH""3$:[M!&?9:@)P<XRU
M0XI$UKN,NE"JV% X8CP113S]N["BRW(7973<9!#J0J>LA3YL4X8&>[ -57B9
MEHRP-6EKH:CS^8QQ@I#ZF9!WZ"=]LK$R=$W-0*!&];'8! ZK,4"DV5$2RB[F
MYJ!11XY],1$IDQ%4(H\K<F3'6&4X*QHZ"WW^935])+H,_:,G(F$,15NT!&E3
M[J-G^_.-3CMKA?8L%8EK.2J1Z.!KO=8.O 98\="1Q69_1PJ2N2J20 E!9_)2
M:_R.9O%?++E*4PJ3(I0 ,WF@+ %I4(22O0B$;01,,:RWT95+ZA@5),BF5B%O
MO@5\$#K(I?FRYGA+^3$;80HOP/%<LZ6DPO<S:\-S X=.E6"AH%1D,[66ER&I
M#8L1C! 5$Q 0$^  8#0 )*<:JP%I2/$0JQ5'P6=97MB:8#C)8Q$T6!*KHWR,
M<M-2:\A $*:K<7AK$[8_RMM6QT"B.-69 MI7T7LN%>-ARJJ:AZ2]O&$Y5#(E
MEI!YE9$@MEF^Y]O^.8\D VUW&1?1 HOQE3?0 B8 )";U-O:;"7IW0>_:.PI[
MG87WBO5:-! B-Z+ :1#&D=([/1!$IU 2"7*1<P5[AHN*>6H&)#8[+VL<)=L5
M(>M#9Z<GK'<8H];XF<A":" \H/]95-G(0^"2 4OU;8FV6N&4%-?1,?V71I?"
M'\*LSV$2)&12JQOZ/"'Q1= G?;6R /Z"L6OU"RGZ*BPTS<3BU/:3'N-'H^='
M:]]P-5@L6%U\D5$+/=EB1.NP+4):M8_BM7T8'T7147Y!MIDU%F^\$YPEQ_L8
M*]*G '="D^42,BP(*M>CD[+Q6LT6E!N8-Q^X,?,&N+[E1T>IE1R(-]W^\7A<
MBA\92+9_.:;>,6^UA0BQ81:6*Q>?G#V(P<^@M!R+X;F6(:G)R$NK_!.J 34.
MH  &L+H+X+K]H#7[11WV$8#?8563AKF0%(;!;-J\RZ@UFX:TN*$;P,S_@ K-
MDAXAS)FG%M5P)2>>*: CNTTKO%2D*5WNPHN7XEJ(1#D \II3(JW@6YL+4KXU
MH*UKV9H>PI86(<\V &<WT%*>4'=WM\^I'2.H"*_V^F33*:_]"R0N@'AK^ $=
MP7CTD(O<3(&]2$RGW0EOPYP1[!@SHM&A0'#+6"%:DGGT2=4;?)\!.3_S<RP^
M93\MG=)%Q8V#%D-(50%?6T?#=1\WO6X^(9G^BT-)F[QO_$$EI<([J#(F"T,O
M]A+$0]RSM)!GSA#"* H,H_96U#PL=U)]@0)K6EU-7&U^A%586YQKU;+%YF#F
M8UU8OE:D/^K%^[ /^B<>,CW3(^G"9(LP3OK&_V4D>/U\L[+7#$!&W-2'_8>3
M7DK8KC6(YD:F3V&3W!&8@JS3C[;(;3KI6!%<?8MOANME2?'08)&L8VH=+4N4
MV2$3:,+ EFNHO%$EO&M,0T,9DX$#-0 #&V<3.Q$5$O /$^!%!B   K  J>$/
MM,0D%A%;G$V[^P5253ESB$O7R+V<J?T)T5&K@N 1K!$NQZL_3">0T^PKVE<,
M <G=Z-=MTZMN#W/^0*GII/P!SND-(-'!-J0G&;4YOD(@!!.BK2PF"2DP ST@
M7C;P,UY' _#;&7!34D*FKNLZRJ:HOYBWOPT%404=B[*8G<WC$1F%>UP&L(\3
M9A6$&*!TGK%J/)K7X2P%2><84UHR9VY2#"YDGQY,C2WN>BG=C;/'#"R-87BL
MS814'U1W1SQNR >!'3"!F@*FNS/K=S7KPP9HU/L(1F;5LTQ=S=97S2H4#$4[
MM!6KG]]75+)F#0UIHU]=D1.Y0X!%YNJ@#D)ZM2IA;$#$:W .YV9TQI*9QGZA
M:(A;<\&\::6 41.@MG3LCWP]LH/^G84>-A%=MXF.@7!D&Q%#N!Y8R,_^%+AO
M*KB/%K@Z';E]Z_B;HAT+83(=A6\^/TD/-LB5$B4YC(C_L;L&15"8(!DJ=LHQ
M<+,<W;*Y;@$1 ,NW_>L/\'2#L!"D^MOIB..+H)+(]1O-KC:KGG.B?)[(,3=%
MX@$0%B[U\"QU>*(WE:(KRM12#2?!XM3/&RTQ/9K?]"G"9[V+RV_()1V\L74^
MJ*WFC&.>0[Y"L ,U,)P\H /#5 ,LAADC< (A(O" \&*3@C(#<P@3HR@C \/(
M.!,YPTA323-C64-3P[EI4VGS&0I:$UI:>AGCHG)"$O+!H8%A45%A@9'1\?$1
M$B(B,A),4G*"PK+B\J(H&3/YB$ES(]TY$_/^PI)R8D+"76*"HM(B,V.#DX/3
MT,# D-[>X #_X/! 7T\_#_$ L<^OS[\?@9\$?A$"YH-0,*#"A \D3*!0X0(&
M#!HV=/#@ 41&$!Q#<!31RR/'#QHQ<N#@ >6NC\"\G2B&8@6+%BX2C:M4[1HK
M5Q\V9+ @X0&#! D.&#!@],"!! K6-=!7D-Z^>0[2K6/0]"H[=>RVODMG[R!"
M@@,C2#B+=L)9M0[5NIT -VX%"G ASKU;BX)>O+5L59AP%R*M6H/M]CV,V(+B
M"XPG9GA\LH,N$+Y^D1C!+7.)829.I/BL(MOF$!XV7* 006A1 P6.,F5@=H)B
M7!M.8N1E>1BQE[S^>9?8O#E8KY(>)%]<B?P#1N,=3G+8 /UD;>?.+3:G'IG#
M]<C%C7?'"-Z#\O#DRXO?!?YZQ>@7Q8, UAE%"IDN7!Q3(7-F_1@R^"N*D4@,
M--B0@PXYG%/#"RF8P. V))@4P0451.!  @4(,, "$5! "P8;D 3""+^-\$LP
M(R@G64:8\2;?9R=LIEEGG\W'0GTO)'((@-:\T (V)HSPRG,_61 76@.=M4\]
M55FUS@).+J! 4UDY]0X^"9E%EV 79*!=BAV5*$PW)'1&)@HMSI<"?L>PP"9^
M*R!#S@TY\$#G#COT (00/,S@P@P]X."9"C7TH,,-,Y!P@@N7(#-("HW^( *@
M38X\,LXXF$ #S2:6;-+)*0,.&$JH U)C" NL -F<+(-5@$&7E%5FXC#%J%"C
M,C<ULXBE ]Y0 Z^:&-*""B@XB)FL*+30C TWF.,4._ \"RU5]H0E5C])_C/0
M/P1M:U!!USHD&"X5M:<1""2%%!)'YJZ$D44I@0<B,"+&)Q^M+-S83"6,6,,"
M"JT$B4$%00U55%)*$;4 .U)!E20]ZG#%@)-:=>65.M*&Y0]"9BDD@5E&.@2R
M6R#3]9 $>IULP<DJUP(88'UQN)=AB,ULUZI]#<98SKAD %UM&'7D2YB9Z;9;
M-OB)YDH'&EPP06H+K%9  4HI,(]#ME!4$4K^&07=#8/%]/;2;[]=1J)'YNU"
M$HCC=2<9=K5-AUUU<+<M761M-R>9=5U>E")VU]W-''/2;:"!!CQ;MY$(W'B6
MGPLMM)#?3/?:M"^.R@QHS@X(OK 3@]SD+8&$%%J(X0(F*V8!2AR)6 *0KILM
M&4GS>N:9BV/K)F.:;]9ZR O*^/Z""RMD<QD('?CTDUYL"134M%9!'+&364VY
MU3P+%Q07A[?PW.5*[Y%H(G"_L6CFC"J<_^;NZ>LWX(%W[D"G#T((L<,,+?AY
M0^TV^'".#".D( @9L  &-CB!"OICC0#QYQ"4@H0D(H&32VRJ$IPHQ2=&!2I3
MB$(3-+#&"E3PHQ#^I.H"@[' 8R[R)7GIQH"TJDDSF+$,163"%)QH1+"T03;,
M$",<,(B3.=I1L6C%0Q[3TD<]\K$P:VEK'V=AR%BTU2T(@&LV%.D2>,JEKBRJ
M"VTFV<"[M/8ES-!+332Q"33ZTR/BD88# 9.  Z!4,(,1I2GO@(I![,&DB%TE
M8<W:BE>&:+TE;JQC:(F-D=C2EK7HQ61Q48O*5O80EN%E+W^!F6(2@QB(R,PO
MA%F,1!X3G=N\"A@D4-S05OB2\X4&!9LQWM*:]H"G': UKE%  V(SF\)IYS:]
M*-;X7F*FKX6-&R:B#$?*HS:UI6<[@WL.==Y6M[=-!VYR.U[/KHG-YT3^YYH:
MB,5ZXJ9-PA7N,3SSTGMD12/']6A-,RDCKB(%@V3P1TX'.L<,7C"L!J%*::&;
M4 ,L!( ,21$BK=)%"$:P#2 =%$@?\(XOB)&-B"(M1B_YS.Y:X+OZ)*,^D!/-
M"#3"@<=(B"YH:5@1'0:])T$)*RRM'CX(XK&'S 8RL6,),%HBME\"LUYI4N7N
M3,4F^I #!SJ GYUX\(,\U:\%-/!! =.T/QW8X 4D0($@8C! &AA0!KZ+E*T:
M* E+84(&$LP4*"C(P5#1$%2H^$1.5L!*$1@OI*O:DD7.!:L5%2,%M5I&)/[S
M'VA8\ 8VJ"$,;A@<8>RP!3U4%E&?QP '1#;^LL^Z!Q&M9T0C5JMA2^RL(/_Q
M@( H,B);REIQ-J(<+681;26A6WA8HD-@JFER_-D$(V!P#7_QA*X#*]A1E+*4
M!*PCD !!(A*AI\>)/:QZ53IBQF#J+;-(,2UI@4M:2%J7[-7ED721Y%QBEI?#
ME) PF>2+>&UA@9R1LS8U#0EFBG7*,57T?*9BY4>51J1\#&6645M*4QI"F(F$
M<A>]4-QO.@/,!!-C;&432;G(@S:/I*VARSE)X:Y9';=I4SN#DR8VH;.>PHE8
MQ(<SG(D-1\X15V3%*'[,SJ"#0LJL*)V28]/C:'(C9B "MP*BYX$,I:!M, A(
M%I8 !E SE ($E '^$#@91293+.$<M+4HU&M%LX%#HA6MIS+!L>/8Q";1R+4X
M&YA(RM0B19,6\2M,XJ,>HW05BPT1IFT)%_=B_!XP#4ULVH!)BU3IIJ#::P4T
M:5]1>0 _I,Y/!S)8P?YF$*@;^*!0+?B?( XK(!,<\$;*R%&.P"K6!TYP@IKP
ME"@^T8D-TJ _JV"E1Y3VDP!S:3(?$5I%V:2,!P*V&OE25@5K$(EK$.\R\O)&
M"A@K \?J@$J2C6R5H"6/RI[TB)OUK&<#PK#B2E&FGPQE>$#4D=6R*SRV$66M
M76(^0N.+K/J*08]V(H+2S&)@"O M<)F2L$ JQ*3N:))6F&25)4%[8?[^*,L@
M"T+(M8#LNHYLY'8IP,B':))D+>/N862VR9E]EY.=M(5$Q,7>&/<2OJ?\99K:
MQ$H2&.\G$\B'+&?Y6ZIAB57BVN763,D9/_O+7R\:4=F,F1'R=,1[Y#%.AJ7Y
M3!@[,YP;'C'AGG[B<<HB Q.I>M5SQABJ.X:<7'>Q8\9U'%*:@$8U>ERMDL'
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MHSPG0X-P<1@29Q=5^3+?91B#$4FV4#,EA#H$R!X_4V!"(S;=<&7V(BS;X$I
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M(Y5R6QR%4>US(#@0B:\I)O=E&K0I%+,$ +GIIA3@(1?QFZ44D!KA4 A%.]G
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M0ZS#(6UI[,E,-3+'+*E)J31;LYIK6F.UV6Q-=:Z8!XYV0Q;_O3$&/(&)"UI
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MG #K6"-&[N!HV*Q%"^3-HA:<#)*86=H\4KF"9M-"$IE!8&8GH29*VN/^7O?
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MC375):7S>H9F)^&R:!%[0EXT,I]E583@ BJ@",OS 1TK 5M"F04P  ]:0YO
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MBXT6*8-&"\%X"YSR>DG%G+_@$OIR#*]2)D;'02TD*[^W'/S"57:I5N* E^*
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M+X%B\&2/:6$2F\ A$0HRP_%HPJ"=70H^WA,!5_)814%'_D-1 ,B0INJ97D&
M6B).@SHLN>1 \9F1I;=NU.$Q[,-%-(H#(SD8)W.!+:,#-0 #-J!OQ34#/G S
M/D =-%"D-" W2>K^24/S<$9C-"Q(<7%HE#!H<4R9I76(G89P7UXJL15CE=W8
MCRMG-EF9'<)4A&GJ-K VL&))-RR1/CA'8*D$ Z.*)')G'[F#I[.EIQ4ED7XJ
MK^" C=E(3E-W@"H&F)65?E,DN:8R=<7P3H'I5"!B%_B0#X;)-*ZA3WJA8\2
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>!*EO&V!D(Z=Z0K=^%1LT=R]"M(LET(1_?&.!   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2516624d11hqhreporti002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11hqhreporti002.gif
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MNKR[N\3#Q,?&QLG'Q\G(R,G)R=/2TN+AX>+BXO#P\
M
M                                                 "'Y! $  &
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MA Q <H%[R!:+%DOI0BT.G#U'[@< ->;7KR6J5CBZML.5+Y984,*%B]DN7:Z
MN0)<^!7?9WN;_=(;RP0>.#A8F8"CQP3$MK/+BQH2@ 5FFFL1Q!5:N_EERQ]L
M %H^F9, 1P](.:!#QP%5Y_/+>ERC5@S+S$ D$@ 7)4#,$?HE^ HQKCU& 3.4
M#% +/Y_1IN"%B7QQ@P]'.)"%"290,<$2S&#AP!$T7+ %!D$$<<$[&,9H"$0
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-7$![+BA>NN<*@0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2516624d11hqhreporti003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11hqhreporti003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( 0@!8@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM?"/_0)_\F9?_BJ/^%:^$?\ H$_^3,O_ ,50!U=%<I_PK7PC_P! G_R9E_\
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MOB4#_>6*Y=/P!!&>*@@\!Z?HVLPZEK&KOKURJH8HC(9"6'8DY^7/U^GIZ?\
M\(=HO_/N_P#W];_&E'@[0\8:T9OK*_\ 0T 4+30;S5Y4NM:/EP+S%9Q_*%'N
M.W\ZZF**.")8HD5(U&%51@"L7_A#= _Y\/\ R-)_\51_PAN@?\^'_D:3_P"*
MH W:*PO^$-T#_GP_\C2?_%5FZ[I7@_PYI4NI:I L%O'QDS2$NW95&[DG'2@#
MK7=(HVDD8*B@LS$X  [UR'ACQY8>+O$=]:Z7IT[V=I'_ ,A-EPCMD#:!C(SG
M(]<'@5Q=KX2E\?:G8:O8>9I7A8J'6)F87$S D$$9(P2.#G&,=\UZAI'AO2-
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MW)ER&EC'8Y_B7]1CT->J4 %%%% !17*>+/B%H/A#$5Y,\]ZV-MI; -)SW/.
M/K^&:Y&Y^,FHL@:Q\$ZDZ,?EDG8HOZ(1^M 'K-8^K^)+'204=O-N.T2'D?4]
MJ\HN?'GQ&UW;:Z?H=M9>;T*DF0_B6_D*DM_AY\1KIB]QK.FV88$,%^=N>O\
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M?_\ \@R?_$T ;M%87_"9:!_S_P#_ )!D_P#B:/\ A,M _P"?_P#\@R?_ !-
M&[16%_PF6@?\_P#_ .09/_B:/^$RT#_G_P#_ "#)_P#$T ;M%87_  F6@?\
M/_\ ^09/_B:N:=KFFZM(\=C<^:R#+#8RX'X@4 :-%%% !1110 4444 %%%%
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M_P (]<?]#'K/_?<7_P ;I_A3[=_PC5I_:-RMS<_/NE$JRY7>VT%U #,%V@D
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M22'VB39N&<X^[GM0!ZA!&\5O%'),TSH@5I7 !<@<L0  ">O  J2BB@ HHHH
M**** "BBB@ HHHH **\YO-=^*27LZ6OA#3I+=9&$;F[3++G@_P"L';V%0_\
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M7"_#?0M9T2"]&K0SQ&2.!0LLZ.&D56\QP%)QDD<DY;&2!7=4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8M]XHT_3[]K.83^:I .V/(Y&?ZT+XHT]]3_ +/ G\[S?*^YQG./
MRK:HH R?$^KRZ#X9U#5((4FDMHBZH[;5/N3Z#K^%<'_PM#4A!YXLK)X;<LT\
M@+CSH_M2P H#RIY+8;/2NZ\56^FW/A?4(]7FD@T_RM\TL6=R*I#;A@'D$ ]#
M7*6/@[PMJM]<P6^J:A<7,92YOPVU?M FD$Z;_P!V!@LF<)M(Z'K0!H:;XUGE
MO##JUO!IJ"9MTER3$JQ@8QEL ON*#C@@G'2E\5^,+OPYXGT2S$$#Z;=!FO)7
M!WQ+O1 P(.,!I%SD'BM36O"EIKK2M<W-S&[[0K0E044(Z%1N4C!$LF>,_-QC
M K%UL^#]4LY=1O\ 4F6UM[.YL71<@^7N59"$*ER590 1Q]>* ,JZ^(VL1^ ]
M#UBWL[.74KY9IYHMK^6L,(9I"!NR#@*.2>36I;>,=3N_&J:8JV%O92,CV\=P
MCK+=0&/<98Y,["0<#9C.,\TI\ ^%;+1K274&DNM.TVQDCC^V%61$9O,:0@*/
MF[9].U4_"?AKPS>O;3Z5K6JWD.ES1R+;77R!)!%M1BK1JX&P@C!"GKB@!FG^
M/]5&H+)J<5A_9DES?0 PHZ21?9U9]S$L0V54] .:;8?$'69_"-Y=7-E:1:U%
M=VT"0A7\I5G$9C9ANST<YY'(K1F^%VD7'VA9=1U5HY7G=8_-0+$TQ_>%<)W&
M5YSP3]:=JG@?PMI>FZM=L9M,L9(8GN!: !8S"Q=95 4G<"??/I0 Y?%>J1>$
M?$U]<1V;:AHL\\ *(RQ2E$5U;:6)&0PR-W;K6=HGCZ^OK.]DNY; "WN+.))X
M;:0!O.(RIC9]P(S@-G'.<'&*W;/P99+H.K:>VIZA=0:QNDGEF,8?+C!92J#D
MC'4'H*SM(\)Z!?1:C'!JFHWLT-Y!#<S3%0Z/;$,D8^0#:,C.!SGK0!/?_$C2
MK;3]3N;>WN;A[*%YD4IL6X5)!$Q1N> YP3C\Z5_B9X?@F>&ZDGA>.,M(6CX#
MK&)&C]=P4^F,\9S3A\.='\J^A>>]>&ZMY;98V=<6Z22>:P0A<_?P?F+=*BE^
M&6C7$EPT]WJ$BW*,)4WHH9VC$9D.U =V%SC.T')"B@"+6/B#]@;2YH;&X6WE
MN9H;R&>W(GC$<7F':-P&>G/(Q5V7XC:!#<VL+O<;;A;=UE\KY%$ZDQECVSC\
M*?=>!;34(84O]5U6[DBEFD$LTR%B9(_+(P$P% Z!0!GGG)JJ_P ,M$E^S^9/
M?,L*VB!3(N&%L"$S\O<$[L8]L4 -N?B!;W.D_:M)B<2K<V:,EW$5S%<. K@
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M'P^TRZLK"VEO=1(L%/V:3SEW1R&0/YH^7&_(P., $@"NL'  SGWHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2516624d11_ex99-xcx2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11_ex99-xcx2img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ -D# 2(  A$! Q$!_\0
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M1%/>1LTL&MZ5>3A[;3O$&FR-IUXUM)!&8Y()$8 _4BBOSA_X*,?\%/?V4_\
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M-^SKI>G:&=/URX%Q:I)'XGU^\3Q-XAM6:5M6\5^&K>$0-%:R&OG_ /X)J_\
M!Q/^R%_P35_9R\'?!;X:_P#!*C5->\8Q:7 WQ1^+]S\<?#__  D_Q8\8-'$=
M7UK4+W4/@)J-U:Z3'?0M9>'M!&IWL&C>'[+2;(74LUO*J?OA_P %BO\ @B1X
ML\8?\$0OV<OV>/@(TOC;XN?\$\?!^C^(M-TRPL&^W?%/2],\!OI?Q>M= TR'
M,UMXI\0W<*^+-*TY 9]3U*SO_#R!CK"-7PM_P3/_ .#I;]E/X4?LY^!O@)_P
M4&^"WCW2OC/\'-!T_P"'O_">^"_ '@[Q7%X^TGPG:0:+IEWXQTC7]<\+WOA'
MQ19V%@MEJ47]HW$&K7MN-4\N*74'AE /Y\?^"M/_  5._9J_X*)>,/AU\=?@
M1^P5JG[&G[3W@?Q9;Z_K_P 7_"7Q2T_Q!+XXCMI8[W09M5T+1_A7X.(\7^'?
M$-AINJ:!XH%REW-9Q:SI[3%8(&C_ %__ .#HGXP>(?V@_P#@G!_P0V^.WB_R
MK?Q+\8?A-XZ^)6OI%(;FV75_''PM_9P\1:A<.=\OVII+F]N+FVD!3=YY7RD(
M(/T_XE_X.2/C)^W+^W)^SU^S7_P27_93\(W'A;6?'<-OXHN_C?X#T:[U3XA^
M')#%'JFN>)=/\/W,EI\)O G@/36OO$6JZP^KZCJ4^H6VD-YA6*W@E3_@]K@E
MM?A!_P $WK6X@M+6XM_%G[1$4]I8H([6SE'A7X-,]K" S!HX"WEQR#'F1JCD
M DT ?T:?\$A?^"?W[*GP._X)X_LH:/H_P/\ AQ?>(/&'P&^'?C7XA^,-=\&:
M%=>)_&'C+QGX1TO7/%&K:M?7L$FH1W7]I:A/8QB)A#':6UJ8MCL]?R._'OPQ
MIW_!9#_@Z%U3]E[X^B[D_9U_9Q\1^._AE!\.8+J_T*U/@WX!:1JUQKNF:9(S
M"TLHOB9\3(7\0W\R[5O[35(M/+!4CQ_=Y_P3W8']A;]CV-TRC?LT_!8*3@K*
MS_#S1]\>#_=C3<<D AQGH:_BG_X+L? OX]_\$D?^"L?PQ_X+4_LZ>#H?%7PS
M\>>)+;4_'5A)'JTN@:/\26\.#P7\0M%\:?V3LFT'1_BAX9U#4]?T/Q \FI6T
MFOZKJ<":4&LECN@#^V_3/V)?V1='^#P^ =A^SQ\%[?X,MI$_A2;X>P_#_P /
MP^&IM&G>WL?L-U:K"'ENC;6D6G_;3-]IFN"9<@.8A_G;>&?V,? /[!W_  =9
M_!O]GSX4@Z9\,-+^.&A^-/ ]D;F&Z/A?0_B7\&M8\8IHX%L!'96_@K4O$<FB
MV=HWSB"QBF4O%*A'[MZ9_P 'F'_!/ZX^$1\1:G\"OVD+'XQ_V MX_P ,=-TG
MP9?^%9/$"V,0735^(G_"4:9>6NDK=20P66KR^#H+ZZF73XT0)&\L?\Q7[%?[
M2'QF_:S_ .#C_P#9O_:2^.7ANZ\$^-/C)\<]-^(%IX6GM[B&'P_X(\0_"?Q#
MJ?P\CLGGBC,^GZ;X+U#1;FSNLR&ZAG$QD+,R( >@?\'!?[6FA>-?^"[GB5OV
MC_ .O?&K]G/]EK6_ '@F+X%:9XG3PA/K?A3P[H.F:WXBT6/Q#+I&N0Z3:>+?
M&NJW][J4G]G7)O+2Y6R*;FA-?IIIW_!W!^RUI/PWC^#&G_\ !'BQL/A='HJ^
M&5\"6OQ?\)P^%Y]%1%MSH<NCI\"8H=1B6ZCMK.XTN<3C49(VN)Y4(456_P"#
M@G]F_P"//_!.#_@J_P#"?_@LU\%? <?Q'^%>K:]X6UOX@V$NEOK/A[PCXS\-
M>';+P)XF\,^-X[)Q/X>T7Q]X%O6N]$UV7_1?[6O+Z% S6C))^A.A?\'<_P#P
M2CO/ALOB#6?@%\<=/^)_]GM<W/P^B^&/@+4+)]:N[5)I])TWQE'KD8ETZ8P?
M99-8N=$2YM[$0,T<C"&.@#^6[_@GU^W'H_A?_@NE\%_CC^QI\%-?_92^"_[0
MOQC\(?#CQ5^SU;>,X/&OAV70_B)?V6@>(_#$.OV_ACPFFI:)_P );?#7+709
M-.ENM$N+%M/2_EBMQ#:W_P#@K'^V;X6\2_\ !>_XV?$3]J_X6:_^TS\$OV:O
MC3K'PTLO@;#XN?P5I^N>#?AL]QI&@65K?OHVMV^CZ7=:NL6KZI')82OJGVUX
MI7'F'=_55_P0Y_X*E_MS?\%4OVL?CQX[O?V;?@UX _83T"79X?U6\\*VK^,O
M!>N;+2U\/^"_#'C;2M*T2R^(E_.()-=\:?:;9GT& Z?!!?>5)# OY;?\%A_V
M?/VA/^".O_!7S3_^"P/PT^&=I\7OV9?BUX_;7_'MA=6\%]IMIXD\;Z-:P?$/
MP7XREDM-5BT"W\9:W;ZEX@\(Z\=.41O#'I\5V)+%40 W/^(NG]FI?A]'\*$_
MX(YZ6OPWGL)?#USX$A^+'A2'PA]A\L07]BGAVW_9X%C>O)$TD*--=&X2]#WT
MK1.5+?E3_P $6_VK](T#_@OI\,_B#^S%\+->_9X^!/[2'CCQOX+U/X(2^(8_
M%5MH7@_7?!VJ:S)X<_MF/1="2XATGQ/I6D:[!$U@LEO J1$^6L:C^EF/_@[L
M_P""4,WPXA\3-^S]\=8_B%'92SR?#L_#SX?7-I'J\<W[D2?$-?$<MU#IZR?Z
M/'JK^'HF:WU%533Q+%);Q^A?\$%O^"DW_!0;_@II^T!\:?BGX^_9R^$_@+]A
M[3M7\27OP^\5OX.CTCQ%X=UR2[TY/#/@3P=XNM;'3X_&,NBZ=-?/JVMO9S#S
M[VXM1?2-:/':@'X1?MAZ'K'_  6T_P"#E+5OV0/C!XCUKPQ\#_@AX_\ ''P7
ML]'T.YNHKVV^'/PDFNH_$LNDDA[2QOO'&N6BZI>7[A9%L]1@0<VT!A_M[/\
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MV<M%_9P^%G@7XMZ5X%TW]L2\OD_9Q\3_ !U\):%X<55^)FMVY;2[OQ[/I?\
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M72OB=%;3ZC<^)/&]EXET)_#FJOK_ (MN[B?7;^ZGTVX2#SY[^:4(NXRF5BZ
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G1LK*BJ3&SO9ID>[8NX?,0-W.<D#&<],D $@< D]>I?0 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2516624d11_ex99-xcx2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11_ex99-xcx2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  N =@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V/_@Z\_X*
M=?MX_L&?M(_LK>$?V1?VD/&'P2\-^/?@AXI\2>+M(\.:7X/U*UUK7--\>7.F
M66I3_P#"3^&]=EAGAL#]E_T22WCDC5/-21D1E_'C]FC]J+_@[:_;$^$NC_'7
M]FGXD_M&?%GX3>(-1UO2-'\:Z%9_LT6.G7VH^&]2GT?6[6*WU_3-(U)7T_4K
M:>TE:6QCC>2,M"\D9#GZ6_X/=O\ D[3]B?\ [-U\;_\ JR[BOZ-O^#3'_E"I
M\"_^RI?M!_\ JV/$5 '\U_\ QVK?]72?^:GUR_BSX[?\'G7P(T;4O%?B#3OV
MO;W2M*@M]6U"31_@+^SM\=)K>UCNEM/._L/PQ\.?B'?R06[3&YU.W@TZ2.UT
MV.;5M5ABTJSFO(?],BB@#_.%_8D_X/)/VK?AK\3;+X>_\%'?@KX.^(W@"#6H
M_#?C#QO\,/"M[\+_ (W?#V\L[FYL-=U+6?!%YJ,_@SQC/IEW'%%?>$;72?AO
MJED\&HE=5N[I+?23_H5_!7XS?#+]HCX3?#WXY?!KQ=IGCOX6_%/PKI/C/P/X
MLTAW:RUG0=9MEN;68Q3)%=6-[;DO9ZII5_!;:GH^IVUYI6J6EIJ%G<VT7^>+
M_P 'K7[,OP4^%_[17['G[17@#PQH?AGXI_M)>$OC;H_QIET.UM-/;Q?<?!F[
M^$,7@CQKX@L[0QB]\3WNF_$;6/#5YXBNK?[=JFD>%-"TZ>[NHM"MX[7]D?\
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M"'CCP;J]GKOAOQ!I4[.BW>G:E8R2P2B.:.6VN82RW%G>07%G=Q074$T*>@T
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M?R/);O+'!)%_H'5_EO?\&8__ "EB^)'_ &9-\7O_ %;'P"K_ %(: "BOR?\
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MX>0_;C&LGPJ^,?@GXR2G3=EH1=F'Q=X2^!*"^+O?*=/$[0!+>T?^TR;V:.P
M/[F**_/C_@GY_P %1OV+/^"G'@36?&W[)/Q8@\7W?A)=+'Q ^'GB#3+OPI\3
MOAW/K27)TQ/%O@_4P+F*ROY+&_MM.\1:+<:UX4U6[T[4;;2=>OIK&Z6+]!Z
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MK2..&%%BC544*._H _S!/^#U;_E*;\ _^S /A9_ZT5^U57W;_P &S'_!!O\
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MMKOPGTFZ8I:ZI\2](\!Z]J'@33KEQ::@4@O?%-OI5M,PL+TK'*Q%I<X\E_\
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MK)/;NI!Z9K^ +_@X)_X-MK7]EO2M4_X* _\ !,KP]XKT3P3X0US_ (3/XP?
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M@XGPQ\4^!+W29K>--/EM'\%B^T"?3Y+:*%+1HBUN88XTB^1% _FI_P""@_\
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MQIHVLM<^+=3\*:G::@UQK<"V$UE9R^&@)[9V61I)H9XB6@VL4 ?CU_P>[?\
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M7M6T#7-6T?\ L3XG_%3QKX=B^UZIX7T*Z_M"#2(M5@^P^1;7T-M<WD-Q^I%
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<'^'ZWND0^(]+\)G7[V?[+9^*+"(%?UMT4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2516624d11_ex99-xcx1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11_ex99-xcx1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !D 0\# 2(  A$! Q$!_\0
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M_P +Z3>7+^9<7%E#+*^ -S,@).!P.3VKXV\?_P#)1?$O_83N/_1C5]A^$/\
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M[%U;'H=Q'_ 30!ZG3)8HYX7AFC22)U*NCC(8'J"#U%/HH ^+/B7X;A\*>/\
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M;64TP(]50G^E?$N@Z4^O>(M.TE)-CWMS'!O(SMW,!G\,YK[5\7V[7?@K7K9
M2TNG7$8 ]3&PKXR\(ZG%HOC'1M3G_P!3:WL4LGLH89_3- 'VSI.E66AZ3;:9
MI\"PVMM&$C11V'<^I/4GN:NTV.2.:))8G5XW4,KJ<A@>A![BG4 >>_&3PG;>
M)? 5]<%$%[ID;7<$I'.%&77/H5!X]0/2OF_X7_\ )3O#O_7ZE?4GQ/UJVT+X
M<ZW/<.H::U>VB4G!=Y 4 'KC.?H#7RW\+_\ DIWAW_K]2@#W']HO4S:^!K*P
M4D->7JEN>"J*2?U*_E7D_P %?"=MXI\>1F] :TTZ/[6\9&1(P8!5/MDY/J!C
MO7H?[2__ ""_#W_7:;_T%*POV;/^1HUK_KR7_P!#% 'TG2,JNI5@"I&"",@B
MEHH ^//C#X:C\,_$6]AMXTCM+M1=P(BX"JY(( [896X],5Z[^SGKDM]X2U'2
M)69O[.N%:,D_=20$A1_P)6/XUQ7[2'_(]:9_V#5_]&R5M_LR_P#,T_\ ;I_[
M6H ZOXO>%[ZYBD\16,MQ/)';PV?V&WL$G=Q]H5]V6R?3C';T)KPR?7-7TS4;
MN\LI-0M+I1<8F2VCB==TXW9*C(]#CH3@<$U]D5XAXS^ YU'5&F\,+I=C:/;D
M-'<-*6,QDW$@\X&.!Z=,<Y !Q%QX]\8B*[_XFWB)<&\ )AC&W"QXR1TQGG'W
M<C'4U23X@>,C>N/[:U_ :Y^7:N>(01QTXZGT'(Y-=G+\ ]99)PMUH +&X*?N
M)!C>%"=^,8/KM_VL\5U_9^U\7+/]LT'83-@;)?XHP%XQ_>SW^7KSTH J:/K_
M (Y\0ZK8V$.K^)(8YKB**6Y^RJ5A#VZ_,V/<[L'&1\WWJQ]774]&\<ZA93W-
M_J5S!J-FKW8L(7:9EB8!B&S\V#QR<\DG-?0?@CP7I_@W2%BM[:".^GBB%[+!
MNVRNB[<@,>!U],Y)[UY_XC^#>JZYXTU+64N-&%O=7D,Z+/%([A%0A@0,#KCC
M.&ZDC&" 9_P-GFF\5WPEBG0#1K8#S+>./@8Q@J.1Z$\GOT%>\5YA\-/AIJ/@
MG7+J^O)]-DCFL(K<"T5PV]2"Q.[KTZ]_05Z?0!YM\:O!LWBSP7YUC TVI:<_
MGPH@RSH>'0>IQ@X[E0*^<?!7C75?A_KTE]91HY93#<6TX(#C/0]P01UK[7KS
M/QU\%="\87,^I6TKZ;JLIW/,@WQR''5DSU]P1ZG- $.C_'WP7?6*RZA<7&FW
M./GAE@>09[[60'(^N/I7%^/?C]'?6-WI/A>UE6.>(QMJ$Q*,N>#L4<CCN3^%
M<G?? 7QU:W!CM[.UO8\\2PW2*"/HY4_I73^$?V=[Z6YCN?%5W'!;J<FTMGW.
M_L7Z*/IG\* /"Z^GOV</^2?ZC_V%'_\ 1458?CCX#ZIK'B(W'AU])LM+2".&
M&"62167:N#G"'J<G.<G.37H'PF\$ZEX$\+W6F:I-:RS2WK7"M;.S*%*(N#N4
M<Y4T ?,'C_\ Y*+XE_["=Q_Z,:N@^&WQ4O?A]Y]FUFMYIMQ*))(BQ5XVQ@LI
MZ9(QP1S@<BNR\4? 7Q3K7BO5]5MK[2%@O+R6>-9)I P5G) .(R,X/K78^)/@
M;I?B+1[)UG^P:Y!9Q023PC=#,Z(%RRX!/3[PP<=0: -"/X[^ GLO/;4KB.3&
M?L[6DF_Z9 *_^/5X_P#$SXS3^-+"71=.LOLFDM*K,\C9EF"\@$#A1G!QST'-
M4[OX#^/;:Y,46GVUT@/^MANT"G_OLJ?TKK/"?[.MW).EQXJODA@QG[+9OND)
M]&<C _#/U% ')_!;P0_BKQA'?7 D33]+9+AV"\22!@5CS^&3[#WKWSXQ?\DG
MU_\ ZY1_^C4KK-)TBPT+2[?3=-MDM[2!=L<:#I[GU)ZDGDUD>/= N_%/@C4]
M%L9(8[FZ151IF(08=6Y(!/0'M0!\P_!<X^+F@_[TW_HF2OL*O!?A]\$_$GA3
MQSIFMWU[I4EM:F0NL$LA<[HV48!0#JP[U[U0 A 8$$ @\$&OCGXH^ W\"^*6
MMX=[Z;= S6DA'1<\H3ZK_(@]Z^QZRO$/AW3/%.C3:5JUL)[:3!]&1AT93V(]
M: /G;X9_&P^%--M]"UNTDN--B+>5<0G,L0)SMVDX90<]P0/7I7J=W\>? =O9
M^?%?W-S+C/V>*U</],L OZUYUXK_ &=M4MKAYO"]W'>6IZ6]TX25?^!8"L/R
MKG=/^ GCJ\N!'<6=I8Q]Y9[I&'Y(6/Z4 9'Q%^(U_P#$/4H));9;6SM0P@MT
M8MC/)9CW. .W:JWPO_Y*=X=_Z_4KWW2?@GI>@>$]6M;.07>NWUC+;"\N>$C9
MT(^4 ':.>3R<?E7(>#?@7XG\/>,=*U>[OM)>WM+A99%BFD+$#T!C S^- %[]
MI?\ Y!?A[_KM-_Z"E87[-G_(T:U_UY+_ .ABO2?B]\/M6\?V>E0Z5<6<+6DD
MC2?:G900P4#&U3Z5F_"/X7:WX"UG4+S5;FPFCN;<1(+61V((8'G<HXH ]<HH
MHH ^9/VD/^1ZTS_L&K_Z-DK;_9E_YFG_ +=/_:U;_P 6OA3KOCSQ)9ZCI=UI
M\4,-F(&%S(ZL6#LW&U#QAA6C\'OAQK'P_P#[9_M:XLIOMOD>7]E=FQL\S.=R
MK_?'KWH ]0HHHH **** "BBB@ HHHH *QIO%F@6VNKH<VK6J:HS*JVK/\Y+#
M(&/<$5LU\X>)?^3I[+_KZM/_ $4E 'T?13)98X(7FFD6.*-2SNYP% ZDD]!7
M,67Q)\&ZCJ2Z?:>(;*2Z=MB+N(#'T#$8)^AH ZJBJ&KZUIN@V7VS5;V&SMMX
M3S9FPNX]!G\#3],U;3]9M!=Z;>0W5N3CS(FW#. ?Y$?G0!<HK&U/Q9H&C:C%
MIVHZM:VUY*%:."1\.P)P,#W((J[JFK:=HED][J=[!9VR]9)G"C/H,]3[4 7*
M*YS0_'WA7Q)=?9=)URUN+@YQ#DH[8ZX5@"?PKH)98X(GEED6.- 69W. H'4D
M]J 'T5R$'Q2\#W%^+*+Q)9&8MM&2RJ3TX<C;^M/^(/BRT\*^%KZ1M2AL]2EM
M)C8!\$O*J\;000<$KU]: .LHKQ;X*_$&&_TRZM_$?B 2ZS=ZCM@CN)/G=2B!
M0HZ 9SP/>O7-5UC3=#LFO=4OH+.V4X,D[A1GT&>I]A0!=HKG]!\<^&/$\[P:
M/K-M=3H,F($JY'J%8 D>XJ'5_B'X1T+4/L&I:]:070.&BR6*'T;:#M_'% '3
M457LKZTU*SCO+&YAN;:4926%PZL/8BJ6N^)=%\,VR7&M:E!91N2$,K<N1UP!
MR?PH U:*Q= \6Z!XICD?1-4M[SR_OJA(9?<J<$#WQ6U0 45RE[\2_!FGZDVG
MW7B*SCN4;8Z[B0I]"P&!^)KI&O;5+!KXSQ_9%B,QF#979C.[([8YS0!/17S[
MJWQ/^T?&[3UC\2#_ (16!D)\N3;"?W1)+8^]\Q[YQ7NNF:OI^LZ:FHZ==Q7-
MF^[;-&V5."0>?8@T 7:*Y"7XI>!X;]K)_$ED)E;:?F)0'_?QM_6NMCD2:))8
MG5XW4,KJ<A@>A![B@!U%%% !1110 4444 %%%% !7SAXE_Y.GLO^OJT_]%)7
MT?7SAXE_Y.GLO^OJT_\ 124 7/C5K.J>(/'^F>!=.NY8+>7RHYD#$(\DC#!8
M#J%&T_G5K7/V==.M?#$\VF:M>2ZM!$TG[T+Y4Q SM"@97/;DUE>*_P#DZ/3O
M^OJT_P#0%KZ(O/\ CRG_ .N;?RH \ ^']S=_$WX4Z_X0O[B2:_L=DEI<3-N.
M#RBY//!0C/HWM3?V=O$D]OJNI^%;K?MD4W4(;^!UPKK^(V_393?V:/\ D)^(
MO^N,'_H3UE?%K3+[X?\ Q CU[27$(U.&Y82*,8=RXD'U"R*0?7'I0!M^%+6+
MQ]^T%K&M3MYUCI3EX0>58H1''CT&07^HKB/&_BZW\5_$BY;Q)/?+HEC</##;
MV:*S!%;!QN8 %L9+<_C@5[)\ O#2Z/X$_M:3!N=6D,I..5C4E4'_ *$W_ J\
MXUNUM_A9\4;ZXU_0;/6]%U4R3PB6!'*JSY^7>" ZYP1W!'3(H Y'Q'J/@E9+
M>^\%QZ]I=_ X95G*E,@_>#B0LK#\1]*](\<^(M6\2?L[:)JAE=FEN4BU!AP7
M"%TRV.,%E4_4BJE[\4/ ES>6=KX?^&=C>2RRJC)<:? C,"<;4"!LL>,?RKT3
MQ[XID^'G@6SFTWPI:K!<$));858+5V^8JRH,-D[AD8&>_(R >0Z6/A#KV@0Z
M7,M_H.L>4JG49RTB-+CDD!BNTGU"\=Q7IGC3X;:(?A9NEU#4+\Z)87$]E<27
M ;<2@/I@K\BX Z"O-_&'C3X8^(O#DWV/PG<6.M,G[J2WBCA5)/5BK?,OU7)]
MNM=W\-?#^M3? 76;"X63S-1BN3812$Y"-$%7 /0%@2/KGO0!SWP(\!Z-KM@?
M$EY]H^WZ=J0$&R3"?*J,,C'/)-5_B>]_XZ^-=KX--V;>R@>.*/C(4M&)'?'<
MX./P%-^!_P 0+3PX_P#PBEY8W+7&HZBOE2)C",P5,,"01C;VS4]W_P G8K_U
M\Q_^DHH @^*/PNLOA[I6G^(_#=_>0R0W"Q/YDF7#$$JZL ,'@Y'N*M?#WX+:
M7XL\"KK>K7]T+Z_\QH&B88BPQ4%@1\Q)!)Y''YUVO[0?_),Q_P!?T7\FK;^#
M?_))M!_ZYR?^C7H \O\ @?KM[X>\1^(O#-[.TMA8P3W!4<A'B<*Q7TR#^@K@
MF\5:-XH\97NM^.?[6N+5R3;6EDRG8N>$RS#"@>G)//'?M_A9!'=_''Q9;RKN
MBEBOD<>JF=0:Q=&GTCX4^+M8T/QCX;AUBV9E-O.]I'(X49PR>9V8$9 /!7ZT
M <QJ^MZ#I7B&TU;P"VL:<\7+)=E?E.?X65B2I'!#?KGCU[XM?$RX/P]T-=*W
MVLWB"W\Z5U;YHH@!N0'U);&?0'UK)M/B%X/UOQ;IVEZ#\,M-NK>Y;RW$UA"D
MNXD88!0P"@9)S^8QS7_:,M;>RO\ PY;6D$5O;Q6LJQQ1($1!N7@ < 4 ;.B_
MLZ:=<^&H9=3U:\BU::(.?*"^5"Q&=I4C+8Z'D?A67\([V^L/%VN?#?6+N:>Q
MDBN+94#G$;J2&*9^Z&7<?RKZ)A_U$?\ NC^5?.?A+_DZ'4O^OJ\_]!:@#"U#
MX?Z);?'2V\(1_:?[+D*!LR?O.8MY^;'K[5Z9\4- /@_X)/I'AY[E+*&X7SB7
MRQB=V+ D=MS#\*Y+XEWW_"&?'S3_ !+=P236K11SA8\9("F,@9XR,9_$5Z%K
MOQ5$?PNB\8:3HLES!<RM!Y5TP41?,R[G"YRN5Q@'N.E 'C/AF3X3:AX9BTS7
M8-0TW6?+(?4\NZ;R3@A58C XX*CZ]Z^B/A]X=M/#?A*TM+'6)]5MG42)<22;
MD((_Y9@<*OMS7A>M^/OAGXC\./\ ;O!\UMK;1'Y[**.)1+C[V\,"1G^\I^E=
MM^SIIVJVOA;4KN[\Q;"ZG4V:/G^$$.X'H25&?530![/1110 4444 %%%% !1
M110 5FR^'M$FU5=5ET?3Y-14AA=O;(900, [\9X'O110 2^'M%GU1=4FT?3Y
M-14AENWMD,H(Z$.1GCMS6B0&4JP!!&"#WHHH S],\/Z-HK2-I6D6%@TH D-K
M;)$7 Z9V@9ZTNIZ%I&M"(:KI5C?B+/E_:K=)=F<9QN!QG _*BB@"U:6EM86L
M=K9V\-M;Q#;'%"@1$'H .!534] T;6FC;5=(L+\Q B,W5LDNS/7&X''0444
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)O?A1P*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2516624d11_ex99-xcx1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2516624d11_ex99-xcx1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N =<# 2(  A$! Q$!_\0
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MTB:O+_'?_)0_$O\ V%;K_P!&M7VU;?\ 'K#_ +@_E0!\Z_\ "T?B]_T+,O\
MX*)JBN/C)\4-+B,]_P"'XHHAR6N=-F11^.X5]*4A 92K $$8(/>@#POPM^T7
M;7=U%:^)=,6S#X!N[5BR*?4H<D#Z$U[E#+'/"DT+K)%(H9'4Y# ]"#7R_P#'
MWPOI6@>*+&\TR*.W_M&)WG@C&%#J0-X';=GMW!/>O4O@%JESJ/PT2*Y+,+*[
MDMHF8DDIA7'X#>0/I0!ZC117+>)/B-X4\)R>3JVKQ)<_\^\0,D@^JJ#M_'%
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M8_$FG_8-7OH+NUWA_+>XC W#H> /4T >I_"CQM)XW\'I=7>!J%J_V>ZP,!V
M!#@=L@_GFBN>^"O@#7_ \NM'6HX42\6'R_*E#Y*;\YQT^\** /&_C;_R5[7?
M^W?_ -)XZ^FOA[_R3CPW_P!@V#_T 5SGBGX*>&_%WB.[UR_O=5CNKK9O2"6,
M(-J*@P#&3T4=Z[K1M+@T/1+'2K9Y'@LX$@C:4@L548!)  SQZ4 7J*** "BB
MB@#X[^,W_)6M>_WXO_1*5]=:9_R"K/\ ZX)_Z"*X#Q-\$O#7BKQ%=ZW?7VK1
MW-T5+K!+&$&%"C ,9/11WKT6"%;>WBA0DK&@0$]< 8H DKY,^+_@V^\'^-Y=
M7M4D73[Z<W-M<)TCE)W,F>Q!R1[=.AQ]9U6O]/L]4LI;._MHKFVE&'BE0,K#
MZ&@#S[P)\9/#_B;388M3O;?3=64!98KAPB2-TRC'@Y].H_6NUOO$VA:;:FYO
M=9L((0,[WN% /TYY_"O.=7_9Y\)7\[36-Q?Z=D?ZJ*0/&#ZX8$_K69'^S7HH
M<&77[]E]%B13^?- '+>/?C=J^I^(X;?P5>3V]E$/+5UA!:Z=CUVLI..@ QGK
M7NG@6+Q%'X3M&\579N-6ES)(#&B>4#T3" #('4^I-9WA/X5^%/!TR75A8M/?
M(,"[NF\R1?=>@4\GD 5VE 'S-XT^(/Q#\&>/Y;2_U222RAN1-!%Y,:)<6^[*
MC(0'D?*?0YKW#PY\1/"WB>TCFL=7M5F9<M;32B.5#W!4\GGN.*O^)?"6A^+K
M 6>MV$=S&IRC9*O&?56'(_KWKS&\_9O\/2RLUIK&I0*3G8X23'L.!0!Z3KGB
M_P ,Z+8RRZKJ]BD6TYC,JNSC'0(,EOH!7R-ING/XM^(HM] M9+>*[U!I8(T
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M9D*6=V8X8"?^6A0MN/T&0/KGTKW:HX((;6WC@MXDBAC4*D<:A54#H !T%24
M%%%% 'Q!X[_Y*'XE_P"PK=?^C6K[:MO^/6'_ '!_*O,-6^ 7A76=9OM4N-0U
ME9[VXDN)%CFB"AG8L0,QDXR?4UZDB".-4&<* !F@!U9^N:)8>(M&N=*U. 36
MEPNUU/4>A![$'D&M"B@#XO\ %GAG6?AEXR6-)I8WB<3V%ZG'F*#P1[CH1_0C
M/TS\,_B#:^//#ZRL8XM5MP%O+=>,-_?4?W3^G2M?QAX,TCQOH_\ 9NK1R;%8
M/'-"0)(F]5)!QGH>*Y;PS\%M"\):[!J^E:OK:7$605:>(I(IZJP$8RI_P/4
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M]K=&QLW8QM5?[YZY[5V% 'RW\'?B;!X)N;G1-=$D>F7$N\2;23;2]#N7KM(
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=)I[I@UK \,<9BB ZG:H.6)Z'. !TR:*[RB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
